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Abstract
Various aspects of the pathogenesis of canine atopic dermatitis have been elucidated
such as the role of certain allergens, antigen presenting cells, allergen-specific T
lymphocytes, IgE and mast cells. However, gaps in our understanding still remain,
such as the role of antigen-specific IgG and cytokine subsets. Canine atopic
dermatitis is commonly treated using allergen-specific immunotherapy, but the
mechanisms of its action are still incompletely understood. The studies in this thesis
investigate further some aspects of the immunopathogenesis of canine atopic
dermatitis and the changes that occur during allergen-specific immunotherapy.
To investigate IgG responses to D.farinae antigens, a semi-quantitative, Western
blot, digital image analysis system was developed and validated. Both healthy and
atopic dogs mounted D. /armae-specific total IgG, IgGl and IgG4 responses to
separated antigens. D. farinae-specific IgG2 and IgG3 responses were difficult to
detect. The profile of IgG binding was similar in the two groups, both in terms of the
number of bands recognised and their molecular weights. The most commonly
recognised band in both groups was a 98 kDa antigen, most likely to be the major
allergen Der f 15. These results indicate that D. farinae antigens are recognised by
the canine immune system regardless of whether or not a dog is atopic. They also
demonstrate that antibody class switching to IgE in atopic dogs does not appear to
inhibit IgG production. The IgG antibody response does not appear to be protective
against the development of clinical atopic disease, but whether or not it plays any
role in the pathogenesis of the disease remains to be determined.
In atopic dogs undergoing allergen-specific immunotherapy (ASIT) against D.
farinae with alum-precipitated vaccines, there was no significant increase in D.
farinae-specific total IgG, IgGl or IgG4, even in dogs showing apparent clinical
improvements. In contrast, ASIT using aqueous vaccines resulted in significant
increases in D. farinae-specific IgG responses. These results suggest that aqueous
ASIT may elicit the production of IgG blocking antibodies in atopic dogs, an effect
not detected using alum-precipitated vaccines.
IV
To investigate the cytokine milieu in dogs with atopic dermatitis, real-time
quantitative RT-PCR was used to detect the expression ofmRNA transcripts of the
Thl cytokine IFN-y, the Th2 cytokine IL-4, the Treg cytokine TGF-|3 and inducible
NO synthase (iNOS) as a measure of the innate immune response. The
housekeeping gene for 18S ribosomal RNA (rRNA) was chosen as internal control to
normalise variations in the amount of starting material between samples and between
individuals. The expression of TGF-p and iNOS were lower in lesional skin
compared to non-lesional skin in atopic dogs, whilst IFN-y was expressed in a
significantly higher level in lesional skin compared to healthy controls. IL-4
expression did not differ between the groups. These cytokine profiles show distinct
differences to those reported using non real-time, semi-quantitative RT-PCR. These
differences may reflect the various methodological approaches used and illustrate the
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1.1 Introduction to atopic dermatitis in humans and dogs
Atopic dermatitis (AD) is a pruritic, chronic and relapsing inflammatory skin disease
that frequently occurs in humans and dogs. The cause is usually associated with a
genetic predisposition to become IgE-sensitised to allergens commonly occurring in
the environment to which the majority of subjects do not produce a prolonged IgE
antibody response. The concept of "atopy" (derived from the Greek atopia, meaning
"different" or "out of place") originally was proposed in 1923 to include asthma and
allergic rhinitis, but AD was added to the group of atopic disorders in 1933 on the
basis of association of this form of eczema with asthma and allergic rhinitis. Unlike
the respiratory manifestations in humans, atopic disease in dogs usually manifests as
dermatitis and respiratory signs are not commonly seen.
1.1.1 Hypersensitivity and atopic dermatitis
Atopic dermatitis, also known as eczema in humans (Johansson and others 2004), is
commonly seen in clinical practice. The recent interest in this allergic skin disease
has been sparked by reports of its increasing prevalence (Scott and others 2001;
Johansson and others 2004) and the significant adverse impact that it can have on
quality of life. The mechanism of atopic dermatitis has been actively investigated
and the pathophysiology involves a complex series of interactions between resident
and infiltrating cells orchestrated by pro-inflammatory cytokines and chemokines;
however, the pathophysiological puzzle ofAD is far from being elucidated
completely.
Atopic dermatitis has been classified as a type I hypersensitivity reaction which
implies a role for IgE and mast cell-effector mechanisms. Two types ofAD,
however, have been described in humans: an extrinsic form associated with IgE-
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mediated sensitisation, which affects 70-80% of patients; and an intrinsic form with
normal IgE levels, which affects 20-30% of patients (Novak and Bieber 2003a). In
extrinsic AD, memory T cells expressing the skin homing receptor, cutaneous
lymphocyte-associated antigen (CLA), produce increased amounts of Th2 cytokines.
These include IL-4 and IL-13 (Akdis and others 1997; Teraki and others 2000),
which are known to induce isotype switching to IgE synthesis, as well as IL-5, which
plays an important role in eosinophil development and survival (Leung and others
2004). These CLA+ T cells also produce abnormally low levels of IFN-y, a Thl
cytokine known to inhibit Th2 cell function. Intrinsic AD is associated with less IL-
4 and IL-13 production than extrinsic AD (Akdis and others 1999a). Furthermore,
IL-10 appears to play an important immunoregulatory role in both forms ofAD
(Laouini and others 2003; Howell and others 2005).
Canine atopic dermatitis mediated by allergen-specific IgE antibody is measured by
demonstrable intradermal tests or in vitro tests. On rare occasions, however,
reactivity to allergen is not demonstrable in patients that otherwise appear to be
suffering from classical AD. Moreover, many normal dogs show positive
intradermal skin tests to environmental allergens or have elevated allergen-specific
IgE, and yet show no disease.
The pathogenic role played by allergen-specific IgE in atopic dermatitis is supported
by numerous studies but the absolute requirement for IgE has been questioned.
Other components of the immune system, i.e. Langerhans cells, T cells, and
eosinophils, as well as changes in the inflammatory milieu with chronicity, are also
actively involved as the disease progresses.
A summary of the current thoughts as to the possible pathogenesis of atopic
dermatitis might go as follows: inhaled or percutaneously absorbed allergens
encounter allergen-specific IgE on Langerhans' cells, whereupon the allergens are
trapped, processed, and presented to allergen-specific T lymphocytes. There is a
subsequent preferential expansion of allergen-specific Th2 cells, which produce IL-3,
IL-4, IL-5, IL-6, IL-10 and IL-13. The imbalance in allergen-specific Th2 cells and
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allergen-specific Thl cells culminates in enhanced production of allergen-specific
IgE by B lymphocytes. With chronicity, changes occur in cytokine expression with
lower levels of IL-13 and increased IFN-y.
1.1.2 The prevalence of atopic dermatitis in human and dogs
The prevalence ofAD in US children is 17.2% (Laughter and others 2000) and is
similar to the 15.6% prevalence described in the European childhood population
(Schultz Larsen and others 1996) and the 24% prevalence in 5- to 6-year-old children
in Japan (Sugiura and others 1998). The manifestation ofAD in such a sizable
proportion of the paediatric population in affluent western societies represents a
marked increase over the past several decades. The main reason for this increase
may relate to our modern environment because the gene pool has not changed
substantially over this relatively short period of time. It has been shown that AD
occurs more frequently in urban areas, in smaller families and in higher
socioeconomic classes, suggesting that exposure to antigenic pollutants and lack of
exposure to infectious agents or other antigenic triggers (particularly those that
favour a Thl type T-cell response) early in life might play a role in the development
of the dermatitis (von Mutius 1999; von Mutius 2000).
The prevalence ofAD in the canine population has not been studied using reliable
epidemiological data. In an early report, the prevalence of canine atopic dermatitis
(CAD) was estimated to be 15% (Chamberlain 1974) and recently, estimates of 3-
15% (Reedy and others 1997) and around 10% (Scott and others 2001) have been
stated. However, the true prevalence ofAD in the general dog population remains
unknown.
It is speculated that the prevalence ofAD has increased in dogs as in humans because
dogs are exposed to the same environmental influences as humans. Furthermore,
over the last few decades dogs are spending more time indoors, thus exposure to
common indoor allergens such as house dust mites has also increased. Early
vaccination and the practice of parasitic control and usage of antibiotics is more
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common (Hillier and Griffin 2001b). Robust and valid epidemiological data is
required to support the above theory.
1.2 Genetic and predisposing factors in atopic dermatitis
1.2.1 Human atopic dermatitis
A genetic background for AD has long been proposed because the disease tends to
cluster in families (Kaiser 2004). However, unravelling the genetic basis ofAD is
challenging because it is a multifactorial disease arising from a complex interaction
of several genetic and environmental factors. The concordance rates for
monozygotic twins have been estimated between 72 and 86%, compared to 21-23%
for dizygotic twins (Schultz Larsen and Holm 1985; Larsen and others 1986; Schultz
Larsen 1993). The magnitude of the concordance rates indicates that genetic factors
are decisive in the development ofAD, whereas incomplete concordance for AD
among monozygotic twins suggests elusive non-genetic factors.
In another report, Uehara and Kimura (Uehara and Kimura 1993) studied 270 adults
with AD and found that 60% of their offspring were also affected; the prevalence of
the skin condition was 81% when both parents were affected by AD, 59% when only
one parent was affected by AD and the other one had respiratory atopy, and 56%
when only one of the parents was affected by AD. This study demonstrated the
presence of an autosomal dominant inheritance pattern ofAD.
To identify candidate regions encoding genes for AD, genome-wide screens followed
by positional cloning are employed. Results of various studies show no substantial
overlap and careful interpretation is necessary. Regions on chromosomes 3q, 3p, 17q
and 18q showed suggestive evidence for linkage in at least two genome-wide
screening studies, indicating promising candidate regions for AD (Lee and others
2000; Cookson and others 2001; Bradley and others 2002; Haagerup and others
2004). Interestingly, the susceptibility regions identified for AD show little overlap
with asthma susceptibility regions, suggesting that separate genes might be involved
in the pathogenesis of the different atopic disorders (Hoffjan and Epplen 2005).
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Instead, some of the identified regions overlap with susceptibility regions for
psoriasis, another chronic skin disease (Cookson and others 2001). Thus, genes
expressed in the skin might play an important role in AD pathogenesis, in addition to
genes influencing the atopic diathesis.
Following a genome-wide screen, positional cloning techniques are used to identify
the gene(s) influencing disease susceptibility in the linked region. Although no AD
gene has been identified by positional cloning yet, it is likely it will be discovered by
this approach in the near future.
Candidate gene association study is also useful in identifying susceptibility genes for
AD. Variations in known genes whose biological functions implicate them in the
pathophysiology are compared between unrelated cases and controls. Most
candidate gene association studies focused on genes thought to play a role in allergic
disorders in general, e.g. genes in the cytokine gene cluster region on chromosome
5q31. Variation in three genes has been associated with AD in at least four different
studies; the interleukin-13 (IL13) gene (Liu and others 2000; Tsunemi and others
2002; He and others 2003; Hummelshoj and others 2003), interleukin 4 receptor
alpha (IL4RA) gene (Hershey and others 1997; Oiso and others 2000; Tanaka and
others 2001; Callard and others 2002; Novak and others 2002; Hosomi and others
2004) and serine protease inhibitor Kazal-type 5 (SPINK5) gene (Walley and others
2001; Kato and others 2003; Nishio and others 2003; Kabesch and others 2004;
Kusunoki and others 2005). However, whether IL13, IL4RA or SPINK5 genes
represent atopy susceptibility loci remains to be unravelled.
1.2.2 Canine atopic dermatitis
Distinct breed predispositions (e.g. West Highland white terrier, Labrador retriever,
Boxer), familial involvement and limited breeding trials have demonstrated that
canine AD is genetically programmed (Schwartzman and others 1983; Halliwell and
Gorman 1989; Reedy and others 1997; de Week and others 1997; DeBoer and Hill
1999). A pilot study showed no significant difference in any single gene frequency
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of the different Dog Leukocyte Antigen (DL-A) groups between normal and atopic
dogs (Vriesendorp and others 1975), but the combination of haplotypes DL-A3 and
R15 was found significantly more often in atopic dogs and might be associated with
an increased susceptibility to AD (Vriesendorp and others 1975). However, in one
study only 13 out of 72 dogs of the progeny of patients with AD developed clinical
signs ofAD (Schwartzman 1984). Furthermore, in a Beagle colony with an
autosomal dominant high IgE response, the propensity to develop persistent IgE
responses and clinical signs depends on early and repeated exposure to allergens (de
Week and others 1997), which emphasises the importance of both environmental and
genetic factors in the development of the production of IgE. These findings suggest
that, similar to humans, canine AD is the end result of a complex interaction between
genetic traits and environmental influences. However, studies of genetic factors in
dogs are limited and need further investigation.
1.3 Clinical manifestations of atopic dermatitis
1.3.1 Human atopic dermatitis
Atopic dermatitis in humans is a common chronic inflammatory skin disease often
proceeding the development of asthma and allergic disorders, such as food allergy,
allergic rhinoconjunctivitis and asthma (Spergel and Paller 2003; Leung and others
2004). It is one of the most common skin disorders seen in infants and children and
has its onset before 5 years of age in at least 85% of affected individuals (Kay and
others 1994). The clinical course often results in spontaneous complete remission at
puberty or shortly after puberty in 40% to 60% of patients, although patients who do
not show clearance might show improvement with advancing age (Williams and
Strachan 1998; Wuthrich 1999).
Clinical manifestations include pruritus and chronic or relapsing eczematous lesions
that are typically localised to the ante-cubital and popliteal flexural areas in patients
aged 2 years or older whereas infantile AD generally involves the scalp, face, cheeks,
and extensor surfaces of the extremities (Leung and Bieber 2003). The acute lesions
ofAD present as pruritic, erythematous, excoriated papules with extensive serous
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exudate superimposed on a background of erythema (Leung and others 1998).
Repeated excoriations and trauma lead to the chronic lesions ofAD, which are
characterised by thickened plaques with increased markings (lichenification) and dry,
fibrotic papules (Leung and others 1998). Provocative factors can be psychological,
contact irritants, hormonal effects, heat, humidity and perspiration (Rothe and Grant-
Kels 1996; Friedmann 1999) and colonisation of lesional skin with staphylococci and
Malassezia yeasts is commonly observed (Halbert and others 1995; Herz and others
1998).
Affected individuals ofAD must cope with a significant psychosocial burden, in
addition to the medical aspects of the disease. The discomfort of intense pruritus
often leads to sleep disturbance, reduced functional capacity, and impaired daily
activity performance. Because AD is primarily a disease of childhood, the quality of
life for both the patient and family members, especially parents, is also affected
(Spergel and Paller 2003).
1.3.2 Canine atopic dermatitis
The typical age of onset of canine AD is reported to be between 6 months and 3
years (Griffin and DeBoer 2001a). Initial clinical signs ofAD can be seasonal or
nonseasonal, depending upon the allergens involved, but the majority of dogs with
AD eventually exhibit nonseasonal clinical signs (Scott and others 2001). In dogs,
pruritus has been considered a hallmark ofAD and is typically manifested by foot
licking, scratching, and nose or head rubbing. Clinical manifestations include
pruritus of the face, ears, paws, distal extremities, anterior elbows, and ventrum, or
some combination thereof. Primary lesion, such as erythema, in pruritic areas is
noted in some dogs, while in others no visible primary lesion is presented.
Secondary lesions in atopic dogs are usually those associated with chronic pruritus,
self-trauma, secondary bacterial pyoderma, secondary Malassezia dermatitis,
secondary seborrhoeic skin disease or microbial overgrowth. These above-
mentioned conditions may result in complete or partial alopecia, salivary staining,
papules, pustules, circular crusted papules, excoriations, dry lusterless hair, scaling,
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hyperpigmentation and lichenification (Scott and others 2001). Although non-
cutaneous signs are uncommon in atopic dogs, conjunctivitis, reverse sneezing,
rhinitis, and asthma-like symptoms may occur.
1.4 Diagnosis and management
1.4.1 Diagnosis
1.4.1.1 Fundamental concepts in clinical diagnosis
The clinical signs ofAD are variable, and there is no pathognomonic clinical feature
that, if present, indicates the presence ofAD. Initial diagnosis of AD is based upon
the fulfilment of at least a part of a constellation of strongly associated clinical
criteria along with careful and complete elimination of other relevant differential
diagnoses and concurrent problems (DeBoer and Hillier 2001a). A list of diagnostic
criteria developed in humans has been extrapolated and modified for use in canine
AD (Table 1.1) (Willemse 1986; Prelaud and others 1998).
Following clinical diagnosis, laboratory or clinical evaluations such as serum-based
or intradermal skin tests are conducted to provide additional evidence to substantiate
the diagnosis and also to identify offending allergens. Results of allergy tests
provide information for selection of candidate allergens for allergen-specific
immunotherapy and also as a basis for institution of allergen avoidance measures.
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Table 1.1 Clinical diagnostic criteria of canine atopic dermatitis
Willemse (1986) Prelaud et al (1998)
Major features Major criteria
Patients must have at least three of Patient must have at least three out of
the following features: the following five features:
• Pruritus • Corticosteroid-sensitive pruritus
• Typical morphology and • Bilateral cranial erythematous
distribution: Face and/or digital pododermatitis
involvement or lichenification of
• Erythema of pinnaethe flexor surface of the tarsal joint
and/or the extensor surface of the • Cheilitis
carpal joint • Appearance of first signs between
• Chronic or chronically-relapsing
the ages of 6 months and 3 years
dermatitis
• Individual or family history of
atopy, and/or breed predisposition
Minor features
At least three of the following
features also should be present:
■ Onset of symptoms before 3 years





• Immediate positive intradermal test
to inhalants
• Elevated serum allergen-specific
IgE
• Elevated serum allergen-specific
IgGd
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1.4.1.2 Serum-based allergy tests
Allergen-specific IgE assays detect IgE antibody directed specifically against a panel
of allergens thought to be clinically relevant to the patient's disease. The
radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and
liquid-phase immunoenzymatic assays are commercially used to detect allergen-
specific IgE in the serum. The fundamental principle of these assays is identical: the
patient serum is first reacted with an individual allergen extract bound to either a
solid support or in liquid phase. Unreacted antibodies are washed away, and the
allergen-bound IgE is detected using a reagent specific for IgE previously coupled to
an enzyme or reporter substrate. The amount of bound IgE-specific reagent is
quantified appropriately. Allergy tests are usually carried out by commercial
veterinary allergy laboratories; unfortunately great variation exists due to factors
including source of allergen extracts, reacting phase of allergen, nature of IgE-
specific detection reagent, signal molecule, sample pre-processing, reporting and
interpretation of results, as well as standardisation and quality control procedures
(DeBoer and Hillier 2001b). Allergen-specific IgE serological tests are never
completely sensitive, nor completely specific; therefore, careful interpretation of the
results is warranted.
Allergen-specific IgE serological tests should only be considered if there is strong
clinical evidence for atopic dermatitis, and after all other differential diagnoses have
been ruled out. They are merely tools to aid diagnosis and therapy, and not definitive
diagnostic tests.
1.4.1.3 Intradermal test (IDT)
The primary utility of intradermal testing is in the demonstration of IgE-mediated
hypersensitivity to various environmental allergens based on skin reactivity. It is
based upon the release of histamine from mast cells upon interaction of surface-
bound IgE with intradermally-injected allergenic extracts. Immediate skin test
reactions are read 10-20 minutes after injection with the aid of incident light.
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Reactions are subjectively graded with reference to positive and negative controls
based on the degree of erythema and diameter, height and turgidity of the wheal.
There is a real need for determination of the major allergens in dogs, standardisation
of allergen extracts, standardisation of IDT technique, and selection of the best
criteria for the interpretation of immediate- and late-phase skin reactions in the dog
(Hillier and DeBoer 2001a).
Intradermal testing is only indicated in animals with a history and clinical signs
consistent with atopic dermatitis and should only be performed after other pruritic
diseases have been ruled out.
1.4.2 Management
1.4.2.1 General principles of therapy
Permanent curative therapy for canine atopic dermatitis is currently unavailable.
Treatment is usually required for life and therapeutic modifications over the life of
the dog are necessary. The management of canine AD is multifactorial and includes
various combinations of allergen avoidance, topical therapies, allergen-specific
immunotherapy, fatty acids and antihistamines, antimicrobial drugs, anti¬
inflammatory drugs, systemic glucocorticoids, and occasionally immunosuppressive
drugs (Olivry and Sousa 2001; Scott and others 2001). Education of the client is also
of key importance to the successful long-term control of the atopic dog. A treatment
plan should be developed for each individual taking account ofmultiple variables,
including seasonality, severity of skin lesions, cost, willingness and ability of the
client to administer the treatment, and acceptability and risk to the patient. In general,
over 90% of atopic dogs can be satisfactorily controlled (Scott and others 2001).
1.4.2.2 Glucocorticoids
Glucocorticoids are among the most commonly used anti-inflammatory and
immunosuppressive drugs used in veterinary practice. Their mechanism of action
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arises from transactivation (glucocorticoid response element (GRE) binding) or
transrepression (interaction with transcription factors) (Barnes 1998). The main anti¬
inflammatory effects of glucocorticoids is due to repression of gene activation by
interference with multiple ubiquitous transcription factors (de Bosscher and others
2000). Glucocorticoids also activate anti-inflammatory genes to translate proteins
such as lipocortin-1, which is thought to cause a reduction in the action of
phospholipase A2 on cell membranes, which results in inhibition of the arachidonic
acid cascade (Croxtall and others 1996).
When used to treat canine AD, glucocorticoids should be used at as low a dose as
possible, as infrequently as possible and in alternate day regimes whenever possible
to reduce potential side effects.
1.4.2.3 Cyclosporine
Cyclosporine (cyclosporin A, CsA) is a cyclic polypeptide isolated from the
Tolypocladium inflatum fungus that possesses immuno-modulating properties from
its capability to block the activity of cytoplasmic calcineurin phosphatase, thereby
preventing the induction of genes encoding cytokines and their receptors (Mascarell
and Truffa-Bachi 2003). It exhibits anti-allergic properties because it inhibits (1) the
functions of cells that initiate immune reactions (i.e. Langerhans cells and
lymphocytes) and (2) the functions of effector cells of the allergic response (i.e. mast
cells and eosinophils) (Marsella and Olivry 2001). It has recently been shown that
the administration of CsA for the treatment of canine AD is as effective as that of
glucocorticoids, and adverse effects are minimal (Steffan and others 2006).
1.4.2.4 Antihistamines
The beneficial effect of antihistamines for control of pruritus in dogs has been
established (Paradis and others 1991a; Paradis and others 1991b; Miller Jr. and
others 1993) although the true efficacy of antihistamines to relieve the pruritus of
canine AD has not been confirmed. Sedative actions of first generation HI-blockers
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may in part be responsible for clinical benefit. The effects of antihistamines may be
additive or synergistic when used along with other medications such as essential fatty
acid (EFA) supplements or corticosteroids (Paradis and others 1991b; Scott and
Miller 1993a; Scott and Miller 1993b).
1.4.2.5 Essential fatty acid supplements
Essential fatty acids (EFAs) possess multiple anti-inflammatory and immuno-
modulating properties and it has been shown that EFAs are beneficial in the
management of pruritus in dogs (Bond and Lloyd 1992; Scarff and Lloyd 1992; Scott
and Miller 1993b; Bond and Lloyd 1994; Sture and Lloyd 1995b). Their
mechanisms of action in the treatment of allergic inflammation includes the
modulation of prostaglandins (PG) and leukotrienes (LT) (Bjorneboe and others
1987; Lee and others 1991; Broughton and others 1997), the inhibition of cellular
activation and cytokine secretion (Endres and others 1989; Carrick and others 1994;
Rossetti and others 1995; de Caterina and Libby 1996) as well as the alteration of the
composition and function of the epidermal lipid barrier (Linde 1992; Fartasch and
Diepgen 1992; Marsh and others 2000). The synergistic effect of EFAs and
antihistamines (Paradis and others 1991a; Scott and Miller 1993b; Paterson 1995) or
glucocorticoids (Scott and Miller 1993a; Scott and Miller 1993b; Bond and Lloyd
1994) has also been described. Taken together, because of the low potential for risk
and their good potential for benefit, trial therapy with optimised diets or supplements
is often warranted as part of the overall management of dogs with AD.
1.4.2.6 Allergen-specific Immunotherapy
Allergen-specific immunotherapy is a valuable therapeutic option for non-seasonal
atopic dermatitis (Scott and others 2001). ASIT is the only form of therapy that
specifically addresses the underlying allergic reaction, as compared to drugs that
counteract the effects of the allergic reaction. It is defined as the practice of
administering gradually increasing quantities of an allergen extract to an allergic
subject to ameliorate the symptoms associated with subsequent exposure to the
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causative allergen (Bousquet and others 1998). Possible mechanisms underlying the
mode of action ofASIT are discussed in detail in section 1.9.2.
1.5 Cutaneous micro-organisms and atopic dermatitis
Patients with atopic dermatitis are highly susceptible to certain cutaneous bacterial,
fungal and viral infections (Lubbe 2003), and cutaneous infections are indeed
frequently observed in dogs and humans with AD. Skin infections could be a
consequence of changes in the skin caused by AD itself, or it could be an important
component of the pathogenesis ofAD through their effects on the immune system
and by perpetuating the cutaneous inflammatory response (DeBoer and Marsella
2001c).
1.5.1 Staphylococci and superantigens
Bacterial skin disease is a very common and important complication. The major
microbial pathogens involved are the pathogenic staphylococci; Staphylococcus
aureus in man and S. intermedius in the dog. About 80% of human patients with AD
are colonised with S. aureus (David and Cambridge 1986; Hoeger and others 1992;
Monti and others 1996), and numbers of staphylococci are elevated both in lesional
and, to a lesser extent, non-lesional skin of atopic dermatitis patients (Leyden and
others 1974; Lubbe 2003). Furthermore, the degree of colonisation correlates with
the severity of clinical signs in human atopic dermatitis (Herz and others 1998). S
intermedius is present in muco-cutaneous sites, skin surface and hair coat of healthy
dogs, but the reason why atopic dogs exhibit increased susceptibility to
staphylococcal pyoderma is not fully understood and is probably multifactorial.
Adherence by bacteria to host cell surfaces is recognised to be an important virulence
factor and is appreciated to be an initial step in the colonisation and subsequent
invasion (Beachey 1981; Cree and Noble 1995). Increased adherence by S. aureus in
humans and by S. intermedius in dogs to corneocytes have been demonstrated and is
one possible explanation for the high incidence of staphylococcal infection in atopic
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patients (Cole and Silverberg 1986; Simou and others 2005; McEwan and others
2005). Furthermore, there is a causative relationship between the numbers of
bacteria present on the skin and the severity of disease in AD patients, whilst
treatment-induced removal of the bacteria is associated with improvement in skin
lesions in most cases (Nilsson and others 1992; Guzik and others 2005; Baker 2006).
Other factors possibly involved in the altered skin colonisation by S. aureus in AD
are altered epidermal barrier, defective bacterial clearance, and decreased innate
immune responses (Baker 2006).
Exacerbation of the inflammatory immune response caused by increased colonisation
of skin by S. aureus is largely mediated by the release of staphylococcal enterotoxins
(SE), such as SEA, SEB and toxic shock syndrome toxin (TSST)-l, also referred to
as superantigens (Proft and Fraser 2003). Staphylococcal superantigens activate T
cells bearing superantigen-specific TCR VP families by directly linking MHC II and
TCR molecules in a non-antigen specific manner (Huston 1997; Baker 2006).
Superantigens are capable of activating a large number of T cells (up to 30% of all T
cells) without prior antigen processing and are different from regular antigens, which
need processing by APCs and activate only specific T cells (usually less than 0.1% of
all T cells) (Saloga and Knop 1999; Sugimoto and others 2006). In humans, there is
an association between these VP domains and house dust mite specific TCRs (Herz
and others 1998).
In addition to T cells, superantigens can also mediate effects on other cell types and
are strongly pro-inflammatory. Superantigens modulate the effector function of
eosinophils by inhibiting apoptosis, increasing expression of activation antigens on
the eosinophil surface, and enhancing the oxidative burst of eosinophils in vitro
(Wedi and others 2002). They also stimulate Langerhans cells and macrophages to
produce IL-1, TNF-a and/or IL-12 (Leung 2000), which up-regulate the expression
of adhesion molecules on endothelial cells (ICAM-1 and VCAM-1) or increase CLA
expression on T cells, thus facilitating the recruitment ofCLA+ memory T cells to
the skin (Baker 2006). TSST-1 induces MHC class II and co-stimulatory molecules
on B cells, augmenting IgE production (Hofer and others 1995).
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SEA, SEB, SEC, SED, SEE and TSST-1 have been detected in up to 40% of S.
intermedins strains isolated from dogs (Adesiyun and Usman 1983; Hirooka and
others 1988), but a role in canine atopic dermatitis remains to be established.
Superantigens can also act as conventional antigens. The majority of patients with
AD mount an IgE response to staphylococcal superantigens and this has been linked
to exacerbation AD by activating mast cells, basophils and other Fcs-receptor
bearing cells armed with the relevant antitoxin (Leung and others 1993). Anti-
staphylococcal IgE has been detected in dogs with AD complicated by recurrent
staphylococcal pyoderma (Morales and others 1994), but its significance is unclear.
1.5.2 Malassezia and atopic dermatitis
Malassezia is part of the normal skin flora but a proportion of patients with AD
develop a hypersensitivity response to cutaneous Malassezia (Nordvall and
Johansson 1990; Broberg and others 1992). Most healthy individuals develop IgG
antibodies to Malassezia, but in 30-80% ofAD patients, IgE and/or T cell reactivity
to the organism is present (Scheynius and others 2002). Production of IgE antibodies
against Malassezia occurs very frequently in AD, and rarely in healthy individuals or
non-atopic patients with Malassezia dermatoses (Wessels and others 1991).
Histamine release tests have confirmed the biological activity of circulating
Malassezia-specific IgE antibodies in 70% ofAD patients, supporting a role for these
antibodies in the disease process (Nissen and others 1998). PBMC proliferative
response to Malassezia is also significantly higher in AD patients than in healthy
individuals (Tengvall Linder and others 1996). Malassezia is capable of modulating
cytokine production (favouring a Th2-type response) and can play a role in
maintaining IgE-mediated skin inflammation in AD (Tengvall Linder and others
1996). However, no evidence has been found for superantigenic activity by
Malassezia in patients with AD (Johansson and others 1999).
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Malassezia dermatitis and otitis are common complications in dogs suffering from
AD. Intradermal testing using Malassezia extracts demonstrated that dogs with AD
and Malassezia dermatitis exhibit significantly greater responses than those with AD
and no Malassezia dermatitis (Morris and others 1998). Specific IgE antibody levels
to M. pachydermatis are significantly higher in atopic dogs than in healthy dogs, and
are not dependent on the presence of elevated cutaneous numbers ofMalassezia
(Nuttall and Halliwell 2001a; Chen and others 2002b). However, PBMCs isolated
from atopic and healthy dogs have similar responses to Malassezia extracts in vitro
(Morris and others 2002). Whether Malassezia species are actively involved in the
pathogenesis of atopic dermatitis remain to be established.
1.6 Atopic dermatitis and house dust mite allergens
1.6.1 Mites found in household dust (domestic mites)
Traditionally, the common name 'house dust mite' has been used collectively to
include those members of the family Pyroglyphidae (order Acari, suborder Astigmata)
that live permanently in house dust. However, mites belonging to other families are
also present in house dust, and the term 'domestic mites' is proposed to be used for
the various free-living mites that inhabit human dwellings, including house dust mite
(family Pyroglyphidae), storage mites (families Acaridae, Glycyphagidae and
Chortoglyphidae) and their predator mites (family Cheyletidae) (Platts-Mills and
others 1997).
Most of the 46 species of Pyroglyphidae are nest-dwellers or feather-associates of
birds (Wharton 1976), and only 13 are recorded from house dust, ofwhich six,
Dermatophagoides pteronyssinus, Dermatophagoidesfarinae, Hirstia domicola,
Malayoglyphus intermedins, Malayophyghus maynei, and Euroglyphus maynei have
been recorded in temperate human habitats repeatedly and throughout the world.
Another two species have more limited distributions, Dermatophagoides siboney, so
far restricted to Cuba, and Dermatophagoides microceras (frequently misidentified
as Dermatophagoidesfarinae), predominantly found within Europe. In tropical
climates, the storage mite Blomia tropicalis (family Glycyphagidae) can be a
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prevalent mite in dwellings (Fernandez-Caldas and others 1993), along with other
Pyroglyphid mites.
1.6.2 Increasing exposure to house dust mites
The increased prevalence ofAD seen over the past several decades may relate to
increasing exposure to dust mite allergens due to changes in Western lifestyles and
housing conditions. Mite growth and proliferation are dependent on several factors,
particularly temperature and humidity. Features ofmodern housing such as
insulation, central heating and reduced ventilation have raised indoor temperature
and humidity, which significantly increases the level ofmite infestation in homes
(Munir and others 1995; Hirsch and others 2000).
1.6.3 The importance of Dermatophagoides species house dust
mites
The most important allergy-causing mites found in homes worldwide are the house
dust mites Dermatophagoidesfarinae, Dermatophagoides pteronyssinus,
Euroglyphus maynei, and the storage mite Blomia tropicalis (Arlian and others 2002).
It has been shown that most homes contain multiple mite species, and the most
prevalent mite species and allergens in homes differ geographically, between homes
within a geographical region, and among areas within a home (Arlian and others
1992). Information regarding the mite species present in a geographical area is
crucial when performing diagnostic testing and prescribing immunotherapy.
The name Dermatophagoides is derived from the Greek words dermis meaning
'skin', phagos, referring to feeding, and the suffix -oides meaning 'to look like', and
it roughly translates as 'thing that looks like those that eat skin.' D. pteronyssinus
prefers more humid conditions, and D. farinae is most common in dry continental
climates. Data from intradermal and serological testing suggest that D. farinae is the
most common antigen implicated in canine atopic dermatitis in the UK (Sture and
others 1995a; Nuttall and others 2001b; Foster and others 2003), Europe (Noli and
others 1996; Bensignor and Carlotti 2002), the USA (Hillier and others 2000; Zur
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and others 2002a), Australia (Mueller and others 2000) and Japan (Yamashita and
others 2002). However, studies investigating house dust mite species found in
British homes rarely identify the presence ofD.farinae (Eaton and others 1985;
Colloff 1987; Young and others 1990; Hart and Whitehead 1990; Chen and others
2002b; Jackson and others 2005; Raffan and others 2005; Nuttall and others 2006).
The high proportion of positive intradermal and serological reactions to D. farinae in
CAD from geographical areas where prevalence and exposure is very low requires
further work to clarify whether this reflects true hypersensitivity to D. farinae or
whether cross-reactivity to other allergens is occurring (Jackson and others 2005).
1.6.4 Dermatophagoides species allergens
1.6.4.1 Allergens relevant to humans
Allergens from the house dust mites Dermatophagoidesfarinae and
Dermatophagoidespteronyssinus are major environmental trigger factors for atopic
dermatitis in human (Thomas and Smith 1999). More than 17 different
Dermatophagoides allergens have been identified (Table 1.2). The group 1 (cysteine
proteases) and 2 allergens are recognised to be of primary importance because of
their high IgE-binding frequency (Chua and others 1988; Dilworth and others 1991)
and can account for much of the allergenicity of extracts. The groups 3 (trypsin), 6
(chymotrypsin) and 9 (collagenase) family members are serine proteases which
provoke hyper-reactivity as well as tissue inflammatory reactions (Yasueda and
others 1993; Smith and others 1994; Nishiyama and others 1995; King and others
1996; Bennett and Thomas 1996; Kawamoto and others 1999). The groups 4
(amylase), 5, 7, 8 (glutathione S-transferase (GST)), and 10 (tropomyosin) members
have been identified as additional major allergens (Lake and others 1991; O'Neill and
others 1994; Lin and others 1994; Shen and others 1995; Aki and others 1995; Mills
and others 1999). Recent studies on high-molecular size allergens have elucidated
new major antigens including the groups 11 (paramyosin, 98 kDa), 14
(apolipophorin-like 177 kDa molecule) and 15 (chitinase-like protein, identified
using canine IgE) (Fujikawa and others 1998; Tsai and others 1999; Epton and others
1999; McCall and others 2001).
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Although many proteins produced by Dermatophagoides mites induce IgE antibody,
the majority of the allergenic activity resides in a small number of dominant
allergens. Frequently, over 50% of the IgE binding activity of mite extracts could be
attributed to the group 1 and 2 allergens (Chapman and others 1980; van der Zee and
others 1988). However, recent studies suggest that 13 allergens of
Dermatophagoides mites elicit IgE response in more than 40% of mite allergic
humans (Thomas and Smith 1999). Further research is required to clarify the
importance of individual allergens.
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1.6.4.2 Allergens relevant to dogs
Dermatophagoides species are equally important in causing atopic dermatitis in dogs
(Sture and others 1995a). The spectrum of Dermatophagoides allergens relevant to
dogs is less clear, but the low molecular weight molecules defined as major allergens
for humans do not appear to be major allergens for dogs. Studies using anti-canine
IgGd (Noli and others 1996), anti-canine IgE (Nuttall and others 2001b) and
recombinant FceRIa (Shaw S.C. 2000; McCall and others 2001) detected major
allergens of 60±70 kDa and 90±109 kDa on Western blots ofD. farinae and D.
pteronyssinus. However, although 69 per cent of atopic sera also recognised Der f 1
using FcsRIa in one study (McCall and others 2001), others detected very little
binding to group 1 and 2 allergens using either FcsRIa (Shaw S.C. 2000), anti-canine
IgE (Nuttall and others 2001b) or anti-canine IgGd (Noli and others 1996). Another
study using anti-canine IgE reported that 45 per cent of atopic sera recognised both
Der p 1 and 2 and Der f 1 and 2 (Masuda and others 1999). These conflicting results
could arise from the variable purity of the allergen preparations (Le Mao and others
1998) and specificity and sensitivity of different antisera (Steward and Male 1998).
The major Dermatophagoides allergen in canine AD has recently been cloned,
expressed and named Der f 15 (McCall and others 2001). The majority of atopic dog
sera also recognised 98/109 kDa allergens in D. pteronyssinus (Shaw S.C. 2000).
Another 60-kDa major Dermatophagoides protein (Der f 18) (Weber and others 2003)
is also important in canine AD and is recognised in 57 % to 77 % of dust mite-
sensitised dogs. Both Der f 15 and Der f 18 are homologous to insect chitinases and
are located in the mite gut suggesting it has a function in the digestion rather than in
moulting (McCall and others 2001; Weber and others 2003). The importance of
other mite allergens in the involvement of canine AD remains the subject of intensive
study.
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1.7 The role of B cells and immunoglobulins in atopic
dermatitis
The typical sequence of events in atopic dermatitis consists of exposure to an antigen,
activation of T cells specific for the antigen, production of IgE antibody, binding of
the antibody to Fc receptors ofmast cells, and triggering of the mast cells by re-
exposure to the antigen, resulting in the release of mediators from the mast cells and
the subsequent pathologic reaction (Abbas and Lichtman 2003). The
pathophysiology involves a complex series of interactions between resident and
infiltrating cells orchestrated by pro-inflammatory cytokines and chemokines
(Boguniewicz and Leung 2006).
1.7.1 IgE
IgE antibody is responsible for sensitising mast cells and provides recognition of
antigen in allergy. FcsRI is an IgE receptor expressed mainly on mast cells and
basophils, but it is also found on Langerhans cells. The affinity of this receptor for
IgE is extremely high (Kd > 10"10 M), and therefore it readily binds monomeric IgE
molecules even at the low normal plasma concentrations of this antibody isotype.
Another IgE receptor with lower affinity (Kd > 10"7 M) termed FceRII / CD23 has
been found on human B lymphocytes, monocytes and eosinophils but its role in
atopic dermatitis is less clear.
The high-affinity IgE receptor expression facilitates ingestion of allergens by
Langerhans cells via FcsRI-mediated uptake. It has been shown that Langerhans
cells in the lesional skin of human patients with atopic dermatitis display up
regulated expression of FcsRI (Stingl and Maurer 1997; Kraft and others 1998) and
that Langerhans cells from AD skin lesions are 1000-fold more efficient in
presenting house dust allergen to T cells than are Langerhans cells that lack surface
IgE (Maurer and others 1995).
In addition to assisting allergen presentation, IgE antibody also plays a pivotal role at
the effector level through the binding to FcsRI on mast cells, basophils and
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eosinophils. Upon re-exposure to offending allergen, IgE cross-linking of FcsRI+
cells by specific antigens results in the release of variety of preformed (e.g. histamine,
etc.) and de novo synthesized chemical mediators (e.g. peptide leukotrienes,
prostaglandins, etc.) (Marone and others 1986; Marone and others 1987), and
cytokines (Brunner and others 1993; Li and others 1996) that exert their effects by
interacting with specific receptors on target organs (Vigorito and others 1986;
Marone and others 1988). Cross-linking of surface IgE by allergen, furthermore,
induces FceRI and IgE synthesis (Helm and others 1998).
Serum IgE concentrations increase from the age of 1 year to 4 years and then plateau,
which coincides with the peak age of onset of atopic dermatitis in dogs (Racine and
others 1999). Female dogs have significantly higher mean IgE concentrations than
do male dogs (Racine and others 1999), while in humans higher mean IgE values are
observed in males than in females (Warren and others 1982; Omenaas and others
1994). However, no consistent female bias in atopic dermatitis has been found (Scott
and others 2001).
1.7.1.1 Total serum IgE in atopic dermatitis
Total serum IgE concentrations are elevated in 43% to 82% of human patients with
AD (Juhlin and others 1969; Johnson and others 1974). Although serum IgE has a
short half life of 5 to 7 days, the levels do not fluctuate in close association with
clinical flares and remissions (Johansson and others 1970). When severe AD is
treated with systemic steroids, the clinical improvement that ensues is not
accompanied by a decrease in the serum level of IgE. The IgE level returns to
normal when patients with a history of severe dermatitis have been free from their
disease for at least 2 years (Johansson and others 1970).
In dogs however, although serum IgE concentrations are considerably greater than
those in humans (Hammerberg and others 1997), there is no significant difference
between dogs with AD and clinically normal controls (Wilkie and others 1990; Hill
and others 1995; Jackson and others 1996; Fraser and others 2003) and measurement
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of total serum IgE would be of no benefit in the preliminary clinical investigation of
a suspected atopic dog (Hill and others 1995). Various authors have speculated as to
the reason for these differences between dog and humans and it is currently assumed
that greater exposure of the canine population to parasites accounts for this
discrepancy.
1.7.1.2 Allergen-specific IgE in atopic dermatitis
Levels of allergen-specific IgE are frequently elevated in human and canine atopic
dermatitis and are considered a hallmark of the disease (Leung 2000; Halliwell and
DeBoer 2001). Serological or skin tests detecting allergen-specific IgE are routinely
used to identify allergens for avoidance or specific immunotherapy (Scott and others
2001). However, the absolute requirement for IgE is questioned. Two forms ofAD
have been delineated in humans, including an extrinsic form associated with IgE-
mediated sensitisation involving 70% to 80% of patients and an intrinsic form
without IgE-mediated sensitisation involving 20% to 30% of the human patients
(Novak and others 2003b). Allergen-specific IgE is also present in healthy humans
and dogs and the titres do not fluctuate consistently during exacerbations, remissions
or treatment, suggesting that heterogeneous IgE antibodies with variable receptor
binding affinities might exist (Halliwell and others 1998; Marone and others 1999;
Griot-Wenk and others 1999). The presence of positive skin tests in some healthy
individuals though (Halliwell and others 1998; Lian and Halliwell 1998), suggests
that other tolerogenic mechanisms arc also present.
1.7.1.3 House dust mite specific IgE in atopic dermatitis
The biochemical and IgE binding characteristics of the known house dust mite
allergens in humans are summarised in Table 1.3 (Thomas and others 2002). There
is extensive structural and immunochemical data on the group 1 and 2 allergens, and
more than 80% ofmite-allergic patients have IgE antibodies to these proteins. IgE to
the group 1 and 2 allergens appears to be very dominant in the allergic response of
children. It has been shown that children attending an allergy clinic had strong IgE
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binding to Der p 1 and 2 and sporadic responses to 1-3 additional allergens, whereas
adults presenting at a clinic for allergy diagnosis had lower IgE binding to Der p 1
and 2 but recognised a diverse array of allergens (O'Brien and Thomas 1994).
Similar phenomenon with bands equivalent to Der f 2 predominating in very young
patients have also been demonstrated (Shibasaki and others 1994). While IgE
binding to the group 1 and 2 allergens is high, the responses to other allergens must
be considered. The report by van der Veen et al (van der Veen and others 2001)
which showed that whole extract induced far stronger late phase reactions than a
mixture of Der p 1 and 2, despite a similar early response, is evidence for this.
Knowledge on major or important mite allergens has to be accumulated to elucidate
their crucial roles in allergen sensitisation and provocation, as well as to enable
effective allergy diagnosis and vaccines to be developed.
Major allergens of D. farinae to dogs are of 60-70 kDa and 90-109 kDa on SDS-
PAGE (Noli and others 1996; McCall and others 2001; Nuttall and others 2001b),
and they have recently been identified and characterised as Der f 18 (Weber and
others 2003) and Der f 15 (McCall and others 2001) respectively. The majority of
dogs with IgE specific for D. farinae also have IgE to Der f 15 chitinase. In one
study, 95% (40 of 41) of naturally sensitised atopic dogs and 100% of experimentally
sensitised laboratory beagles had positive IgE response for the high molecular weight
98/109 kDa allergen (McCall and others 2001). Der f 18-specific IgE was detected
in 57% to 77% ofD. farinae-sensitised dogs (Weber and others 2003). Both Der f
15 and Der f 18 are homologous to chitinase molecules and are both localised to the
mite gut, suggesting a role in digestion other than moulting (McCall and others 2001;
Weber and others 2003).
Most previous studies demonstrated little to no IgE binding to either low molecular
weight allergens in crude Dermatophagoides extracts or purified group 1 and 2
allergens in dogs (Shaw S.C. 2000; McCall and others 2001; Nuttall and others
2001b). However, a study from Japan reported that at least 38% of atopic dog sera
recognised Der p 1 and Der p 2, and 44% of samples recognised Der f 1 and Der f 2
in ELISAs and dot blots using monoclonal anti-canine IgE (Masuda and others 1999).
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It might be possible that the spectrum of reactive allergens may differ between
Japanese and European or US dogs (Nuttall and others 2006). The discrepancy could
also arise from impurity of the allergen preparations (Le Mao and others 1998) and
specificity and sensitivity of different antisera (Steward and Male 1998).
Identification and characterisation of the full repertoire ofmite allergens will be an
important step toward understanding their decisive roles in allergic sensitisation,
improving diagnostic agents, and developing immunotherapeutic vaccines. Why
humans and dogs respond to different allergenic components of house dust mites
remains to be determined.
1.7.2 IgG and IgG subclasses
Immunoglobulins (Ig) are effector molecules of the humoral immune response and
production of an Ig specific for a foreign molecule is the primary event responsible
for recognition of an antigen. They are classified into one of five heavy (H) chain
isotypes: IgM, IgG, IgE, IgD or IgA and in most species IgG antibodies can be
further subdivided into four subisotypes (or subclasses) (Table 1.4). Each subisotype
has a distinct effector function, such as the ability to cross the placenta, activate
complement, respond to different types of antigen or bind to Fc receptors (Table 1.5).
The IgG subclasses in humans are named in order of their abundance in serum, with
IgGl being the most abundant.
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Table 1.3 IgE binding frequency to house dust mite allergens in humans1
Group Species2 IgE binding
1 Dp, Df, Dm, Ds, Em 80-100
2 Dp, Df, Ds, Em, Ld, Tp, Gd, As 80-100
3 Dp, Df, Ds, Em 16-100
4 Dp, Em 40-46
5 Dp, Bt, Ld 50-70
6 Dp, Df 40
7 Dp, Df, Ld 50
8 Dp 45
9 Dp 90
10 Dp, Df 50-95
11 Df, Bt 80
12 Bt 50
13 Bt, Ld, As 10-23






1 based on the table in Thomas and others 2002.
2
Allergen described for the species designated by initials: Dermatophagoides
pteronyssinus, Dermatophagoidesfarinae, Euroglyphus maynei, Dermatophagoides
siboney, Dermatophagoides microceaus, Lepidoglyphus destructor, Blomia
tropicalis, Tyrophagus putrescentiae, Glycophagus domesticus, Acarus siro.
3
Binding frequency (% patients, variation due to patient selection).
Table 1.4 IgG subclasses in various species
Species Human Dog Mouse Rat Rabbit Chicken
Subclass IgGl IgGl IgGl IgGl IgG IgG
IgG2 IgG2 IgG2a IgG2a
IgG3 IgG3 IgG2b IgG2b
IgG4 IgG4 IgG3 IgG2c
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Table 1.5 Properties of human IgG subclasses1
IgGl IgG2 IgG3 IgG4
Physiochemical properties
Heavy chain yl y2 y3 y4
Molecular mass (kDa) 146 146 170 146
Amino acids in hinge region 15 12 62 12
Inter-heavy chain disulfide bonds
(in hinge region)
2 4 11 2
Susceptibility to proteolytic
enzymes
++ +/- +++ +
Biological properties










Half-life (days) 21 20 7 21
Placental transfer +++ + ++ +/-
Classical pathway of complement
activation
++ + +++ -
Alternative pathway of
complement activation
- - - -
Reactivity to proteins ++ +/- ++ +/-
Reactivity to polysaccharides + ++ (-) (-)
Reactivity to allergens + (-) (-) ++
Binding to Fcyl (CD64) ++ - +++ +
Binding to Fcyll (CD32) ++ (2) +++ -
Binding to Fcylll (CD 16) ++ - ++ -
Functional valency 2 2 2 1
Meulenbroek and Zeijlemaker 1996
2: FcyRII allotype dependent
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The IgG subclass distribution in specific antibody responses has been found to vary
with structure of the antigen (nature of carrier, number and nature of the epitopes,
physicochemical properties), its dose and route of entry, as well as with genetic
constitution of the host (Meulenbroek and Zeijlemaker 1996). Whereas antibodies
against bacterial and viral protein antigens such as tetanus toxoid or outer-membrane
components, which are T cell-dependent antigens, can be detected in all four IgG
subclasses, IgGl is the prevailing isotype and IgG2 generally provides only a
marginal contribution (Ferrante and others 1990). On the other hand, IgG antibodies
against polysaccharide antigens, which are usually T cell-independent, generally
exhibit a much more pronounced subclass distribution. It has been shown that
immunisation with encapsulated bacteria (e.g.: Haemophilus influenzae and
Neisseria meningitidis) leads to an almost exclusive IgG2 anti-polysaccharide
response (Siber and others 1980). Repeated, long-term antigenic stimulation with T
cell-dependent antigens may lead to a marked IgG4 antibody response (Aalberse and
others 1983).
The binding of IgG subclasses to antigen can result in direct inactivation of
infectious agents by blocking of functional sites with enzymatic or receptor binding
activity. More importantly IgG antibodies aggregated by antigen can interact with
other components of the immune system by either activating the complement cascade
or by binding to Fey receptors on various cell types (Clark 1995; Male and others
1996; Janeway and others 1999). Both of these processes can assist in the
opsonisation of antigen and in the triggering of inflammation and the enhancement of
an immune response against an infectious agent (Male and others 1996; Janeway and
others 1999). The four IgG subclasses differ from each other with respect to their
effector function (Table 1.5). This difference is related to differences in structure,
notably with respect to the interaction between the variable, antigen-binding Fab-
fragments and the constant Fc fragment. In particular, the length and flexibility of
the hinge region are different. The capacity of the four human IgG subclasses to
activate complement via the classical pathway decreases in the order: IgG3 > IgGl >
IgG2 > IgG4 (Meulenbroek and Zeijlemaker 1996). Phagocytosis is initiated by an
interaction between the Fc fragment of the Ig and receptors, and Fc receptors for IgG
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(FcyR) are expressed primarily on effector cells of the immune system including
macrophages, monocytes, myeloid cells and dendritic cells. The four human IgG
subclasses show differences in their interaction with FcyR's. Binding of the Fc part
of IgG to a FcyR is instrumental in the induction of the cell's effector function;
therefore, FcyR's play a key role in bridging IgG antibody activity and cellular
effector mechanisms. The latter comprise phagocytosis, endocytosis, antibody-
mediated cellular cytotoxicity, release of a range of inflammatory mediators, antigen
presentation and clearance of immune complexes. Moreover, since several FcyR-
bearing cell types have the capacity to present antigens to T lymphocytes, FcyR-
induced phagocytosis also plays a role in antigen presentation and amplification of
the immune response. The ability of the four IgG subclasses to initiate opsonisation
via binding to FcyRI and FcyRII decreases in the order: IgG3 > IgGl » IgG4 and
IgG3 > IgGl > IgG2 respectively (Meulenbroek and Zeijlemaker 1996). The
binding of IgG subclasses to FcyRIII is restricted to IgGl and IgG3 (Huizinga and
others 1989; Parren and others 1992).
The role of IgG antibody in atopic dermatitis is controversial and paradoxical.
Evidence supporting and refuting the involvement IgG and IgG subclasses in AD
will be discussed in detail in chapters 3 and 4.
1.8 The role of T-cells and cytokines in atopic dermatitis
1.8.1 Recruitment and activation of naive T cells
T cell responses are initiated in the T cell areas of secondary lymphoid organs where
nai've T cells encounter antigen-loaded dendritic cells (Banchereau and Steinman
1998). Skin-selective homing for effector and memory T cells represents an
immunologic event in the pathogenesis ofAD. The cutaneous lymphocyte-
associated antigen (CLA) is a cell surface molecule preferentially found on T
lymphocytes present in the skin. CLA interacts with the vascular receptor E-selectin,
an adhesion molecule that is induced in endothelial cells under inflammatory
conditions (Picker and others 1991), which forms the basis of the selective and
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immediate recruitment ofCLA+ T cells into the skin on invasion of allergens
(Trautmann and others 2001; Akdis and others 2002).
The expansion and differentiation of nai've (CD45RA+ in humans) CD4+ T cells is
triggered by the binding of allergen/MHCII complexes on antigen presenting cells
(APCs) (i.e. dendritic cells) to allergen-specific TCR/CD3 complexes in combination
with costimulators. The binding between the T cell surface molecule CD28 with
costimulatory molecules B7-1 (CD80) and B7-2 (CD86) expressed on activated
APCs as well as the interaction ofCD40L on T cells with CD40 on APCs provides
essential signals for differentiation into activated (CD45RO+ in humans) CD4+ T
cells (Delves and Roitt 2000). When an immune response is initiated, naive helper T
cells produce IL-2 and proliferate. After entering the cell cycle, progeny become
competent to produce effector cytokines such as IFN-y (the signature of Thl cells) or
IL-4, IL-5 and IL-13 (the signature of Th2 cells) (Bird and others 1998). The
propensity of an individual to mount a Thl or Th2 response depends upon several
factors, including the cytokine environment in which T-cell development takes place,
the genetic background of the host, pharmacologic factors, and the costimulatory
signals involved in T-cell activation.
1.8.2 T lymphocyte subsets
Two distinct CD4+ T cells (helper T cells) subsets were first described in a detailed
analysis ofmurine T-cell clones; one clone produced IL-2, IFN-y, tumor-necrosis
factor (TFN)-a, lymphotoxin-a and the other produced IL-4, IL-5, IL-6 and IL-13
(Mosmann and others 1986; Abbas and others 1996). These two populations were
termed Thl and Th2 cells, respectively. Since then Thl and Th2 cells have also been
found in humans and other species (Romagnani 1991; Maggi 1998).
Although individual cells may exhibit complex and quite heterogeneous patterns of
cytokine production, it is customary to define CD4+ T cells that have differentiated to
produce IL-4 but not IFN-y as Th2 (or Th2-like) cells and those that produce IFN-y
but not IL-4 as Thl (or Thl-like) cells (Maggi 1998). Each T-cell subset produces
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cytokines that serve as its own autocrine growth factor and promote differentiation of
nai've T cells to that subset. Also, the two subsets produce cytokines that cross-
regulate each other's development and activity (Fiorentino and others 1989; Fitch
and others 1993). The net result of cytokine-mediate self-amplification and cross-
regulation is that once a T-cell immune response begins to develop along one
pathway, namely Thl or Th2, it tends to become progressively polarised in that
direction (Abbas and others 1996).
Recently, another T-cell subset that can inhibit T cell responses in vitro and in vivo
and can prevent and ameliorate autoimmunity in several animal models has been
described (Sakaguchi and others 1995; Shevach 2002). These cells have been named
as T regulatory (Treg) cells. Natural Treg cells and adaptive Treg cells have been
described, and both are antigen-specific, but they exert their regulatory activity in a
non-specific way, which may be based on cell-to-cell contact, or the release of
immuno-regulatory cytokines, such as transforming growth factor (TGF)-(3 or IL-10
(Chen and others 1994; Roncarolo and others 2001; Bluestone and Abbas 2003).
1.8.2.1 Thl responses
Thl cells secret IFN-y, IL-2 and tumor necrosis factor (TNF)-a, which promote
macrophage activation, production of opsonising and complement-fixing antibodies,
antibody-dependent cell cytotoxicity (ADCC) and delayed-type hypersensitivity
(DTH) reactions (Mosmann and Coffman 1989; Abbas and others 1996). The
principal function of Thl cells is to elicit phagocyte-mediated defence against
infections, because Thl cytokines promote the ability ofmacrophages to
phagocytose as well as destroy microbes (Abbas and others 1996). However, if the
Thl response is not effective in eradicating infectious agents or excessively
prolonged, it may become dangerous for the host, due to both the activity of
cytotoxic cytokines and the strong activation of phagocytic cells (Maggi 1998).
Some Thl cells acquire cytolytic capacity, and the cytokines produced by Thl cells,
notably IL-2 and IFN-y, promote the differentiation ofCD8+ T lymphocytes into
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active cytotoxic cells. This is another way in which the Thl subset participates in the
elimination of intracellular microbes (Abbas and others 1996).
The signature cytokine ofThl cells, IFN-y, has two key functions. First, it enhances
the microbicidal function ofmacrophages by stimulating the synthesis ofphagocyte
oxidase and inducible nitric oxide synthase (iNOS) to kill phagocytosed microbes
(Hibbs, Jr. and others 1988; Jungi and others 1996). Second, IFN-y stimulates B
cells to produce certain IgG subclasses, such as IgG2a in mice (Finkelman and others
1988; Coffman and others 1993), which bind to high-affinity Fey receptors and
complement proteins and are therefore the principal antibodies involved in the
opsonisation and phagocytosis of particulate microbes. IFN-y can also up-regulate
expression of class I and class II MHC molecules and costimulators on APCs
(Restifo and others 1993; Seliger and others 2000). Finally, it can also inhibit
switching to IL-4-dependent isotypes, such as IgE and IgGl in mice, or its
homologue, IgG4, in humans (Coffman and others 1993). The net effect of these
activities of IFN-y is to promote macrophage-rich inflammatory reactions while
inhibiting IgE-dependent eosinophil-rich reactions.
IL-12 stimulates the differentiation ofCD4+ helper T lymphocytes into IFN-y-
producing Thl cells and the equilibrium between IL-12 and IL-4 is important for the
balance between Thl and Th2 responses. Activated mononuclear phagocytes and
dendritic cells are the physiologically most relevant producers of IL-12 (Chehimi and
Trinchieri 1994). IL-12 induces IFN-y production from resting and activated NK and
T cells (Kobayashi and others 1989; Chan and others 1991; Chehimi and Trinchieri
1994). It has an important role in the host resistance to infection, in particular to
intracellular pathogens, by activating macrophages through induction of IFN-y from
NK and T cells and by enhancing cell-mediated immune responses, dependent on
Thl cell development. It also can enhance the cytolytic functions of activated NK
cells and CD8+ cytolytic T lymphocytes (CTLs). Being produced during early innate
immune reactions against intracellular microbes and stimulating adaptive immune
responses that protect the host against these microbes, IL-12 is an important link
between innate and adaptive immunity (Abbas and Lichtman 2003).
34
IL-2, produced by T cells on antigen recognition, is responsible for the proliferation
and differentiation of antigen-specific cells (Blackman and others 1986; Farrar and
others 1986). It exerts its actions through the binding of high-affinity receptors (IL-
2R) in an autocrine, paracrine and perhaps endocrine fashion (Smith 1988). Non¬
polarised T cells can be expanded with IL-2 and retain the capacity to differentiate
into either Thl or Th2 when re-stimulated under polarising conditions (Sad and
Mosmann 1994). However, repeated activation of CD4+ T cells in the presence of
IL-2 makes these cells sensitive to apoptosis by the Fas pathway (van Parijs and
others 1996).
The major cellular source of TNF-a is activated mononuclear phagocytes, although
antigen-stimulated T cells, NK cells and mast cells can also secrete this protein
(Bradding and others 1994; Kobayashi and others 2000). The principal physiologic
function ofTNF is to stimulate the recruitment of neutrophils and monocytes to sites
of infection and to activate these cells to eradicate microbes (Abbas and Lichtman
2003). In severe infections, TNF is produced in large amounts and causes systemic
clinical and pathologic abnormalities (Abbas and Lichtman 2003). TNF is strongly
pro-inflammatory and a disease-related increase in the number of cells expressing
immunoreactivity for TNF in asthmatics was observed (Kobayashi and others 2000).
TNF can also increase the activity of dendritic cells (Skok and others 1999) but
inhibits mast cells and FcsRI expression (Rossi and others 1998).
1.8.2.2 Th2 responses
The principal effector function of Th2 cells is in IgE-mediated and eosinophil / mast
cell-mediated immune reactions. IL-4, IL-5, IL-6 and IL-13, produced by Th2 cells,
promote mast cell and eosinophil growth, differentiation and activation, and provide
optimal help for IgE and non-opsonising and complement fixing IgG (Abbas and
others 1996; Maggi 1998). In addition, some Th2-derived cytokines, such as IL-4
and IL-13 inhibit several classical macrophage functions (Mosmann and Coffman
1989) while IL-13 also induces adhesion molecules on endothelial cells (Thornhill
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and others 1990; Howells and others 1991; Sironi and others 1994; Till and others
1997). Th2 responses are less damaging to the host under normal circumstances;
furthermore, Th2 cells may appear late in immune responses, and serve to limit the
injurious consequences of Thl-mediated protective immunity (Abbas and others
1996).
IL-4 is the major inducer ofB-cell switching to IgE production and is therefore a key
initiator of IgE-dependent, mast cell-mediated reactions (Galli 1993). It is essential
for the development of Th2 cells from nai've CD4+ T cells and functions as an
autocrine growth factor for differentiated Th2 cells (Seder and Paul 1994; Paul and
Seder 1994). IL-4 exerts anti-inflammatory action by antagonising the macrophage-
activating effects of IFN-y and thus inhibits cell-mediated immune reactions (Xiao
and others 2003).
IL-5 is the principal eosinophil-activating cytokine (Wardlaw and others 1995) and
serves as the link between T cell activation and eosinophilic inflammation. The
major actions of IL-5 are to activate mature eosinophils and stimulate the growth and
differentiation of eosinophils (Lopez and others 1988; Sanderson 1992; Rothenberg
and Hogan 2006), which are crucial in late phase inflammatory responses. IL-5 also
supports IgE synthesis by IL-4 stimulated B cells and enhances basophil histamine
release (Lalani and others 1999).
In relation to eradication of helminth infection, the two main Th2 cytokines, IL-4 and
IL-5, function in concert: IL-4 stimulates production of IgE, which opsonises
helminth and binds eosinophils, and IL-5 activates the eosinophils to destroy the
parasites (Abbas and Lichtman 2003).
IL-13 is another important Th2 cytokine and shares many of its biologic activities
with IL-4 because IL-4R and IL-13R complexes share the IL-4Ra chain required for
signal transduction. However, it is unable to drive the differentiation of naive CD4+
T cells into a Th2 phenotype, and it does not support the proliferation of activated T
cells either (Sornasse and others 1996). It has been shown in mouse models that IL-
36
13 is a central mediator in allergic asthma (Wills-Karp and others 1998; Grunig and
others 1998) and a key cytokine for Th2 cell-mediated reactions in the lung
(Chiaramonte and others 1999). In humans, IL-13 may affect T-cell functions and
Thl-cell differentiation indirectly through its down-regulatory effects on the
production ofpro-inflammatory cytokines, particularly of IL-12 by monocytes,
which direct Thl development (de Vries 1998). Human IL-13 also plays an
important role in the regulation of Ig class switching, and enhances IgE production
(Chomarat and Banchereau 1997). Recombinant canine IL-13 can stimulate IgE
production by PBMCs isolated from dogs sensitised to flea allergens (Tang and
others 2001), suggesting that IL-13 is also an important mediator of IgE production
in canine allergic disease.
1.8.2.3 Regulatory T cells
Two groups ofTreg cells, natural Treg cells and adaptive Treg cells, have been
described (Bluestone and Abbas 2003). Natural Treg cells emerge from the thymus
during ontogeny as a population already dedicated to suppressing the response
against self-antigens (Sakaguchi and others 1995; Shevach 2002) and are
characterised by their CD4+ CD25+ phenotype. These cells have been suggested to
develop under the control of the transcription factor FoxP3 (Hori and others 2003).
Adaptive Treg cells also derive from the thymus but acquire suppressive activity in
the periphery and are devoted to regulate the response not only against self but also
against non-self antigens (Bluestone and Abbas 2003). Two distinct subsets of
adaptive Treg cells have been reported: type 3 T helper (Th3) cells that can be
induced by the oral administration of antigen (Chen and others 1994) and T
regulatory 1 (Trl) cells, which are induced by the administration of antigen in the
presence of IL-10 (Roncarolo and others 2001). Treg cells appear to exert their
regulatory effects via expression of inhibitory cell-surface molecules and/or by the
production of immuno-regulatory cytokines, such as IL-10 and TGF-P (Chen and
others 1994; Roncarolo and others 2001).
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IL-10 was originally termed cytokine synthesis inhibitory factor because it was
identified as a soluble factor able to inhibit cytokine secretion from mouse Thl cells
(Moore and others 1990). IL-10 has anti-inflammatory and suppressive effects on
most haematopoietic cells and participates in induction of peripheral tolerance
(Moore and others 2001). It indirectly suppresses T-cell responses by potently
inhibiting the antigen-presenting capacity of APCs, including dendritic cells,
Langerhans cells and macrophages. IL-10 down regulates expression ofMHC II and
co-stimulatory molecules such as CD54, CD80 and CD86 (Moore and others 2001).
IL-10 also potently inhibits the secretion of cytokines and chemokines by
macrophages, neutrophils, eosinophils, mast cells, keratinocytes, endothelial cells, as
well as APCs, which influence T-cell differentiation, proliferation and migration
(Moore and others 2001). In addition, IL-10 directly regulates T cells by inhibiting
their ability to produce IL-2, TNF-a (de Waal Malefijt and others 1993) and IL-5
(Schandene and others 1994) and to proliferate (Bejarano and others 1992; Taga and
others 1993). On the other hand, IL-10 also has many immuno-stimulatory effects
and can enhance the survival of human B cells and their differentiation into plasma
cells (Moore and others 2001). Furthermore, IL-10 inhibits T-cell apoptosis (Cohen
and others 1997) and has clear stimulatory effects on CD8+ T cells as it increases
their proliferation and cytotoxic activity (Groux and others 1998).
T cells are influenced by TGF-P at all stages of their development (Letterio and
Roberts 1998), and TGF-P inhibits T-cell proliferation, cytokine production and
cytotoxicity. However, it also has positive effects on T-cell function via inhibition of
T-cell apoptosis (Zhang and others 1995), enhancement of nai've T-cell proliferation
and induction of cytokines (Cerwenka and others 1994; Cerwenka and others 1996).
The effects of TGF-P on APCs can be stimulatory or inhibitory depending on the
presence of other cytokines, their state ofmaturation and levels of receptor
expression (Letterio and Roberts 1998). TGF-P is required for the differentiation of
Langerhans cells and can increase their viability (Borkowski and others 1996). Low
concentrations of TGF-p induce chemotaxis, expression of a variety of cytokines and
phagocytic activity ofmonocytes (Letterio and Roberts 1998). Additionally, TGF-P
suppresses IFN-y production, decreases MHC II expression and limits the production
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of nitric oxide and reactive oxygen intermediates by activated macrophages (Bogdan
and Nathan 1993; Letterio and Roberts 1998).
1.8.2.4 T cell subsets cytokine profiles
Whilst mouse CD4+ T-cell clones can be classified into distinct populations on the
basis of their patterns of cytokine production (Romagnani 1995), in human cells this
is much less so. Individual cells may exhibit complex and quite heterogeneous
patterns of cytokine production, with various combinations of IL-2, IL-4, IL-5, IFN-y,
IL-10 and TGF-J3 (Abbas and others 1996; Grewe and others 1998), suggesting that
the transcription and expression of different cytokine genes are regulated
independently. However, Thl (IFN-y-secreting) and Th2 (IL-4-secreting) polarised
responses can still be distinguished and the degree of polarisation and heterogeneity
of T lymphocytes may reflect the nature of the antigenic and environmental stimuli
to which the cells have been exposed (Abbas and others 1996; Maggi 1998) although
the expression of IL-2, IL-6, IL-10 and IL-13 is less restricted in humans
(Romagnani 1991; Romagnani 1995). In the absence of clear polarising signals,
CD4+ T cell subsets with a less restricted lymphokine profile than Thl or Th2 cells,
designated ThO, usually arise, that mediate intermediate effects depending on the
ratio of lymphokines produced and the nature of the responding cells (Maggi and
others 1988; Paliard and others 1988; Mosmann and Coffman 1989; Street and others
1990). Mixed (ThO) cytokine patterns are most noticeable early after lymphocyte
activation (Kelso 1995). The cytokine response of the single ThO cells can remain
unrestricted or further differentiate into a polarised Thl or Th2 pathway under the
influence of micro-environmental signals or because of a particular genetic
background (Seder and Paul 1994).
1.8.2.5 Antagonism of Thl and Th2 responses
While IL-4 inhibits the development of Thl cells, IFN-y inhibits the development of
Th2 cells (Romagnani 1994; Abbas and others 1996). Moreover, the expression of
transcription factor GATA-3, which allows the differentiation of Th2 cells, inhibits
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Thl development; conversely, expression of transcription factor T-bet, which allows
the differentiation ofThl cells, inhibits Th2 development (Rengarajan and others
2000). Transcription factors expressed by, and cytokines released from, Thl or Th2
cells exert a mutual antagonistic effect on the development of the other subset.
1.8.3 The Th1/Th2 hypothesis in atopic dermatitis
1.8.3.1 Th2 cytokines in human atopic dermatitis
A considerable number of studies have associated human AD with Th2 polarisation.
Th2 cells produce IL-4 and IL-13 which stimulate IgE and IgG4 antibody production,
and IL-5 which recruits and differentiates eosinophils, thus explaining why the mast
cell/eosinophil/IgE-producing B cell triad is involved in the pathogenesis of allergy
(Romagnani 1994). The great majority of allergen-specific T-cell clones generated
from peripheral blood lymphocytes of atopic donors express a Th0/Th2 phenotype,
with high production of IL-4 and IL-5 and no or low production of IFN-y, whereas T
cell clones specific for bacterial antigens derived from the peripheral blood from the
same atopic donor show a prevalent Thl/ThO phenotype (Wierenga and others 1990;
Kapsenberg and others 1991; Yssel and others 1992; Ebner and others 1993). Skin-
derived Dermatophagoidespteronyssinus (DP)-specific Th2-like CD4+ T cell clones
were generated after contact challenge with DP (van Reijsen and others 1992).
Furthermore, the Th2 hypothesis in atopy is confirmed by studies on the effect of
allergen-specific immunotherapy (IT) on the cytokine profile of T cells. Decreased
production of IL-4 and increased production of IFN-y was observed in bee venom-
sensitised patients treated with specific IT (Jutel and others 1995; McHugh and
others 1995), and successful immunotherapy is associated with a shift from the Th2
seen in allergy towards a Thl response leading to a decline in allergen-specific IgE
and an increase in allergen-specific IgG production (Renz 1995; Smith and Sly 1998).
Most importantly, however, production of the immunosuppressive /
immunoregulatory cytokine IL-10 is also induced leading to T cell tolerance and
prevention of tissue inflammation (Bellinghausen and others 2001).
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Allergen-specific Th2 clones from PBMCs and the skin of atopic patients have been
isolated in various studies (Mudde and others 1992; Neumann and others 1996;
Punnonen and others 1997; Bohle and others 1998), and these Th2 cell clones secrete
large amounts of IL-4 and IL-5 but under-express IFN-y. In contrast, stimulation of
PBMCs with non-allergenic antigens expands non-polarised or Thl clones
(Romagnani 1998). There is a relatively consistent difference in the balance or ratio
of Thl to Th2 cytokines in atopics vs. non-atopics (Smith and Sly 1998).
Several studies proposed that Th2-type cells play a key pathogenetic role in AD
(Plaut 1990; Kay and others 1991; Bos and others 1992). The frequency of Th2
clones isolated from the skin usually exceeds that from PBMCs (Grewe and others
1998), suggesting there is either selective recruitment of Th2 cells or local in situ
Th2 differentiation in the skin. However, by analysing T-cell cytokine expression
during the development of atopy patch test lesions, a biphasic expression pattern is
observed (Grewe and others 1995; Thepen and others 1996). At relatively early time
points (24 h after allergen application), increased expression of IL-4 mRNA and
protein was observed, after which (48, 72 and 96 hours after allergen application) IL-
4 expression declined to background levels. By contrast, increased IFN-y mRNA
expression was not detected in 24 h patch-test lesions, but was strongly over-
expressed at later time points (48-72 h). These observations may be best explained
by a model in which the initiation ofAD is driven by activation of Th2-type cells,
whereas the chronic inflammatory reaction is dominated by a Thl-type response
(Grewe and others 1998).
It has also been found that early immunisation with the offending allergen is critical
for the initiation of immunological changes resulting in the development of atopy.
The selective development of a Th2 cytokine profile in high-risk children who
develop atopy is due to increased production of Th2 cytokines, possibly caused by
impaired allergen-induced IFN-y production in the neonatal period (van der Velden
and others 2001). Furthermore, the decreased allergen-induced IL-10 levels
observed in the atopic children at 12 months of age may result in a lack of down-
regulation of the inflammatory process (van der Velden and others 2001).
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1.8.3.2 Thl cytokines in human atopic dermatitis
Thl-type cytokines are also expressed in atopic patients. Chronic AD skin lesions
have significantly fewer IL-4 and IL-13 mRNA-expressing cells, but greater numbers
of IL-5, IL-12 and IFN-y mRNA-expressing cells than in acute AD (Grewe and
others 1998; Leung and others 2004). Moreover, increased in situ expression of the
Th2-type cytokines was observed together with increased expression of the Thl-type
cytokine IFN-y within identical involved skin areas of the same patients (Grewe and
others 1994; Ohmen and others 1995). Furthermore, peak levels of IFN-y mRNA
expression was present at 48-72 hours after allergen application in atopy patch tests
(Thepen and others 1996). Taken together, the data suggest that expression of Th2-
type and Thl-type cytokines in AD is not mutually exclusive, and that both Th-cell
subsets contribute to the pathogenesis of the disease (Grewe and others 1994; Ohmen
and others 1995; Hamid and others 1996; Morita and others 1997).
1.8.3.3 Treg cytokines in human atopic dermatitis
In addition to mutual antagonism of Thl and Th2 responses, regulation of the
immune system is also carried out by the activity of other T-cell types, which have
been named Treg cells. Treg cells are a highly heterogeneous family, which includes
type 3 Th (Th3) cells, T regulatory 1 (Trl) cells, and CD4+ CD25+ T cells. Th3 cells
mainly produce TGF-P and their regulatory function is attributable to TGF-P-
dependent mechanisms (Weiner 2001), whereas Trl cells are mainly able to produce
IL-10, with or without TGF-P (Roncarolo and others 2001). In contrast, CD4+
CD25+ T cells do not produce cytokines and act via a contact-dependent mechanism
(Suri-Payer and others 1998). Another feature of CD4+ CD25+ T cells is the
expression of the transcription factor Foxp3 (Fontenot and others 2003).
In both experimental animal models and humans, genetic alterations which heavily
hamper the development and/or the function of Treg cells can result in the
appearance ofmultiple and severe inflammatory disorders, including allergy
(Kanangat and others 1996; Chatila and others 2000; Curotto de Lafaille and others
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2001). Suppressive cytokines ofTrl cells, IL-10 and TGF-P, and receptors for these
cytokines are abundantly expressed in the skin ofAD patients whereas FoxP3+
CD25+ T cells are not present (Verhagen and others 2006). It seems that IL-10
produced by Treg cells acts mainly by shifting the allergen-specific antibody
production from the dangerous IgE to the protective IgG4 isotype rather than by
inducing a Th2-cell tolerance (Nouri-Aria and others 2004). It has been shown that
IL-10-secreting Trl cells can inhibit the allergen-specific proliferation of IL-4-
secreting Th2 as well as of IFN-y-secreting Thl cells. A previous study has also
demonstrated an over-expression of IL-10 in atopic skin in humans (Ohmen and
others 1995)
It has been proposed that the suppression of allergic disease following successful
ASIT is mediated by the production of IL-10 by Treg cells (Akdis and others 1998a).
TGF-P either secreted by or associated with the cell membrane of Treg cells is also
an attractive candidate to inhibit allergic responses (Singh and others 2001). For
both IL-10 and TGF-P, it may be critical that these cytokines are expressed in a
particular temporal and/or cellular context to achieve optimal immunotherapy and
minimise adverse effects (Verhagen and others 2006).
So far, the experimental evidence in favour of an important role of Treg cells on
dampening allergen-specific Th2 responses is still poor and contradictory, due to the
heterogeneity of Treg cells and to the incomplete knowledge of their origin and
function. In contrast, solid data published over the last few years has shown that
allergen-specific Th2 responses are subjected to the negative control of Thl -
polarising cytokines (IFN-y, IL-12), which are produced in response to chronic and
repeated stimulation of Toll-like receptors (TLRs) present on the cells of the innate
immune system (Braun-Fahrlander and others 2002; Romagnani 2004a). Therefore,
it is more likely that IL-12 or IFN-a-producing dendritic cells and IFN-y-producing
NK cells, and Thl cells themselves, play even more important regulatory effects on
allergen-specific Th2 responses than classic Treg cells (Romagnani 2004b;
Romagnani 2006).
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1.8.3.4 Cytokine expression in canine atopic dermatitis
Limited studies have been performed investigating the production ofThl and Th2
type cytokines in canine atopic dermatitis. Expression of T cell subset cytokines in
canine AD will be discussed in detail in chapter 6.
1.8.4 CD8+ cells in atopic dermatitis
Distinct subpopulations ofCD8+ T cells ( Tel / Tc2 / TcO cells) can be
compartmentalised along broadly similar lines to CD4+ T cells - with IFN-y
secretion representing Thl / Tel cells, IL-4 secretion representing Th2 / Tc2 cells
and an unrestricted cytokine profile representing ThO / TcO cells (Croft and others
1994; Noble and others 1995; Sad and others 1995; Kemeny 1998). The role of
CD8+ T cells in atopic dermatitis is still unclear and probably complex. Some
studies suggest a suppressive function of IFN-y-producing CD8+ T cells with
inhibition of IgE production and consequent down-regulation of allergic sensitisation
(McMenamin and Holt 1993; Renz and others 1994). In contrast, under certain
circumstances Tc2 CD8+ T cells are required for IgE responses and have been shown
to promote IgE class switching in vitro (Erard and others 1993; Le Gros and Erard
1994). Th2-like CD8+ T cells are present at sites of allergic inflammation (Gemou-
Engesaeth and others 1997; Ying and others 1997) but it is not clear if sufficient
antigen is available to activate them or the extent to which they contribute to allergic
inflammation (Kemeny 1998).
1.9 Immunological changes during allergen-specific
immunotherapy
Allergen-specific immunotherapy (ASIT) is the practice of administering gradually
increasing quantities of an allergen extract to an allergic subject to ameliorate the
symptoms associated with subsequent exposure to the causative allergen (Bousquet
and others 1998). It is a widely used therapeutic option for allergic diseases and is an
effective treatment of allergic rhinitis and venom anaphylaxis (Theodoropoulos and
Lockey 2000). The goal of immunotherapy is to alter the inappropriate
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immunological reactivity to innocuous environmental substances. Whereas the
symptoms of immediate and delayed type allergic reactions can be ameliorated by
various pharmacologic treatments, ASIT represents the only curative approach for
specific allergies (Akdis and Blaser 2000).
1.9.1 History of allergen-specific immunotherapy
Desensitisation and hyposensitisation, the terms most commonly used previously for
many years, refer to a reduction or loss of sensitivity (Anderson 2000), but these
terms do not reflect the mechanisms believed to be important, nor the agents being
used. Allergen immunotherapy as designated by a WHO position paper (Bousquet
and others 1998) or allergen-specific immunotherapy proposed by the American
College ofVeterinary Dermatology Task Force on Canine Atopic Dermatitis (Griffin
and Hillier 2001b) are more appropriate terms.
Almost a century ago, long before the immunopathological mechanisms that underlie
IgE-mediated allergy were understood, Noon (1911) immunised patients suffering
from pollen-induced hay fever with subcutaneous injections of pollen extracts (Noon
1911). Although this was based on the erroneous belief that seasonal hay fever
might be caused by a grass-pollen toxin, successful outcomes were recorded and
protection was found to last for at least one year after the treatment was discontinued
(Noon 1911; Valenta 2002). The first successful treatment using ASIT in a dog with
seasonal hay fever was also reported long ago (Wittich 1941). Since then, numerous
studies have been performed to analyse the underlying immunological and molecular
mechanisms as well as environmental factors and genetic background that influence
the development of allergy. However, due to the exceedingly complex interaction of
numerous immunological cells, molecules, cytokines and the influence of the
microenvironment, the immunological mechanisms by which ASIT achieves clinical
improvement are still incompletely understood.
The differentiation, phenotype and activity of allergen-specific T cells are controlled
by various allergen-specific factors, including antigen concentration (Secrist and
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others 1995), antigen conformation (Akdis and others 1998b) and the site of antigen
exposure (Constant and others 2000). Together with the finding that the profile of
allergens and epitopes that are recognised by IgE does not change substantially
during the natural course of allergic disease (Ball and others 1999a), modulating
allergen-specific T cells using specific antigen is an excellent basis for the antigen-
targeted immunotherapy of allergy (Valenta 2002).
The most effective and frequently used form of allergen immunotherapy clinically is
injection immunotherapy (Bousquet and others 1998). It involves repeated
subcutaneous injections of increasing doses of allergen extract. Numerous clinical
studies have documented the efficacy of immunotherapy, but the underlying
immunological mechanisms remain a matter of controversy (Durham and Till 1998;
Bousquet and others 1998).
1.9.2 Potential mechanisms of ASIT
Most research into immunotherapy mechanisms has examined the effect of
subcutaneous immunotherapy rather than immunotherapy by alternative routes.
Mechanisms might have a degree of heterogeneity, reflecting variability in the types
of allergic diseases treated, different patient populations, the use of different
adjuvants, and the route, dose, and duration of treatment (Till and others 2004).
Proposed possible potential mechanisms ofASIT are summarised in Table 1.6.
1.9.2.1 Serum antibody responses
In 1935, more than 30 years before the characterisation of IgE antibodies, Cooke et
al provided the first insight into the mechanisms of injection immunotherapy by
showing that allergic patients who were treated by ASIT developed antibodies which
blocked allergen-induced inflammation (Cooke and others 1935). A few years later,
the factor was identified as IgG antibodies, and due to their ability to inhibit
immediate skin reactions to allergen provocation, were designated blocking
antibodies (Loveless 1940).
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Although quantitative changes in IgG antibody do not always correlate with clinical
protection (Djurup and Mailing 1987; Muller and others 1989; Ewan and others
2006), recent findings demonstrated clear involvement of those antibodies.
Immunotherapy induced IgG antibodies (mainly IgGl and IgG4) compete with IgE
for their binding sites on the allergen, reducing cross-linking of IgE on mast cells
(Mothes and others 2003) and basophils (Garcia and others 1993), thus inhibiting
release of histamine and other mediators. Blocking antibodies also strongly suppress
allergen-specific T cell responses in vitro by reducing CD23-dependent IgE-
facilitated allergen presentation by B cells to T cell clones, which might reduce Th2
activation and the subsequent release of Th2 cytokines (van Neerven and others 1999;
Wachholz and others 2003).
It has been found that a 10-50 times lower threshold amount of antigen is required
for the induction of IL-4 than for IFN-y (Carballido and others 1994). Increasing
antigen concentrations favours IFN-y production by T cells, whereas IL-4 decreases
at high antigen doses (Carballido and others 1994). Low antigen concentration and
suboptimal antigenic peptide-binding capacity ofMHC II molecules generate weak
T-cell activation, resulting in IL-4 dominated Th2 cytokine pattern and IgE
production (Akdis and Blaser 2000). Such regulatory effects of allergen
concentration on cytokine secretion may also reflect a physiologic mechanism in
ASIT in which repeated high allergen doses are injected over a longer period of time
(Carballido and others 1993; Blaser and others 1998).
1.9.2.2 T-Iymphocyte responses
1.9.2.2.1 Peripheral responses
Studies of patients being treated with venom or inhalant allergen immunotherapy
which examined cells isolated from peripheral blood demonstrated a reduction in
proliferative responses to allergen, with an overall deviation from a Th2 to Thl
response (Jutel and others 1995; Ebner and others 1997); but other studies have not
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reproduced these findings (Wachholz and others 2002; Francis and others 2003). A
possible explanation is that inhibition of peripheral T-cell proliferation and Th2
cytokine production is not the fundamental event in immunotherapy (Till and others
2004). In contrast, production of IL-10 in peripheral blood in response to
immunotherapy is highly consistent (Bellinghausen and others 1997; Akdis and
others 1998a). It has been demonstrated that allergen-induced IL-10 and TGF-(3
secretion by allergen-specific T cells occurs in parallel to a global suppression of Th2
proliferative responses and cytokine production (Jutel and others 2003).
Selective recruitment of allergen-specific T cells to allergic tissue sites in allergic
patients has been identified via CXCR1 on CD4+ cells, and CXCR1 expression on
circulating CD4+ T cells from patients receiving grass pollen immunotherapy is low
or absent compared with symptomatic patients with allergic rhinitis (Francis and
others 2004). The effect of immunotherapy on other T-cell chemokine receptors
remains to be determined.
1.9.2.2.2 T-lymphocyte responses in tissue
It seems reasonable when dealing with allergy to various allergens that studies of the
immunological changes within the allergic tissue are of greatest relevance (Till and
others 2004). In grass pollen immunotherapy, clinical improvement is accompanied
by a decrease in the size of late-phase skin responses (Varney and others 1993).
Using in situ hybridisation detecting specific cytokine mRNAs in skin, increased
IFN-y and IL-2 mRNA-expressing cells are present although reduction in numbers of
IL-4 or IL-5 mRNA expressing cells is not observed (Varney and others 1993). IL-
12 mRNA expression is also increased after immunotherapy and correlates positively
with IFN-y mRNA expression and inversely with IL-4 expression (Hamid and others
1997). Increased allergen-dependent IFN-y mRNA expression without reductions in
IL-4 and IL-5 mRNA after immunotherapy are also documented in nasal mucosal
biopsy specimens (Durham and others 1996). Changes in protein concentration are
also consistent with cytokine mRNA level (Klimek and others 1999). IL-10 mRNA-
expressing cells in the nasal mucosa of grass sensitive patients after immunotherapy,
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and expression of IL-10 is allergen driven, as well as immunotherapy dependent
(Nouri-Aria and others 2004).
1.9.2.2.3 IL-10 and regulatory T cells
Immunotherapy-induced IL-10 increase is recorded in various studies (Bellinghausen
and others 1997; Akdis and Blaser 2001a; Francis and others 2003). The anti¬
allergic properties of IL-10 include modulation of IL-4-induced B-cell IgE
production in favour of IgG4 (Jeannin and others 1998), inhibition of IgE-dependent
mast cell activation (Royer and others 2001) and inhibition of eosinophil cytokine
production and survival (Takanaski and others 1994). In human T cells IL-10
suppresses production of pro-allergic cytokines, such as IL-5 (Francis and others
2003), and is able to induce a state of antigen-specific hyporesponsiveness or anergy
(Groux and others 1997). Intracellular IL-10 is significantly increased after 1 week
ofASIT in the antigen-specific T cell population and activated CD4+ cells (Akdis
and others 1998a). After 4 weeks of therapy, intracytoplasmic IL-10 is also
increased in monocytes and B cells, suggesting an autocrine action of T-cell-secreted
IL-10 as a pivotal step in the induction phase of T-cell anergy (Akdis and others
1998a). Flowever, due to lack of a unique marker that defines all cells with
regulatory activity, the properties of T cells producing IL-10 after immunotherapy
are contentious. There is no conclusive evidence to identify whether natural Treg
cells or adaptive Treg cells (Th3 and/or Trl) are actively involved in the up-
regulation of IL-10 after ASIT. But the production of IL-10 and TGF-P by T cells
represents an important component of successful immunotherapy and is a marker of
successful down-regulation of allergen-specific T-cell responses after
immunotherapy (Till and others 2004).
The biology of regulatory T-cell induction is relatively poorly understood, but recent
evidence suggests that dendritic cells seem likely to play a critical role (Penna and
others 2005). However, the involvement of tolerogenic dendritic cells in
immunotherapy remains to be investigated.
49
1.9.2.3 B-lymphocyte responses
In untreated patients with birch pollen allergy, seasonal exposure to birch showed an
increase in cells with surface expression of CD23, CD40 and HLA-DR at the same
time IgE antibodies increased, whereas no such increases occurred in patients given
immunotherapy (Hakansson and others 1998). Allergen-specific IgG antibodies
induced by immunotherapy can disrupt formation of allergen-IgE complexes that
bind to APC and facilitate allergen presentation (Wachholz and others 2003; Nouri-
Aria and others 2004).
1.9.2.4 Inflammatory cytokines
The eosinophil and basophil stimulator IL-5 is down-regulated after AS IT (van
Bever and others 1998; Oda and others 1998; Jutel and others 2003). In vitro
degranulation of neutrophils after stimulation is higher in asthmatic patients than in
healthy control subjects and returns to normal levels after immunotherapy
(Monteseirin and others 2001). In nasal mucosal biopsy specimens from patients
receiving grass pollen immunotherapy, the number of eosinophils is lower in treated
patients, and both eosinophils and IL-5 correlate with symptoms after
immunotherapy (Wilson and others 2001). Studies of serum cytokine levels for dust
mite allergy demonstrate a reduction in IL-ip and TNF-a and augmentation of IL-2
and IL-6 after ASIT, which indicates a reduction in inflammatory responses (de
Amici and others 2001).
1.9.2.5 Mast cells and basophils
It is possible that several different mechanisms are responsible for the observed long-
term effects of injection immunotherapy and for the clinical observation that this
form of allergen-specific immunotherapy can prevent the progression of allergic
disease from less severe to more severe symptoms.
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1.10 Aims and objectives of the studies in this thesis
Our current understanding of the immunopathogenesis of canine atopic dermatitis is
relatively poor compared to humans and murine models. Until recently, most
publications have concentrated on the clinical signs, the results of skin testing and
IgE serology, and treatment options.
The aim of these studies was to investigate further some aspects of the
immunological mechanisms that may be involved in canine atopic dermatitis. Two
main areas were targeted for investigation:
1. The role of D. farinae-specific IgG and IgG subclasses in the disease.
This area has received relatively little study in the canine disease as most research
has focussed on IgE. However, the role of IgG requires further clarification as the
balance between IgE and IgG production may throw some light on the nature of the
immunological responses generated to environmental allergens. Also, some
investigators have claimed a specific role for subclasses of IgG in the pathogenesis of
the disease (Willemse and others 1985b). IgG may also play a role in the mechanism
of action of allergen-specific immunotherapy. To perform these studies, the aim was
to develop and validate a semi-quantitative Western blot analysis system that would
allow characterisation of the IgG response to separated proteins of
Dermatophagoidesfarinae.
2. Further characterisation of cytokine profiles in atopic dogs.
Previous studies investigating the cytokine profiles in the skin of atopic dogs have
yielded inconsistent results. The aim in these studies was to develop real time,
quantitative RT-PCR techniques to measure mRNA transcripts for four cytokines
representing different immunological classes: IFN-y as an archetypal Thl cytokine;
IL-4 as an archetypal Th2 cytokine; TGF-P as an example of a regulatory
(immunosuppressive) cytokine; and inducible nitric oxide synthase (iNOS) as a
measure of the innate immune response. To develop these assays, the aim was to
clone the gene for each of these cytokines, express it in a vector system and use the




2.1 Atopic and healthy dogs
2.1.1 Study population
Dogs diagnosed with atopic dermatitis were recruited from the dermatology clinic at
the Royal (Dick) School ofVeterinary Studies Hospital for Small Animals, Easter
Bush Veterinary Centre, Roslin, Midlothian, EH25 9RG, UK (n=43) and from the
Animal Dermatology Clinic, 2965 Edinger Avenue, Tustin, CA 92780, USA (n=15).
Samples from UK dogs were either collected under Home Office licence or were
residual to diagnostic use. Control samples were taken from healthy dogs presented
for euthanasia by a local rescue centre to the Royal (Dick) School of Veterinary
Studies Hospital for Small Animals (n=20). These dogs had behavioural problems
and were assessed as being unsuitable for re-homing. Euthanasia was performed
with intravenous administration of sodium pentobarbitone (Euthatal®, Merial Animal
Health Ltd., Harlow, Essex, UK) at a dosage of 150 mg per kg body weight. All
procedures on euthanised animals were carried after recognition of death, as assessed
by cessation of heartbeat and respiration, absence of reflexes, including corneal and
palpebral reflexes, and glazing of eyes.
2.1.2 Inclusion criteria for the healthy control dogs
None of the healthy dogs had a history of pruritic skin disease or systemic conditions
likely to affect immune function. All the dogs were clinically ascertained to be free
of skin lesions at the time of sampling. No topical or systemic anti-inflammatory
medications had been given for at least three weeks (eight weeks for injectable depot
preparations) prior to examination.
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2.1.3 Inclusion criteria for the dogs with atopic dermatitis
The diagnosis of atopic dermatitis was based on a combination of consistent history
of chronic seasonal or perennial pruritus that was responsive to glucocorticoids,
typical clinical signs, exclusion of other causes of pruritic skin disease, and one or
more positive reactions in an intradermal test or IgE serological assay (Willemse
1986). All the atopic dogs included in this study were tested positive to D. farinae
either on intradermal testing or IgE serology. Ectoparasitic infestation was ruled out
based on negative results ofmultiple skin scrapings, coat brushing or serological
testing (IgG enzyme-linked immunosorbent assay (ELISA) for Sarcoptes scabiei)
where necessary. All dogs were placed on a rigorous flea control programme for a
minimum of six weeks using topical fipronil (Frontline®; Merial, Harlow, UK) or
selamectin (Stronghold®; Pfizer Animal Health, Sandwich, UK). Dogs that
experienced complete resolution of clinical signs after treatment were excluded.
All dogs underwent a six-week, home cooked or commercial diet trial. Novel single
carbohydrate and protein sources were selected on the basis of previous dietary
history. Provocative exposure to the normal diet was used to confirm adverse food
reaction in dogs that clinically improved during the trial diet. Dogs that completely
responded to the diet trial were excluded.
Staphylococcal pyoderma was managed with appropriate systemic antibiotics and
topical treatment with either 2.5% benzoyl peroxide (Paxcutol®; Virbac, Bury, St.
Edmonds, UK) or 10% ethyl lactate (Etiderm®; Virbac). Malassezia dermatitis was
treated with a 2% miconazole / 2% chlorhexidine shampoo (Malaseb®; Leo Animal
Health, Princes Risborough, UK). Otitis externa was treated with topical polyvalent
and/or systemic anti-microbial products according to the requirements of each case.
Dogs that experienced a complete resolution of pruritus after antimicrobial treatment
were excluded.
No topical or systemic anti-inflammatory or antimicrobial medication was given for
at least three weeks (eight weeks for injectable depot preparations) before
examination.
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2.1.4 Allergen-specific IgE tests
2.1.4.1 Intradermal skin tests
Dogs with a presumptive diagnosis of atopic dermatitis were intradermally tested
with 57 allergens (Table 2.1) as follows. Dogs were sedated with 0.15 mg/kg
xylazine (Virbaxyl" ; Virbac) intramuscularly. A rectangular area from the lateral
flank was clipped and 0.05 ml of each allergen extract, 0.1 mg/ml histamine (positive
control) and buffered saline (negative control) with 0.4% phenol diluent as
preservative were injected intradermally via a 25-gauge needle. The degree of
swelling, erythema and induration at each injection site were subjectively assessed
after 20 min. The saline and histamine wheals were arbitrarily assigned scores of 0
and +4 respectively. The degree of erythema and swelling at each test site was
subjectively scored 0, +1, +2, +3 or +4 in comparison to the negative and positive
control sites. Reactions greater than or equal to +2 were considered relevant (Nuttall
and others 1998).
The intradermal skin tests were performed and assessed according to these standard
criteria by the clinician in charge of each case (P.B. Hill, S. Colombo, K.L. Thoday
or A. Neuber; Dermatology Clinic, University of Edinburgh Hospital for Small
Animals or C.E. Griffin, R. Muse, W.S. Rosenkrantz, or C. Mendelsohn; Animal
Dermatology Clinic, 2965 Edinger Avenue, Tusti, CA 92780).
2.1.4.2 Allergen-specific IgE serology
Serum samples from dogs that did not undergo intradermal skin tests, or in which
skin tests were negative, were analysed using allergen-specific IgE serology
(ASIgES) (FcsRIa-based ELISA, Allercept™, Heska Corporation, Fribourg,
Switzerland). Allergens included in the test are listed in Table 2.2.
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Table 2.1 Intradermal test allergens
Greer - Greer laboratories, Lenoir, NC, USA; Artu - Artuvetrin® Test; Artu
Biologicals, Lelystad, The Netherlands; PNU - protein nitrogen units; NE - nitrogen
equivalent.
Allergen extract Source Concentration
Controls
Histamine Artu 0.1 mg/ml
Diluent Greer n/a
Dust and dust mites
Dermatophagoides pteronyssinus Greer 1/1000 w/v
Acarns siro Artu 100 NE/ml
Dermatophagoidesfarinae Greer 1/1000 w/v
Tyrophagus putresceantiae Artu 100 NE/ml
Euroglyphus maynei Artu 100 NE/ml
House dust Greer 1000 PNU/ml
Epithelials
Human epithelia Artu 10 pg/ml
Cat epithelia Greer 100 pg/ml
Horse epithelia Greer 500 PNU/ml
Sheep epithelia Greer 500 PNU/ml
Mixed feathers Artu 100 pg/ml
Cotton Enters Greer 1000 w/v
Insects
American cockroach Greer 500 PNU/ml
German cockroach Greer 500 PNU/ml
Flea Greer 1/1000 w/v
Mixed moths Greer 500 PNU/ml
Horse fly (Tabanus) Greer 500 PNU/ml
Mosquito (Culicidae) Greer 500 PNU/ml
Moulds
Aspergillus spp. Greer 1000 PNU/ml
Alternaria tenuis Greer 1000 PNU/ml
Botrytis cinerea Greer 1000 PNU/ml
Penicillium spp. Greer 1000 PNU/ml
Grain smut Greer 1000 PNU/ml
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Table 2.1 contd. Intradermal test allergens
Trees
White ash Greer 1000 PNU/ml
Ash Artu 1000 NE/ml
Tag alder Greer 1000 PNU/ml
Alder Artu 1000 NE/ml
American Beech Greer 1000 PNU/ml
Beech Artu 1000 NE/ml
White oak Greer 1000 PNU/ml
White birch Greer 1000 PNU/ml
Birch Artu 1000 NE/ml
American elm Greer 1000 PNU/ml
Elm Artu 1000 NE/ml
Box elder Greer 1000 PNU/ml
Elder Artu 1000 NE/ml
Eastern sycamore Artu 1000 NE/ml
White pine Greer 1000 PNU/ml
Weeds
Yellow dock Greer 1000 PNU/ml
Jerusalem oak Greer 1000 PNU/ml
Lambs quarter Greer 1000 PNU/ml
Common mugwort Greer 1000 PNU/ml
Nettle Greer 1000 PNU/ml
English plantain Greer 1000 PNU/ml
Brassica spp. Greer 1000 PNU/ml
Chrysanthemum spp. Greer 1000 PNU/ml
Red clover Greer 1000 PNU/ml
Grasses
Kentucky blue grass Greer 1000 PNU/ml
Meadow fescue Greer 1000 PNU/ml
Orchard grass Greer 1000 PNU/ml
Perennial rye grass Greer 1000 PNU/ml
Sweet vernal grass Greer 1000 PNU/ml
Timothy grass Greer 1000 PNU/ml
Velvet / Yorkshire fog Greer 1000 PNU/ml
Red top / bent grass Greer 1000 PNU/ml
Couch grass Greer 1000 PNU/ml
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Table 2.2 Allergens tested in allergen-specific IgE serology
Timothy Yellow dock Aspergillus
Cocksfoot Meadow fescue Penicillium mix
Meadow grass Beech Cladosporum
Rye grass Willow Alternaria
Sheep sorrel Poplar Acarus siro
English plantain Ash Tyrophagus putrescentiae
Nettle Maple (Sugar) Dermatophagoides farinae
Lambs Quarter Hazel Dermatophagoides pteronyssinus
Mugworth Pine (White) Parakeet feathers
Alder Grand fir Cat epithelium
Oak Plane tree Cockroach
Birch (White) Norway spruce Flea saliva
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2.2 Sample collection
2.2.1 Archived skin samples
Skin samples from atopic and healthy dogs previously collected in our laboratory by
Dr. Tim Nuttall under Home Office licence (project licence no. 60:2336) subjected to
the Animal (Scientific Procedures) Act 1986 were available for study. These
samples were a very useful resource because they had been previously assayed using
conventional RT-PCR and therefore allowed an opportunity for comparative study
with newer methodologies.
Skin samples had been taken whilst the dogs were sedated for intradermal testing
(Chapter 2.1.4.1) as follows. 0.5-1.0 ml of 1% lignocaine (Xylocaine®; Astra-Zeneca,
Kings Langley, UK) was infiltrated into the subcutis under the biopsy sites, which
were marked with a circle in indelible pen. Non-lesional skin biopsies, with no
clinical evidence of excoriation or inflammatory skin disease, were taken from the
flank. Lesional skin biopsies were taken from areas of erythema and macular-
papular dermatitis on the trunk or proximal limbs, with no evident excoriation,
staphylococcal pyoderma or Malassezia dermatitis. The skin biopsies were taken
with a 6-mm biopsy punch (Stiefel Laboratories, High Wycombe, UK) and placed
immediately into RNAlater® (Ambion Inc., Huntingdon, UK) to preserve ribonucleic
acid (RNA). Samples in RNAlater® were kept at 4°C overnight, and were
transferred to a -20°C freezer for long-term storage. The biopsy sites were closed
with a single interrupted polyglactin suture (Vicryl®; Ethicon Inc., Somerville, NJ,
USA).
As some of these samples were a number of years old, the integrity of the RNA was
checked prior to analysis (see Chapter 6.3.1).
2.2.2 Control tissue samples from healthy dogs
Skin biopsies were taken from healthy dogs presented for euthanasia immediately
after confirmation of death. Popliteal lymph nodes were also excised from these
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dogs to act as positive control material for the amplification of gene transcripts
(Chapter 2.9). These tissues were divided into 5 mm3 portions and stored in
RNAlater® as described.
2.2.3 Serum collection
Archived atopic serum samples were available from two previous studies. The first
was a study investigating antibody and cytokine responses in atopic dogs (Nuttall
and others 2001b; Nuttall and others 2002a; Nuttall and others 2002b). The second
was a study investigating the efficacy of allergen specific immunotherapy in atopic
dogs (Colombo and others 2005). 10-20 ml blood samples had been collected into
plain glass tubes by jugular venepuncture. Control blood samples were collected by
cardiac puncture immediately after euthanasia. The tubes were kept at room
temperature for 1 -2 hours to allow clotting. After centrifugation at 2,200 g for 5 min,
sera were obtained by collecting the supernatant, aliquoted and stored at -20°C until
use.
2.3 House dust mite Dermatophagoides farinae extract
Whole body freeze-dried housedust mite Dermatophagoide farinae (D. farinae)
antigen (Greer Laboratories, Lenior, NC, USA) was reconstructed into 1 mg/ml in
sterile phosphate buffered saline (PBS), aliquoted and stored at -20°C until use.
2.4 Sodium dodecyl sulphate - Polyacrylamide gel
electrophoresis (SDS-PAGE)
2.4.1 Buffers and solutions
Resolving gel:
■ 0.25 M Tris-HCl (Sigma, Dorset, UK) pH 8.8
# • • • (R)
• 10% w/v acrylamide/methylene bis-acrylamide solution (37.5:1) (ProtoGel ;
National Diagnostics, Staffordshire, UK)
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• 1% w/v sodium dodecyl sulphate (Fisher, Leicestershire, UK)
• 1% w/v ammonium persulphate (Bio-Rad Laboratories, Hempstead, UK)
• 0.1% v/v N,N,N',N'-tetramethyl-ethylenediamine (TEMED) (Sigma, Dorset,
UK)
Stacking gel:
• 0.128 M Tris-HCl (Sigma, Dorset, UK) pH 6.8
• 4% w/v acrylamide/methylene bis-acrylamide solution (37.5:1) (ProtoGel®;
National Diagnostics, Staffordshire, UK)
• 0.5% w/v sodium dodecyl sulphate (Fisher, Leicestershire, UK)
• 0.02% w/v ammonium persulphate (Bio-Rad, Hempstead, UK)
• 0.002% v/v N,N,N',N'-tetramethyl-ethylenediamine (TEMED) (Sigma, Dorset,
UK)
Reducing loading buffer:
• 0.125 M Tris-HCl (Sigma, Dorset, UK) pH 6.8
• 4% w/v sodium dodecyl sulphate (Fisher, Leicestershire, UK)
• 20% v/v glycerol (BDH Chemicals Ltd., Poole, England)
• 0.005% w/v bromophenol blue (BDH, Poole, England)
• 10% v/v 2-mercaptoethanol (Sigma, Dorset, UK)
Non-reducing loading buffer:
• 0.125 M Tris-HCl (Sigma, Dorset, UK) pH 6.8
• 4% w/v sodium dodecyl sulphate (Fisher, Leicestershire, UK)
• 20% v/v glycerol (BDH, Poole, England)
• 005% w/v bromophenol blue (BDH, Poole, England)
Electrophoresis buffer:
• 25 mM Tris-HCl (Sigma, Dorset, UK) pH 8.3
• 0.2 M glycine (Fisher, Leicestershire, UK)
• 1.0% w/v sodium dodecyl sulphate (Fisher, Leicestershire, UK)
Molecular weight markers:
• Broad range protein marker (Bio-Rad, Hempstead, UK)
Coomassie blue:
■ 0.1% w/v Coomassie Brilliant Blue R-250 (BDH, Poole, England)
■ 25% v/v methanol (Scientific Laboratory Supplies, Nottingham, UK)
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• 5% v/v acetic acid (Fisher, Leicestershire, UK)
Destain solution:
• 45% (v/v) methanol (Scientific Laboratory Supplies, Nottingham, UK)
• 9% (v/v) acetic acid (Fisher, Leicestershire, UK)
2.4.2 Technique
The gel apparatus was assembled according to the manufacturer's instructions
(MiniPROTEAN II®, Bio-Rad, Hempstead, UK). The glass plates were cleaned with
70% ethanol and SDS-PAGE was performed according to Laemmli's method
(Laemmli 1970) using a 10% tris-glycine polyacrylamide resolving gel and a 4%
stacking gel in a discontinuous buffer system. Ingredients for stacking gel and
resolving gel were mixed in the order of acrylamide stock, water, Tris-HCl buffer,
10% SDS, ammonium persulphate and TEMED. Air bubble formation was avoided
by gentle pipetting. Resolving gel buffer was carefully poured into the glass plate
assembly and overlaid with water to ensure a flat surface and to exclude air as
oxygen inhibits the polymerisation of the acrylamide. Water was drained off from
the solidified resolving gel. Stacking gel buffer was poured on top of the set
resolving gel, an appropriate comb was inserted to form the wells and allowed to set.
D. farinae extract and molecular weight standards were diluted 1:1 and 1:20
respectively with sample loading buffer and heated at 95°C for 5 minutes using a
water bath. The extract was then layered into a single broad well with the molecular
weight marker alongside (Figure 2.1). The gels were then placed in the
electrophoresis tank according to the manufacturer's instructions (MiniPROTEAN
II®, Bio-Rad, Hempstead, UK), filling the inner compartment with the tank buffer.
Enough tank buffer was added to the lower compartment to cover the base of each
gel. Electrophoresis was carried out at 200 V for 40 minutes, or until the dye front
was within 2 mm of the bottom of the gel (Figure 2.1).
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Figure 2.1 Schematic representation of a single well gel
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2.4.3 Staining and imaging
2.4.3.1 Coomassie blue
Gels were stained in 0.25% Coomassie blue (BDH, Poole, England) for 10 minutes
with gentle shaking. Background staining was eliminated by rinsing the gel in
destain with frequent changes of solution.
2.4.3.2 Imaging of stained gels
Coomassie blue stained gels were transilluminated with white light and
photographed (Kodak Digital Science™ Image Station 440CF, Kodak, Rochester,
NY, USA).
2.5 Immunoblotting
2.5.1 Buffers and solutions
Tris-buffered saline (TBS):
• 20 mM Tris-HCl (Sigma, Dorset, UK) pH 7.5
• 0.5 M NaCl (Fisher, Leicestershire, UK)
Anode buffer I:
■ 0.3 M Tris-HCl (Sigma, Dorset, UK) pH 10.4
• 10% v/v methanol (Scientific Laboratory Supplies, Nottingham, UK)
Anode buffer II:
• 25 mM Tris-HCl (Sigma, Dorset, UK) pH 10.4
• 10% v/v methanol (Scientific Laboratory Supplies, Nottingham, UK)
Cathode buffer:
• 25 mM Tris-HCl (Sigma, Dorset, UK) pH 9.4
• 40 mM 6-amino-n-caproic acid (Sigma, Dorset, UK)
■ 10% v/v methanol (Scientific Laboratory Supplies, Nottingham, UK)
Blocking buffer:




• 1% skimmed milk (0% fat dried milk powder, Sainsbury, Edinburgh, UK) /
TBS w/v
Washing buffer:
• 0.05% v/v Tween 20 (Fisher Leicestershire, UK) / TBS (TBS-T)
Immunological reagents
• Purified dog IgG (Sigma, Dorset, UK)
• Horseradish peroxidase (HRP) -conjugated polyclonal goat anti-dog IgG (Bethyl
Laboratories Inc., Montgomery, TX, USA)
• Monoclonal mouse anti-dog IgE antibody (E6-71A1; Custom Monoclonals
International, W. Sacramento, CA, USA)
• Monoclonal mouse anti-dog IgG subclass antibodies (mAbs B6, E5, A3G4 and
A5; kindly provided by Dr. M. Day, University of Bristol, Langford, UK)
• HRP-conjugated bovine monoclonal anti-mouse IgG (MCA1421; Serotec,
Kidlington, UK)
• 3,3'-diaminobenzidine (DAB) substrate (Vector Laboratories Inc., Peterborough,
UK)
• Luminol (ECL™ (Amersham Pharmacia Biotech, Little Chalfont, UK)
2.5.2 Technique
2.5.2.1 Electrophoretic transfer
Appropriate amounts of 1 mg/ml crude D. farinae extract were diluted in reducing or
non-reducing sample buffer and SDS-PAGE was performed as previously described
(Chapter 2.4.2) using a single well to resolve the proteins into bands across the width
of the gel.
Separated proteins on gels were transferred to 0.45pm polyvinylidene difluoride
(PVDF) microporous membranes (Minipore Immunobilon™-P Transfer Membrane,
Millipore Corporation, Bedfore, MA, USA). Gels were carefully removed from the
glass cassettes and immersed in cathode buffer for 15 minutes to equilibrate. The
PVDF membranes were pre-soaked in methanol for 15 seconds, and then rinsed in
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anode buffer II for 5 minutes prior to blotting. For each transfer, two pieces of filter
paper (Chromatography paper 3mm, Whatman International, Maidstone, UK) soaked
in the anode buffer I and one piece soaked in the anode buffer II were laid on the
anode electrode plate of the semi-dry electrophoretic transfer cell (Trans-Blot® SD,
Bio-Rad, Hempstead, UK). Air bubbles between layers were removed by carefully
rolling a pipette over the surface of each layer when assembling the transfer stack to
ensure an even transfer. The PVDF membrane was placed on top of the filter papers
and the unstained gel placed on top of the membrane. Another three sheets of filter
papers soaked in cathode buffer were then placed on top of the gel. The transfer
stack was assembled (Figure 2.2) and run at 80 mA per gel for 1 hour. After blotting,
the apparatus was dismantled and one gel was stained with Coomassie blue (BDH,
Poole, England) (Chapter 2.4.3.1) to ensure protein transfer had occurred. The
PVDF membranes were air-dried and stored at 4°C.
Figure 2.2 Schematic representation of the Western blot transfer stack
I
Cathode electrode plate
Filter paper wetted in cathode buffer,
three sheets
I I PVDF membrane
Filter paper wetted in anode buffer II,
one sheet





The stored PVDF membranes were briefly immersed in methanol followed by
equilibration in TBS for two minutes. The molecular weight markers and a narrow
strip to identify protein bands were removed. The remaining portion of the PVDF
membranes were cut longitudinally into 4-mm wide strips (to facilitate testing of a
large number of samples for antibodies directed against the blotted proteins) and
placed into individual lanes of an 8-channel incubation tray (Bio-Rad, Hempstead,
UK). All sites on the membrane which did not contain blotted protein from the gel
were non-specifically blocked by immersing strips in 1 ml blocking reagent for one
hour at room temperature on an orbital shaker, and washed with TBS-T three times
for five minutes. Individual strips were incubated with predetermined, optimal
dilution of serum samples (Chapter 3.2.5) for one hour at room temperature,
followed by thorough washing with frequent changes ofwashing buffer. Secondary
(and tertiary where appropriate) antibody was then added at appropriate dilutions and
incubated at room temperature for different periods of time depending on the
experiment.
2.5.3 Staining and imaging
The molecular weight standards were stained with Coomassie blue (BDH, Poole,
England) (Chapter 2.4.3.1) as previously described. The substrate DAB was used for
colorimetric blots and the luminol substrate ECL™ was used for chemiluminescent
blots (See Chapters 3 and 4 for details). The DAB solution was prepared according
to manufacturer's instructions. 1 ml of the working solution was added to each strip
and incubated for one minute with gentle agitation, followed by washing with tap
water. The strips were then air-dried and stored at room temperature. The
chromogenic strips, along with the molecular weight standard, were aligned and
digitally scanned using a flatbed scanner (Epson 1650, Hemel, Hempstead, UK) set
at 8-bit grey scale. The scanned images were imported into the image analysis
software (Chapter 2.5.4) and evaluated.
67
For chemiluminescent blots, the protein surface of the strips was covered with ECL
for 1 minute. After draining off excess luminol solution, the strips were wrapped in
cling film and placed protein side down on the lightproof image plate on a Kodak
Digital Science™ Image Station 440CF Chemiluminescent Imaging System (Kodak,
Rochester, NY, USA) along with Coomassie blue stained molecular weight markers,
and recorded as digital image file using validated exposure conditions (Chapter 4.2).
The Image Station 440CF (IS 440CF) is fitted with a high resolution charged coupled
device (CCD) camera and is specifically designed for chemiluminescence and
fluorescence imaging, but the system also provides chromogenic detection and
general purpose laboratory imaging of autoradiography films, Coomassie Brilliant
Blue and silver stained gels and cell culture plates. In addition, this highly sensitive,
multi-purpose imaging system eliminates the complexities associated with
darkrooms and central imaging labs as well as the high costs and potential hazards of
radiation-based imaging systems.
2.5.4 Image analysis
The Kodak Digital Science™ ID Image Analysis Software (Kodak, Rochester, NY,
USA) was used to generate density profiles of bands on the gel and bands on the
Western blot. This software can automatically search the defined lanes for bands and
create a density profile for each lane. It identifies the bands that are present and
generates a wide variety of quantitative data for each band, allowing quantitative
measurements to be obtained without operator bias. The molecular weights of
experimental bands were calculated by comparing their mobility relative to the
molecular weight standards. The software could also determine the intensity of each
band, which was proportional to the amount of protein present (see Chapter 3.2.5).
The sum intensity was automatically calculated by addition of the intensity values for
all the pixels identified within the rectangular area of the band. Net intensity was
automatically calculated by addition of the intensity values for all the pixels
identified within the rectangular area of the band followed by subtraction of the




2.6.1 Buffers, solutions and reagents
Tris-acetate-EDTA (TAE) buffer:
• 40 mM Tris-HCl (Sigma, Dorset, UK) pH 8.5
• 0.1% v/v acetic acid (Sigma, Dorset, UK)
• 1 mM ethylenediaminetetraacetic acid (EDTA) (Sigma, Dorset, UK)
Tris-acetate (TE) buffer:
• 10 mM Tris-HCl (Sigma, Dorset, UK) pH 7.5
• 1 mM EDTA (Sigma, Dorset, UK)
6x DNA electrophoresis loading buffer
• 15% w/v ficoll type 400
• 0.25% w/v bromophenol blue
• 0.25% w/v xylene cyanol
DNA electrophoresis loading buffer
• 0.25% w/v Orange G (Sigma, Dorset, UK)
Luria-Bertani (LB) broth
• 1 % w/v tryptone (Difco, Surrey, UK)
■ 0.5% w/v yeast extract (Gibco, Paisley, UK)
• 0.1% w/v NaCl (Sigma, Dorset, UK)
LB plate
• 1% w/v tryptone (Difco, Surrey, UK)
• 0.5% w/v yeast extract (Gibco, Paisley, UK)
• 0.1% w/v NaCl (Sigma, Dorset, UK)
• 1% w/v agar (Invitrogen, Paisley, UK)
2.6.2 DNA quantification
DNA was quantified by measuring its absorbance in a spectrophotometer (DU650
Spectrophotometer, Beckman-Coulter, USA) and optical density (OD) was measured
at 260 and 280 nm. One OD260 unit was equivalent to 50 pg/ml double-stranded
DNA (dsDNA). The concentration ofDNA samples were calculated using the
equation:
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• DNA pg/ml = OD260 of the DNA sample x 50 x dilution factor
The purity of the samples was assessed by the ratio OD26o/OD28o- Samples with a
ratio less than 1.8 indicated that contamination by protein might have occurred, and
DNA samples were re-precipitated again.
2.6.3 DNA digestion with restriction endonucleases
Restriction enzymes EcoBl, Ncol and Bell were obtained from New England Biolabs
(New England Biolabs Inc. Hertfordshire, UK) and Notl was obtained from Promega
(Promega, Southampton, UK) and were used with the supplied buffers according to
the manufacturer's instructions. The reaction was set up in a total volume of 20-200
pi and incubated for 2 hours at a 37 °C temperature block (dri-block® DB-ZA,
Techne, UK) (50°C for Bell). The reaction mix consisted ofDNA to be digested,
10% of the appropriate 10x buffer, 0.1 pl/ml bovine serum albumin (BSA, Promega,
UK), approximately 1 unit of restriction enzyme per pg ofDNA and nuclease free
water (Promega, UK) to the final volume. Enzymes were inactivated by incubation
at 65°C for 20 minutes to avoid interference with subsequent enzymatic reactions, i.e
amplification.
2.6.4 Plasmid DNA analysis by electrophoresis
DNA was analysed by gel electrophoresis on agarose gels (Invitrogen, Paisley, UK).
1% agarose gels were made by adding 3 g of agarose (Invitrogen, UK) to 300 ml of
TAE buffer and dissolving by heating to boiling point in a microwave. The mixture
was allowed to cool to approximately 50°C before the addition of 0.5 pg/ml ethidium
bromide (Sigma, Dorset, UK). The gel was poured into a flat bed mould into which
combs had been inserted, and then allowed to set for at least 1 hour before use.
DNA samples were made up to a 10-20 pi volume with TAE, and mixed with 1/6
volume of 6x loading dye (15% w/v ficoll type 400, 0.25% w/v bromophenol blue
and 0.25% w/v xylene cyanol) or 1/2 volume loading buffer (0.25% w/v Orange G,
Sigma) in distilled water. Electrophoresis was carried out at 100V in a horizontal
tank (Bio-Rad, Hempstead, UK) containing TAE buffer. The size ofDNA bands
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was estimated by comparison with DNA molecular weight standards (DNA ladder,
New England BioLabs, Hertfordshire, UK). Bands were visualised using a short
wave UV transilluminator (Syngene, Scientific Laboratory Supplies, Ltd., UK) and
recorded.
2.6.5 Preparation of Luria-Bertani (LB) medium and plates
To prepare 1 litre of LB medium, 10 g tryptone (Difco, Surrey, UK), 5 g yeast
extract (Gibco, Paisley, UK) and 10 g sodium chloride (Sigma, Dorset, UK) were
dissolved in 950 ml distilled water. The pH of the solution was adjusted to 7.0 with
NaOH and the final volume was brought up to 1 litre. The solution was then
subjected to autoclaving on liquid cycle for 20 minutes at 15 pounds per square inch
(psi). After the solution was cooled to 55°C, 100 pg/ml of ampicillin was added and
stored at 4°C.
To prepare LB agar plates, LB medium was prepared as above and 10 g/1 agar was
added before autoclaving. After autoclaving and cooling to ~55°C, 100 pg/ml of
ampicillin was added and the solution was poured into 10-cm plastic Petri dishes and
allowed to solidify. Plates were then inverted and stored at 4°C in the dark.
2.6.6 Transformation of One Shot® Chemically Competent
Escherichia coli
Fresh PCR products were cloned into a linear plasmid vector pCR®4-TOPO® (TOPO
TA® Cloning Kit for Sequencing, Invitrogen, UK) (Figure 2.3). TOPO® Cloning
reaction was set up using 0.5-4 pi PCR product, 1 pi salt solution and 1 pi TOPO®
vector; sterile water was added to a final volume of 6 pi. The reaction was mixed
gently and incubated for 5 minutes at room temperature and then placed on ice. 4 pi
of the TOPO® Cloning reaction was added into a vial of One Shot® Chemically
Competent Escherichia coli, mixed gently, and incubated on ice for 5 minutes. 50 pi
of transformed cell suspension was placed on a pre-warmed LB plate (Chapter 2.7.5)
and spread quickly and evenly over the plate using an L-shaped glass spreading tool
and incubated overnight at 37°C. A small volume of the cell suspension was
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streaked at one side of LB plate using a Nichrome loop. Streaking was repeated a
few times (Figure 2.4) and the Nichrome loop was flamed and cooled down between
each step. LB plates were placed with the agar facing downwards to minimize
contamination and to reduce the chance of droplets of condensation falling on the
agar surface.







M13 Reverse priming site I T3 priming site
[ 1 1 I
CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCA GAATTAACCC TCACTAAAGG
GTGTGTCCTT TGTCGATACT GGTACTAATG CGGTTCGAGT CTTAATTGGG AGTGATTTCC
—.Spot Pst I Pmo I EcoR I EcoR I Noli
T~ 111 | 1
GACTAGTCCT GCAGGTTTAA ACGAATTCGC CCT1WE&QH9AGGGC GAATTCGCGG
CTGATCAGGA CGTCCAAATT TGCTTAAGCG GG.AEW irfTT IBMTfCCCG CTTAAGCGCC
T7 priming sfte M13 Forward (-20) pnming site
CCGCTAAATT CAATTcdoCC TATAGTGAGT CGTATTa'caA TTCa'cTGGCC GTCGTTTTAC1
GGCGATTTAA GTTAAGCGGG ATATCACTCA GCATAATGTT AAGTGACCGG CAGCAAAATG
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2.6.7 Small scale broth culture and isolation of plasmid DNA (Mini-
prep)
A single bacterial colony picked from a freshly streaked selective plate using a
flamed loop was inoculated into a culture of 1-5 ml LB medium (Chapter 2.7.5) and
incubated for 12-16 hours at 37°C with vigorous rotational shaking at 250
revolutions per minute (rpm) (Orbital Shaker, Forma Scientific, UK). Tubes with a
volume of at least 4 times the volume of the culture providing sufficient aeration
were used. Plasmid DNA was purified using QIAprep® Spin Miniprep Kit
(QIAGEN, West Sussex, UK) using the alkaline lysis method according to the kit
manufacturer's instruction (Figure 2.5). Bacterial cells were harvested by
centrifugation at 6800 g in a table-top microcentrifuge (Sigma 1-13, Scientific
Laboratory Supplies, UK) for 3 minutes at room temperature and the supernatant
discarded. Pelleted bacterial cells were resuspended in 250 pi Buffer PI (Table 2.3),
homogenised and transferred to microcentrifuge tubes. 250 pi Buffer P2 was added
and capped tubes were inverted several times until the solution became viscous and
translucent. 350 pi Buffer N3 was then added and mixed immediately and
thoroughly by inverting the tubes 4-6 times followed by centrifugation at 17900 g for
10 minutes. The supernatants were then transferred to the QIAprep spin column by
decanting or pipetting, centrifuged for 30-60 seconds, and the flow-through
discarded. 0.5 ml Buffer PB was then added to the columns and centrifuged for 30-
60 seconds and the flow-through discarded. 0.75 ml Buffer PE was then added and
centrifuged for 30-60 seconds and the flow-through discarded. Residual washing
buffer was removed by additional centrifugation for 1 minute. QIAprep spin
columns were then placed in clean 1.5 ml microcentrifuge tubes. DNA was eluted
by adding 50 pi Buffer EB to the centre of each spin column, followed by incubation
for 1 minute and centrifugation for 1 minute. The samples were stored at 4°C and
analysed by restriction enzyme digestion.
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Figure 2.4 Procedure for the production of single colonies by the streak plate
technique
Figure 2.5 QIAprep spin procedure
Pelleted bacteria




Table 2.3 Composition of buffers supplied in the plasmid purification kit
Buffer Function Composition
PI Resuspension







EB Elution 10 mM Tris-HCl, pH 8.5
P3 Neutralisation 3.0 M potassium acetate, pH 5.5
QBT Equilibration
750 mM NaCl









50 mM Tris-HCl, pH 8.5
15% isopropanol (v/v)
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2.6.8 Large scale broth culture and plasmid DNA purification
(Maxi-prep)
5-ml LB broth culture from a single colony was prepared (Chapter 2.6.7) and used as
a starter material for the large-scale culture. The starter culture was diluted 1/500-
1/1000 into selective LB broth and incubated overnight at 37°C on a rotary shaker
(Forma Scientific, UK) at 250 rpm. Large-scale plasmid DNA was purified using
QIAGEN® Plasmid Maxi kit (QIAGEN, UK) according to the manufacturer's
instructions. An overnight bacterial culture (250 ml) was centrifuged at 6000 g for
15 minutes at 4°C (Model J2-21 Centrifuge, Beckman, UK) to harvest cells and the
bacterial pellets were resuspended in 10 ml Buffer PI (Table 2.3). 10 ml Buffer P2
was added and mixed thoroughly by vigorously inverting the sealed tube 4-6 times,
and incubated at room temperature for 5 minutes. 10 ml of chilled Buffer P3 was
then added and mixed immediately and thoroughly by vigorously inverting 4-6 times
and incubating on ice for 20 minutes, followed by centrifugation at 20000 g for 30
minutes at 4°C and the supernatant collected promptly. The supernatant was
subjected to centrifugation again at 20000 g for 15 minutes at 4°C, and the
supernatant collected promptly. QIAGEN-tip 500 was equilibrated by applying 10
ml Buffer QBT and the column was allowed to empty by gravity flow. Previously
collected supernatant was applied to the QIAGEN-tip and was allowed to enter the
resin by gravity flow. The QIAGEN-tip was washed twice with 30 ml Buffer QC,
and DNA was eluted with 15 ml Buffer QF.
2.6.9 Preparation of glycerol stock of transformants
For the preparation of glycerol stocks of bacterial cultures, 0.5 ml of sterile 60%
glycerol was added to 1.5 ml of a log-phase bacterial culture. The culture was
vortexed to ensure uniform dispersion of the glycerol before rapid freezing on dry-
ice. After the culture was fully frozen, it was transferred to long-term storage at -
70°C.
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2.6.10 Automatic sequencing of DNA
DNA sequencing was performed using the di-deoxy chain termination sequencing
method, by Mr. Ian Bennet (Department ofVeterinary Pathology, University of
Edinburgh). Reactions were performed using a Sequi-Therm EXCEL™ II DNA
Sequencing kit LC on a 4000L automated sequencing machine (Li-COR DNA
Sequencer, MWG-Biotech, Ebersberg, Germany).
2.6.11 Sequence analysis
Analysis of sequenced DNA by comparison to database sequences was done using
the basic alignment search tool (BLAST) programs on the NCBI website
http://www.ncbi.nlm.nih.gov/BLAST/ (Altschul and others 1990).
2.7 RNA extraction andmanipulation
2.7A RNA isolation
The homogeniser (Ultra-turrax 125®; Janke and Kunkel IKA, Staufen, Germany)
probe was soaked overnight in dilute Decon Neutracon solution (Decon Laboratories,
East Sussex, UK), washed thoroughly and subjected to several changes of 0.1% v/v
diethylpyrocarbonate (DEPC)-treated water. The skin biopsy and positive control
(lymph node) samples stored in RNA-later® (Ambion, Huntingdon, UK ) were
thawed and transferred into 50-ml Fulcan polypropylene phenol-resistant tubes
(Fisher, Leicestershire, UK) containing 2.0 ml TRI-reagent® (Sigma, Dorset, UK).
The samples were then homogenized on ice in 30-second bursts until fully
dissociated in order to achieve optimal disruption of cells or tissues. Contents were
transferred into 1.5 ml eppendorf tubes for the following procedure. 200 pi
molecular biological grade chloroform (Sigma, Dorset, UK) was added and mixed
vigorously by vortexing for 30 seconds in order to effectively denature the
nucleoprotein complexes. After incubation for 5 min at room temperature, contents
were centrifuged for 15 min at 9500 g at 4°C. The upper layer was collected into
fresh tubes and precipitated with an equal volume of isopropanol (Sigma, Dorset, UK)
at room temperature for 10 minutes. The tubes were then centrifuged at 3500 g for
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10 minutes and the supernatant discarded. The RNA pellet was washed in 75%
ethanol, centrifuged at 3500 g for 5 minutes and the supernatant again discarded.
The washed RNA pellet was dissolved in 50-100 pi RNAse free water at 60°C for 10
minutes, and then chilled on ice.
2.7.2 DNAse treatment
Genomic DNA was removed from the RNA preparation by incubating with 4 units of
recombinant DNase I (DNA-free®, Ambion, Huntingdon, UK) per 50 pi RNA
solution at 37°C for 1 h. DNase I was removed by incubating with 0.1 volume of
DNase Inactivation Reagent (DNA-free®, Ambion, Huntingdon, UK ) at room
temperature for 2 min with occasional mixing. After spinning at 3500 g for 1 min at
4°C, the supernatant was transferred into a new tube and chilled on ice.
2.7.3 RNA quantification
RNA was accurately quantified by measuring its absorbance in a spectrophotometer
(DU650 spectrophotometer; Beckman-Coulter, Fullerton, CA, USA) and the optical
density (OD) ofRNA was measured at its maximum absorbance wavelength of 260
nm. One OD unit was equivalent to 40 pg/ml ofRNA. The concentration ofRNA
samples were calculated using the equation:
• RNA pg/ml = OD26o of the RNA sample x 40 x dilution factor
The extraction process was repeated for samples with a 260/280 nm absorbance ratio
of less than 1.5. Samples with a ratio persistently less than 1.5 were discarded. The
RNA solutions were stored at -70°C until processed.
2.7.4 RNA analysis using Agilent Bioanalyzer
The electrodes of the bioanalyzer were cleaned with 350 pi ofRNAse free water for
5 minutes to prevent contamination. Diluted ladder and gel-dye mixture were
prepared according to manufacturer's instructions. Gel-dye mix, conditioning
solution, marker, diluted ladder and samples were loaded into appropriate wells and
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the chip was inserted in the Agilent 2100 Bioanalyzer (RNA 6000 Pico Assay,
Agilent Technologies, UK) for analysis.
2.7.5 Reverse transcription of RNA
Approximately 1 pg of DNased RNA samples were reverse-transcribed in a final
volume of 20 pi in a final concentration of 5 mM MgC^, 1x reverse transcription
buffer (10 mM Tris-HCl [pH 9.0 at 25°C], 50 mM KC1, 0.1% Triton® X-100), 1 mM
each dNTP, 1 U/pl recombinant RNasin® ribonuclease inhibitor, 15 U/pg avian
myeloblastosis virus reverse transcriptase (AMV-RT) and 0.5 pg random primer
(Reverse Transcriptase System, Promega, Southampton, UK) for 1 h at 42°C and 5
min at 99°C. The complementary DNA (cDNA) solution was then diluted to 100 pi
in RNAse free water. cDNA preparations were stored at -20°C.
2.8 Polymerase Chain Reaction
2.8.1 Primer design
Internal oligonucleotide primers for amplifying canine glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), interleukin-4 (IL-4), interferon-y (IFN-y), and
transforming growth factor-p (TGF-|3) had been previously validated in our
laboratory by Dr. Tim Nuttall. Internal and external forward and reverse primers for
canine inducible nitric oxide synthase (iNOS) and 18S ribosomal RNA (18S rRNA)
along with external forward and reverse primers for canine IL-4, IFN-y, TGF-P were
designed from published canine mRNA sequences (GenBank®; National Centre for
Biotechnology Information, URL - http://www.ncbi.nlh.nih.gov). The primer
sequences were designed using an online primer design program Primer3 (Primer3,
URL - http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) to maximise
specificity, priming efficiency and optimise annealing temperature, whilst
minimizing secondary structure formation and complementarity to self or other
primers. The primer sequences were screened against known sequences to eliminate
any cross-reactive oligonucleotides (BLAST®; National Centre for Biotechnology
Information; URL - http://www.ncbi.nlm.nih.gov/BLAST/). For real-time PCR,
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primers were designed with optimal amplicon size of 100 bp. The oligonucleotide
primers were generated by Operon Biotechnologies (Cologne, Germany) or MWG-
Biotech (Ebersberg, Germany), diluted to 200 pM in nuclease-free water (Promega,
Southampton, UK) and stored at -20°C.
2.8.2 Components of standard PCR reactions
Polymerase chain reactions (PCRs) were carried out in 50 pi volumes containing 2 pi
cDNA, 0.2 pM forward and reverse primers, 2.5 units Taq DNA polymerase (Roche,
East Sussex, UK) in a reaction buffer composed of 10 mM Tris-HCl, 2 mM MgCB,
0.2 mM each deoxyribonucleotide triphosphates (dNTPs). The reaction conditions
consisted of initial denaturing at 94°C for 2 min, then cycles of denaturing at 94°C
for 30 sec, primer annealing for 30 sec and elongation at 72°C for 30 sec, before a
final elongation at 72°C for 10 min (GeneAmp® PCR system 2400; Perkin-Elmer,
Cambridge, UK). The optimum annealing temperatures of each primer pair was
established in annealing temperature gradient experiments. GAPDH or 18S rRNA
was used as the positive control housekeeping gene. Negative control reactions
contained distilled water instead of template. Positive and negative control
preparations were run in every PCR reaction. Samples with no positive control
signal or a positive reaction from a negative control preparation were discarded.
2.8.3 PCR analysis by electrophoresis
10 pi of each PCR reaction or diluted plasmid DNA was mixed with 2 pi of the 6x
loading dye and placed in the appropriate well of a 1.2% w/v agarose gel (Invitrogen,
Paisley, UK) in TAE buffer containing 0.5 pg/ml ethidium bromide (Sigma, Dorset,
UK). 2.5 pi DNA ladder was mixed with 0.5 pi loading dye and placed in lane 1 of
each gel. Gels were run for 45 min at 100 V according to the manufacturer's
instructions (Horizon II® gel system, Life Technologies). Completed gels were
placed on the image plate on the Kodak Digital Science™ Image Station 440CF
(Kodak, Rochester, NY, USA) and imaged under 590 nm ultra-violet light.
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Table 2.4 National Centre for Biotechnology Information accession numbers for
canine cytokine mRNA sequences

























































2.8.4 Real-time PCR analysis
Real-time PCRs were carried out in 20 pi volumes containing 1 pi cDNA, 100-1000
nM forward and reverse primers, 100 pM dNTPs, lx reaction buffer, 1:28500 SYBR
Green, 0.75 U Taq DNA polymerase, 0.4-3.2 mM of magnesium chloride and water
to a final volume of 20 pi. Concentrations of the reagents used were determined after
a series of dilution experiments (see Chapter 6). Appropriately mixed solutions for
real-time PCR were loaded into 0.1-ml strip tubes (Corbett Research, Cambridge,
UK) and placed on a 72-well rotor.
The reaction conditions consisted of initial denaturing at 94°C for 5 min, then cycles
of denaturing at 94°C for 30 sec, primer annealing for 30 sec and elongation at 72°C
for 30 sec, before a final incremental raise of temperature from 65°C to 94°C (Rotor-
Gene™Real Time Thermal Cycler, Corbett Research, UK).
A standard curve for each cytokine was generated using cloned plasmid DNA.
Negative control preparations were run in every real-time PCR reaction.
2.9 Statistical analysis
Graphical and descriptive statistical analysis of raw data was performed using
Microsoft Office Excel 2003 (Microsoft Corp., Seattle, WA, USA), MINITAB™
Release 14 statistical software (Minitab Inc., PA, USA) and GraphPad Prism® 4
(GraphPad Inc., San Diego, CA, USA). Specific details of the tests used will be




G responses in healthy and atopic dogs
3.1 Introduction
The role of IgE in the pathogenesis of canine atopic dermatitis has been extensively
studied, but the role of IgG is less well understood. In humans, IgG concentrations
are elevated in various allergic conditions (Shakib and others 1977; Merrett and
others 1984; Gondo and others 1987). Both total serum IgG or allergen-specific IgG
can be raised in dogs suffering from AD, although dogs with no apparent clinical
sensitivity to a particular allergen can also have elevated allergen-specific IgG
(Willemse and others 1985b; Hill and others 1995; Day and others 1996; Fraser and
others 2004). Additionally, allergen-specific IgG antibodies are markedly increased
by allergen injection immunotherapy in humans (Ahlstedt and Eriksson 1977). IgG
was reported to inhibit basophil histamine release and IgE-facilitated presentation of
allergen by B cells to T-cell clones (van Neerven and others 1999; Wachholz and
others 2003) in patients with pollen allergy receiving immunotherapy. Bee venom
injection immunotherapy has been demonstrated to induce the formation of bee
venom anti-idiotype antibodies (Khan and others 1991). Allergen-specific anti¬
idiotype antibodies could also be induced in other types of immunotherapy and bind
to the antibody binding sites of specific IgE and thereby block the binding of allergen
(Simon 2004). These observations have led to proposals that allergen-specific IgG
antibodies might have protective properties in atopic individuals.
In the veterinary literature, non-IgE short term sensitising anaphylactic antibody of a
subclass termed IgGd was demonstrated in dogs by the passive cutaneous
anaphylaxis (PCA) test and Prausnitz-Kiistner (PK) testing (Willemse and others
1985a). Unfortunately, determining that the results became negative after IgG
absorption, which would have proven that the reaginic antibody was an IgG, was not
done. The same group also showed that 89 % of the 62 atopic dogs studied had
allergen-specific IgGd antibodies detected by ELISA although the agreement
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between allergen-specific IgGd and intradermal test (IDT) ranged from 1/14 (7 %)
for cat dander to 22/34 (65 %) for house dust (Willemse and others 1985b). In
another study, IgGd to house dust antigens, Dermatophagoidesfarinae (DF) and
Dermatophagoides pteronyssinus (DP) occurred with similar frequency in normal
and atopic dogs, but significantly higher levels of DP-specific IgGd were found in
normal dogs (Lian and Halliwell 1998). Furthermore, a high percentage of the atopic
population had detectable IgGd to unrelated allergens, despite negative IDTs. The
presence of IgGd directed against apparently irrelevant allergens in atopic patients
and the high levels of IgGd in normal dogs to the most common allergens, DF and
DP, implied an uncertain role of IgGd in canine atopic dermatitis (Lian and Halliwell
1998).
Nomenclature of the subclasses of canine IgG has changed over time and due to lack
of exchange of reagents between researchers, establishing their precise identity is not
possible. The functional equivalent of IgGd to the numerically classified canine IgG
subclasses (IgGl, IgG2, IgG3 and IgG4, described further in Chapter 4) is not clear.
Hill et al (1995) showed that total IgG concentrations were significantly higher in
atopic dogs compared to healthy controls (Hill and others 1995). Fraser et al (2004)
has recently shown that concentrations of total IgGl are higher in atopic dogs than in
healthy dogs, suggesting that the atopic state also leads to activation of IgG subclass
production in addition to IgE. A role for IgG has also been proposed in the
mechanism of action of allergen-specific immunotherapy (ASIT) in dogs. Hites et al
(1989) detected IgG antibodies with specificity for grass (June grass, Bermuda grass,
rye grass, timothy grass and grass mix), weed pollen (careless weed, English plantain,
giant ragweed, short ragweed and weed mix) and tree pollen (maple, olive, elm, birch
and tree mix) allergens in the majority of non-atopic individuals and in all atopic
subjects, and concentrations were highest in atopic dogs receiving allergen-specific
immunotherapy (Hites and others 1989). Furthermore, Fraser et al (2004) has shown
that concentrations of total IgGl can increase following allergen-specific
immunotherapy.
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To date, compared to IgE, there is limited information on the specific IgG response
to D.farinae antigens in atopic dogs. The aim of this study, therefore, was to
develop and validate a semi-quantitative blot analysis system and use it to
characterize and quantify the IgG response using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. The
immunoblotting technique was chosen because it provided a useful tool to show
reactions between antibodies and various distinct allergens with known molecular
weights. ELISA was not used in our study because immunoblotting allowed an
overall surveillance of various allergen-specific antibody responses simultaneously,
whereas in ELISA, specific responses could not be distinguished.
3.2 Validation and optimisation ofmethodology
3.2.1 Specificity of anti-canine IgG antibody
In order to characterise the IgG response to Dermatophagoidesfarinae, it was
essential to demonstrate that the anti-canine IgG used in the study bound to IgG in
dog sera specifically. The aim of the initial experiments was to validate the
feasibility of using a horseradish peroxidase conjugated goat anti-dog IgG (Bethyl
Laboratories, Montgomery, TX, USA) for immunoblotting.
3.2.1.1 Protein profiles of purified canine IgG and IgE
Prior to assessing the specificity of the anti-canine IgG and IgE, the purity of the
canine IgG and canine IgE was examined by SDS-PAGE. 10 pi of 0.2 mg/ml
purified canine IgG and IgE was diluted 1/1 in reducing and non-reducing sample
buffer and separated by SDS-PAGE.
The protein profiles of purified canine IgG and IgE in SDS-PAGE gels are shown in
Figure 3.1. Under non-reducing condition (Fig 3.1 a), intact IgG and IgE molecules
had the molecular weight of approximately 190 and 200 kDa respectively. The
purified canine IgG antibody was not composed of single protein band; a few bands
around the 190 kDa protein were also present and might be different IgG subclass
87
molecules. Under reducing condition (Fig 3.1 b), antibodies were cleaved into heavy
and light chains with molecular weights of approximately 54 and 24 kDa for IgG and
75 and 25 kDa for IgE.
Figure 3.1 Protein composition of the purified canine IgG and IgE used to assess
antibody specificity in immunoblotting
Purified canine IgG (lane 1) and IgE (lane 2) analysed using non-reducing (a) and
reducing (b) sample buffer in SDS-PAGE gels. M: molecular weight marker in kilo-
daltons (kDa).














In order to assess the specificity of the anti-canine IgG and IgE antibodies, 100 pi of
0.2 mg/ml purified canine IgG and IgE was diluted 1/1 in non-reducing sample
buffer, separated by 10% SDS-PAGE gels using a broad well across the top (Chapter
2.4.2) and blotted onto PVDF membranes (Chapter 2.5.2), which were then cut into
strips. The strips were probed with different combinations of the following
antibodies diluted in dilution buffer: 1/1000 goat anti-canine IgG conjugated with
horseradish peroxidase, 1/100 mouse anti-canine IgE, 1/1000 bovine anti-mouse IgG
conjugated with horseradish peroxidase (Table 3.1). Immunoblots were developed
using the chromogenic substrate DAB, or in the case ofweak signals, the
chemiluminescent substrate ECL, to visualise blotting results (Chapter 2.5.3).
The binding of the anti-dog IgG and anti-dog IgE is shown in Figure 3.2 using
chemiluminescent methods (a) and chromogenic methods (b). The signal in lane 1
represented the binding between goat anti-canine IgG to canine IgG antibody
whereas the signal in lane 4 (visible in a) represented the binding between mouse
anti-canine IgE to canine IgE. The results also demonstrated that goat anti-canine
IgG could also bind to canine IgE, or that there was some IgG contamination of the
IgE preparation (lane 5); however, the same quantities of IgG and IgE were used in
this experiment whereas in physiological conditions, IgE concentrations would be a
thousand fold less than that of IgG. Hence, when detecting canine IgG responses in
serum using goat anti-dog IgG in immunoblots, the signal strength contributed from
IgE antibody would be negligible.
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Table 3.1 Antibodies used in immunoblotting assessing specificities









































Figure 3.2 Demonstration of binding between the horseradish peroxidase
conjugated goat anti-canine IgG and purified canine IgG and IgE
Purified canine IgG (lanes 1-3) and IgE (lanes 4-6) were probed with goat anti-
canine IgG, mouse anti-canine IgE as well as bovine anti-mouse IgG (Table 3.1) and
visualised with luminol substrate ECL (a) and chromogenic substrate DAB (b). Goat
anti-canine IgG bound to canine IgG (lane 1) and mouse anti-canine IgE bound to
canine IgE (lane 4, not visible in b due to limited detection sensitivity ofDAB).

















3.2.2 Optimisation of D. farinae extract, canine serum and anti-
canine IgG antibody dilution
In order to determine the optimal conditions to detect D. farinae-specific IgG
responses in dog, reagents were tested at different dilutions. 50 pg and 100 pg D.
farinae extracts (Greer, Lenior, NC, USA) were diluted 1/1 in reducing sample
buffer, separated in two 10% SDS-PAGE gels and blotted onto PVDF membranes,
which were then cut into strips. The strips were probed with a reference dog serum
sample from an atopic dog known to be allergic to D. farinae (at 1/50, 1/100 and
1/200) and mouse anti-canine IgG conjugated with HRP (1/500, 1/1000 and 1/2000)
(Table 3.2). DAB was incubated for one minute to visualise blotting signals.
The results are shown in Figure 3.3 (a) (50 pg D. farinae extract) and Figure 3.3 (b)
(100 pg D. farinae extract). Multiple antigens with molecular weights ranging from
20 kDa to 200 kDa were recognised by dog IgG antibody. As expected, the bands in
Figure 3.3 (b) were generally stronger than those in Figure 3.3 (a) because twice the
amount ofD. farinae extract was present; however, the background staining was also
stronger in Figure 3.3 (b). Also as expected, the general trend was that the less
diluted the serum sample, the stronger the signals. The dilution of the anti-canine
IgG did not have as much effect as the antigen quantity or serum dilution. Based on
the results, the conditions chosen as being optimal in terms of signal strength/noise
ratio were 50 pg D. farinae extract, serum at 1 in 100 and goat anti-canine IgG at 1 in
1000.
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Table 3.2 Reagents used in immunoblotting assessing optimal conditions to
detect D.farinae-specific IgG responses in dog
Blot (a) (b)
Strip 1 2 3 4 5 6 1 2 3 4 5 6
D.
farinae




























1/500 1/1000 1/1000 1/2000
Substrate DAB
Figure 3.3 Optimisation of amount ofD. farinae extract, dilution of dog serum
sample and goat anti-canine IgG
50 jag (a) and 100 pg (b) D.farinae crude extract were separated in SDS-PAGE and
transferred onto PVDF membranes for subsequent blotting. The reference serum
sample was diluted 1/50 (lanes 1 and 4), 1/100 (lanes 2 and 5) and 1/200 (lanes 3 and
6) and goat anti-canine IgG conjugated with horseradish peroxidase diluted 1/500 (A:
lanes 1-3), 1/1000 (A: lanes 4-6, B: lanes 1-3) and 1/2000 (B: lanes 4-6) (Table 3.2).
The more diluted the reagents, the weaker the signals, the better the signal/noise ratio.
M: molecular weight standards in kDa.













3.2.3 Optimisation of substrate incubation time
The chromogenic substrate DAB was chosen to visualise band signals and the
incubation time was also critical because of potential saturation effects. The aim of
this section was to evaluate the impact DAB incubation time had on band strength.
50 pig D.farinae extract diluted 1/1 in reducing sample buffer was separated in 10%
SDS-PAGE gel and transferred onto a PVDF membrane. After removing the
molecular weight standards, 16 4-mm wide strips were obtained and probed with
1/100 diluted dog serum sample and 1/1000 goat anti-canine IgG-HRP. Strips were
then incubated with DAB for different periods of time ranging from 0 seconds to 20
minutes. Strips were dried overnight and scanned at a resolution of 200 pixels per
inch (ppi) as digital files using a Hewlett-Packard Scanjet 3500c. Scanned files were
then analysed using Kodak Digital Science™ 1D Image Analysis Software and data
obtained by the software was imported into Microsoft Office Excel 2003 for analysis.
Immunoblotting strips incubated for different developing times are shown in Figure
3.4. Visible band strength and image analysis data increased with longer DAB
incubation times. The signal strength of three prominent bands with MWs of 170,
130 and 98 kDa is plotted against DAB incubation time in Figure 3.5. Both net
intensity and sum intensity results revealed the same trend which was the longer the
DAB incubation time, the stronger the band strength. Band strength increased
dramatically during the first 2 minutes and then gradually reached a plateau phase.
One minute DAB incubation time was considered appropriate for future experiments
as band intensity was not affected by colorimetric saturation and did not affect the
semi-quantitative assessment of the IgG response.
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Figure 3.4 Immunoblotting strips showing the relation between DAB incubation
time and signal strength
16 strips subjected to the same blotting conditions were incubated with DAB
substrate for different periods of time ranging from 20 minutes to 0 seconds. DAB
incubation time for each strip is as follow: 1: 20 min; 2: 15 min; 3:10 min; 4: 9 min;
5: 6 min; 6: 4 min; 7: 3 min; 8: 2min; 9: 90 sec; 10: 60 sec; 11: 50 sec; 12: 40 sec; 13:
30 sec; 14: 20 sec; 15:10 sec; 16: 0 sec. M: molecular weight marker in kDa.










Figure 3.5 Demonstration of the relationship between DAB incubation time and
signal strength
Blotting results were analysed using Kodak Digital Science™ ID Image Analysis
Software. Data from 3 representative bands with MWs of 170, 130 and 98 kDa are
shown. Band net intensity (top) and sum intensity (bottom) plotted against DAB
incubation time revealed the same trend: band intensity increased dramatically
during the first 2 minutes and then reached a plateau phase afterwards. ■: 170 kDa




















3.2.4 Assessment of assay reproducibility
The purpose of this section was to evaluate the reproducibility of the immunoblotting
conditions previously validated. 15 identical immunoblotting strips prepared as
described in the previous section and subjected to the same blotting conditions are
shown in Figure 3.6. The overall IgG binding profiles and the number of bands
recognised were visually consistent between strips. Data from the image analysis
software for 7 representative bands are summarised in Table 3.3. The coefficient of
variation was calculated using the following equation:
• Cv = o / fi x 100 %
(Cv: coefficient of variation; a: standard deviation; p: mean.)
The coefficient of variation ranged from 6 to 16 % for net intensity and 4 to 9 % for
sum intensity. These intra-assay variation figures were considered to be acceptable
for semi-quantitative analysis of band strength, as long as strips were only compared
within the same experiment.
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Figure 3.6 Immunoblotting strips showing assay reproducibility
15 strips containing separated D. farinae proteins were probed with the same canine
serum, goat anti-mouse IgG-HRP, and visualised using DAB along with a negative
control strip. The overall pattern was the same in all 15 strips. Band intensity as
assessed by the image analysis software did not differ significantly. M: molecular









Table 3.3 Reproducibility of immunoblotting assay
Net intensity Sum intensity
Band (kDa) p (pixels) ct (pixels) Cv (%) p (pixels) ct (pixels) Cv (%)
170 14716 1111 8 38039 3558 9
131 20529 1160 6 55185 4991 9
97 23766 1587 7 61703 2613 4
68 8643 1008 12 34633 2998 9
63 4578 717 16 25203 2392 9
44 5519 702 13 40316 1973 5
34 3942 601 15 37720 1845 5
Digital data showing net and sum intensities from 7 representative bands. The
variation of band intensity measured by net intensity was slightly wider than that
measured by sum intensity, p: mean; a: standard deviation; Cv: coefficient of
variation.
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3.2.5 Assessment of assay linearity
In order to further validate the immunoblotting and image analysis system for semi¬
quantitative measurements, it was important to evaluate assay linearity. The aim of
this section was to determine whether changes in serum concentration resulted in a
linear standard curve.
Twelve strips containing separated D.farinae proteins were probed with 3-fold serial
dilutions of a standard serum sample from 1:10 to 1:106. The standard serum sample
was chosen because it gave a positive response to a number of protein bands in
preliminary experiments. The blotting procedure was the same as previously
validated and described.
Visual observation of the strips clearly showed that the more diluted the serum
sample, the weaker the band signals were. D. farinae-specific IgG responses were
not detectable in serum samples diluted more than 1000 fold. The most obvious
bands with MWs of 170 kDa, 97 kDa, 66 kDa, 57 kDa, 44 kDa, 39 kDa, 34 kDa and
18 kDa were selected and analysed by the image analysis software. The results of
the net intensity and sum intensity are shown in Figure 3.8 and Figure 3.9
respectively. The intensity of each band changed in a linear fashion between log
serum dilution of 1/10 and 1/1000 and linear regression revealed R-squared values
ranged from 0.9207 to 0.9917 for net intensity measurements and from 0.9370 to
0.9881 for sum intensity measurements. These results indicated that by using a
serum dilution of 1/100, the system could be used to reliably semi-quantify IgG
concentrations over a range that was 10x higher or 10x lower than those normally
found in serum.
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Figure 3.7 Effect of serum dilution on band strength
Separated D. farinae antigens transferred onto a PVDF membrane were probed with
a reference canine serum sample at the following dilutions (from strip 1 to 11): lxlO"1,
3x 10"2, 1x10"2,3x10"3, 1x10"^xlO"4, lxlO"4, 3xl0"5, lxlO"5, 3xl0"®and lxlO"6. No
serum sample was added in strip 12 to serve as a negative control. Band signal
intensity was reduced when serum concentration was decreased. When the serum
sample was diluted to more than 1000 fold, D. farinae-specific IgG responses were
not detectable.









Figure 3.8 Demonstration of linear relationship between signal net intensity and
serum concentration
Eight prominent bands with different MWs were chosen for digital image analysis.
The serum concentration (pl/ml) is shown on the X-axis and net intensity (xlO4
pixels) is shown on the Y-axis. Regression lines and R-squared values are shown on
each graph. These linear standard curves indicate that the image analysis system
could determine changes in IgG concentration reliably enough to allow semi¬
quantitative analysis.
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Figure 3.9 Demonstration oflinear relationship between signal sum intensity
and serum concentration
The serum concentration (pi/ml) is shown on the X-axis and net intensity (xlO4
pixels) is shown on the Y-axis. Regression lines and R-squared values are shown on
each graph.
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3.3 Dermatophagoides farinae-specific IgG responses in
healthy and atopic dogs
The objective of this section was to use the previously validated semi-quantitative
blot analysis system to characterise and quantify D. farinae-specific IgG responses in
a number of healthy and atopic dogs.
Serum samples collected from 20 healthy dogs (Chapter 2.1.2) and 20 atopic dogs
(Chapter 2.1.3) were included in this study. 50 pg (1 mg/ml) D. farinae extract
diluted 1/1 in reducing sample buffer was separated in 10% SDS-PAGE gel (Chapter
2.4.2) and electrophoretically transferred onto a PVDF membrane. The molecular
weight standards were cut off and stained with Coomassie blue. The rest of the
membrane was cut into sixteen 4-mm wide strips and blocked for 1 hour with 5%
skimmed milk in TBS. In order to minimise inter-membrane variability, within each
experiment, 8 strips were used to detect D. farinae-specific IgG responses from
healthy dogs and the other 8 strips from the same membrane were used to detect IgG
responses from atopic dogs. Assays were performed in duplicate. For
immunoblotting, 1 ml of 1/100 diluted serum samples was added to individual strips
for 1 hour at room temperature. After thorough washing, strips were incubated with
1 ml of 1/1000 diluted horseradish peroxidase conjugated goat anti-canine IgG for
another hour at room temperature. After another round of thorough washing,
individual strips were developed with 1 ml 3,3'-diaminobenzidine (DAB) peroxidase
substrate for 1 minute and then removed by washing in distilled water. The strips
were air-dried overnight prior to digital image acquisition and analysis.
The Mann-Whitney test was used to compare healthy and atopic dogs for the number
of bands recognised, the molecular weight range of the bands observed, the total
intensity of the bands in each group and the intensity of the most important
individual bands. A p-value of <0.05 was considered to be significant.
A representative set of IgG immunoblots of individual dog sera from the two groups
are shown in Figure 3.10. Both healthy and atopic dogs mounted an IgG response to
multiple antigens from D. farinae. The two most visually obvious bands in both
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groups were seen at molecular weights of approximately 98 and 44 kDa. The
number of bands recognised did not differ significantly between the two groups (p =
0.6652; Figure 3.11) and varied between 3 and 12 in the healthy group and 2 and 10
in the atopic group, with median band numbers of 6.5 and 6, respectively. The
percentage of dogs recognising antigens of various molecular weights is shown in
Figure 3.12. In both healthy and atopic groups, two peaks of frequency were seen.
The first occurred at around 100 kDa and predominantly comprised responses to the
98 kDa antigen. The second occurred between 30 and 60 kDa, a major proportion of
which represented responses to the 44 kDa antigen. However, IgG responses were
seen to multiple other bands ranging in molecular weights from 20 to 180 kDa
(Figure 3.10 and Figure 3.12).
The intensity of each band, and therefore, the magnitude of the IgG response to that
particular protein(s), was provided by the digital analysis software. The intensity of
response in each dog to proteins of various molecular weights is shown in Figure
3.13. The most intense bands were seen at molecular weights clustered around 100
and 44 kDa. Hence, not only were these proteins the most commonly recognised (as
seen in Figure 3.12), they also resulted in the greatest IgG response. The average of
the total band intensity in each strip (i.e., for each dog) was 8335 in the healthy group
and 9997 in the atopic group; the difference approached statistical significance (p =
0.0697). The total response to the 98 kDa proteins were similar in the atopic group
(net intensity 18411) and healthy group (net intensity 16953) and was not
significantly different (p = 0.4094). However, the total response to the 44 kDa
antigen in the atopic group (net intensity 11088) was almost double that seen in the
healthy group (net intensity 6410). Based on the standard curve for this protein, this
actually represented a 6-fold increase in serum concentration, but the difference
between groups was again not statistically significant (p =0.2689).
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Figure 3.10 Binding of canine IgG to separated proteins ofD.farinae in 20
healthy dogs (a) and 20 atopic dogs (b)
Each strip represented one dog. Similar IgG binding profiles were observed. The
most visually obvious bands were 98 kDa and 44 kDa antigens. M: molecular
















Figure 3.11 Number of D. farinae bands recognised by canine IgG in healthy
and atopic dogs
Each box and whisker plot summarises the response of 20 dogs. The box represents
the 25th and 75th quartiles with the horizontal bar indicating the median. The



















Figure 3.12 Proportion of healthy (a) and atopic (b) dogs recognising D.farinae
antigens
Antigens are grouped in 10 kDa intervals and ranged from 15 to 185 kDa. A similar





































Figure 3.13 Scatter plot of band molecular weight against band net intensity in
healthy (a) and atopic (b) dogs
Each dot represents an IgG response to a D. farinae protein in an individual dog.











































In this chapter we aimed to develop and validate a semi-quantitative Western blot
analysis system to allow us to investigate the IgG response to D. farinae allergens in
healthy and atopic dogs. Initially, we demonstrated that polyclonal goat anti-canine
IgG recognised dog IgG but it also cross-reacted with canine IgE in immunoblots
using commercially available whole IgG and IgE preparations. However, the cross-
reactivity of the reagent with canine IgE would not be relevant in these experiments
because serum concentrations of allergen-specific IgE are so low that they cannot be
detected using colorimetric blots, even when employing specific anti-canine IgE
reagents. Interestingly, the anti-canine IgG appeared to have a higher affinity for IgE
than the specific anti-IgE reagent, as evidenced by a stronger band on the blots.
The colorimetric saturation of substrates is of substantial importance if the data
obtained is to be used for quantitative purposes. The development of the colour
signal reached a plateau after approximately two minutes, beyond which there would
be a loss of linearity. A 1 minute development time was therefore determined to be
optimal to ensure that band intensity was not affected by colorimetric saturation.
The IgG response to D. farinae proteins allowed standard curves to be constructed
with a linear and a logistic regression. The stronger the linear relationship between
the two variables (serum dilution and band intensity), the higher the correlation and
the more accurate the quantitative data that can be interpolated from the standard
curve. Linearity of the data was assessed using the square of the correlation
coefficient (R2). The R2 value for D. farinae-specific IgG versus signal net intensity
and signal sum intensity ranged from 0.9207 to 0.9917 and 0.9470 to 0.9881
respectively (Fig. 3.8 and 3.9), indicating good linear fit over a quantifiable range of
antibody concentrations. The intensity of each band changed in a linear fashion
between log serum dilutions of 1/10 and 1/1000. By using serum dilutions of 1/100,
the system could be used to reliably semi-quantify IgG concentrations over a range
that was 10x higher or 10x lower than those normally found in serum.
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Repeatability of the system was also assessed by probing 15 identical strips under the
same blotting conditions and the intra-assay coefficients of variations of intensity for
bands over the whole molecular weight range was typically around 10%. The inter-
assay variation was not measured because all the samples were tested on the same
day, atopic dogs were compared to healthy dogs within the same blot, and dilutions
of reagents were made in batches. Inter-assay variation was therefore not considered
to be relevant for these studies, but it would have to be carefully determined if the
technique was used to investigate large numbers of dogs on different days.
Taken together, after determining the antibody specificity, assay reproducibility and
linearity and confirming the absence of colorimetric saturation of signal intensity, the
immunoblotting and image analysis system proved to be appropriate for semi¬
quantitative analysis of antibody concentrations. This system had a major advantage
over ELISAs because it allowed antibody responses against separated antigens to be
explored. IfELISAs had been used, it would only have been possible to determine
the overall response to all the antigens present in the crude extract.
The image analysis system allowed D. farinae-specific IgG responses to be
compared in healthy dogs and dogs with atopic dermatitis. The profile of IgG
binding was similar in the two groups, both in terms of the number of bands
recognised and their molecular weights. The percentage of individual dogs
recognising these proteins was also similar in the two groups. These results indicate
that D. farinae produces a number of proteins that are recognised by the canine
immune system, both in healthy and atopic dogs.
The strength of the IgG response appeared to be greater overall, and for the 44 kDa
band, in the atopic dogs than in the healthy controls. The lack of significant
differences between the groups might imply that this difference was biologically
irrelevant but this must be interpreted with caution. A larger number of dogs in each
group would have increased the statistical power, which might have yielded a
significant difference.
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These results are in accordance with previous findings that demonstrated the
presence of antigen-specific IgG antibodies in both healthy and atopic dogs using
ELISAs (Willemse and others 1985b; Hites and others 1989; Day and others 1996;
Lian and Halliwell 1998). Furthermore, the increased antigen-specific IgG response
in the atopic group would be consistent with previous reports that showed higher
concentrations of total IgG (Hill and others 1995) and total IgGl (Fraser and others
2004) in atopic dogs. However, it must be borne in mind that these two previous
studies measured total, and not antigen-specific, antibody concentrations. The total
IgG responses seen in these studies could be directed at antigens other than D.
farinae such as additional environmental allergens or proteins produced by
Malassezia or staphylococcal organisms. Secondary infection with these pathogens
is common in dogs with atopic dermatitis and previous studies have shown
significantly greater IgG responses in atopic dogs to both Malassezia antigens
(Nuttall and Halliwell 2001a; Chen and others 2002a) and staphylococcal proteins
(Halliwell 1987; Morales and others 1994; Shearer and Day 1997).
The most important D. farinae antigens recognised, both in terms of frequency and
magnitude were 98 and 44 kDa proteins. It has been previously shown that bands
with the same molecular weights are recognised in IgE blots (Noli and others 1996;
McCall and others 2001; Nuttall and Halliwell 2001a), although the 44 kDa protein
is only seen when reducing buffers are used (Nuttall and Halliwell 2001a),
suggesting that it might be a part of a bigger antigen. It is likely that the 98 kDa
protein is the same as the high molecular weight chitinase that has recently been
designated Der f 15 (McCall and others 2001). This protein is the most important
allergen in atopic dogs that is recognised by IgE. However, the substantial IgG
response to this protein indicates that distinct immune responses dominated by either
isotype do not occur. Hence, although IgE responses are a critical component in the
pathogenesis of canine atopic dermatitis, the concept of Th2 cytokine controlled
class switching is clearly not an absolute phenomenon.
Taken together, the results of this and previous studies suggest that dogs mount an
IgG response to multiple environmental antigens, including house dust mites. This
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response is similar in healthy and atopic dogs, but is possibly greater in magnitude in
atopic dogs. Hence, the presence of D.farinae antigens in the environment does not
appear to be ignored by the canine immune system in healthy dogs and yet the IgG
response does not appear to be protective against the development of clinical atopic
disease. Whether the IgG response plays any direct role in the pathogenesis of the




G subclass responses in normal and atopic dogs
4.1 Introduction
Although hypersensitivity is generally mediated by IgE reaginic antibodies, IgG
anaphylactic antibodies have been demonstrated and characterised in a number of
other species (Binaghi 1983; Goodwin 1983). The nonreaginic anaphylactic
antibodies in different animal species share common features and differ from IgE
antibodies in heat susceptibility, mercaptoethanol sensitivity and short-term
sensitising (S-TS) property. IgG anaphylactic antibodies have been identified as
IgG4 in man (Reid and others 1966) and guinea pigs (Margni and Hajos 1973), IgGl
in mice (Nussenzweig and Benacerraf 1964), IgG2a in rats (Bach and others 1971)
and IgG2 in sheep (Esteves and others 1974). These antibodies are all relatively
unaffected by heat or sulfydryl reduction and their persistence at passively prepared
skin sites is much shorter than that of IgE. The demonstration of their anaphylactic
activity in animals can be achieved by the passive cutaneous anaphylaxis (PCA) test,
which is similar to the Prausnitz-Kiistner reaction. In terms of biological activity, the
existence of IgG anaphylactic antibodies in so many species must reflect a
physiological need (Binaghi 1983). However, the role of IgG anaphylactic
antibodies in atopic dermatitis was not investigated in these studies performed in the
late 1970s and early 1980s.
The nomenclature to designate the subclasses of IgG in animals was mostly based on
historical grounds and did not take into consideration the possible structural
homologues between subclasses of different species. Although IgG antibodies and
their associated effector systems were obviously conserved and homologous between
species, the numbers of IgG subclasses vary and direct functional equivalence
between subclasses in each species might not exist.
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Four subclasses of IgG have been identified in humans and they received the
denominations of IgG 1, IgG2, IgG3 and IgG4 according to serum concentrations in
normal subjects. Similar nomenclature was applied to canine IgG subclasses (Mazza
and others 1993). Studies investigating the IgG subclasses in various allergic
conditions in humans supported possible involvement of IgG subclass antibodies in
allergic diseases.
High levels of IgE and IgG4 subclass were observed in the serum ofAD patients,
suggesting the involvement of IgG4 in some immediate hypersensitivity diseases
(Shakib and others 1977). Specific IgG4 to environmental allergens was also
detected and high levels of this antibody were found in patients with AD and allergic
respiratory diseases (Nakagawa and others 1983; Merrett and others 1984). Walker
first reported an association between the exacerbation of eczema in patients with AD
and the exposure to airborne allergens such as pollen and house dust (Walker 1918).
There have been many studies correlating worsening of symptoms and exposure to
dust mites, as well as improvement of signs after environmental control (Beck and
Korsgaard 1989; Harving and others 1990; Colloff 1992; Sanda and others 1992).
Studies investigating allergen-specific IgG subclass responses in various allergic
conditions, however, demonstrated that specific subclass responses were allergen-
dependent. Patients suffering from extrinsic allergic alveolitis (EAA) due to
Aspergillus fumigatus typically demonstrated strong IgG subclass reactivities with a
predominance of IgGl and IgG2, while no specific IgE was found (Trompelt and
others 1994). In allergic bronchopulmonary aspergillosis (ABPA) patients showed
strong reactivities of all IgG subclasses and IgE but an intense IgG4 reaction
appeared as a typical marker for ABPA (Trompelt and others 1994). It has also been
shown in atopic children sensitised to birch pollen that specific antibodies of the
IgGl and IgG4 subclasses to the major birch-pollen allergen, Bet vl, are found in
93% of patients, whereas non-atopic children generally have no/low allergen specific
IgG to birch pollen (Harfast and others 1998). Kemeny et al demonstrated that IgGl
antibodies to house dust mite (HDM) were detected in most atopic patients (94%)
and healthy controls (97%), and an IgG4 response to HDM was present in 66%
113
atopics and 53% non-atopics (Kemeny and others 1989). However, the level of IgG4
antibodies were significantly higher in the atopic group (Kemeny and others 1989).
Another study investigating specific IgG subclass responses in asthmatic patients
sensitised to D. farinae has shown that the level of Der fl -specific IgG2 was
significantly higher in the non-atopic controls than in the atopic group, but the Der
f2-specific IgG2 and IgG4 were significantly higher in the atopic group than in the
control group (Hong and others 1994). Mori et al has recently detected elevated
levels of storage mite Blomia tropicalis-specific IgG3 subclass in AD patients and
asthmatic patients (Mori and others 2001).
There are only a few studies of specific IgG subclasses to various allergens in dogs
with atopic dermatitis. Studies by Day (Day and others 1996) suggested that IgGl
and IgG4 were involved in canine AD, depending on the allergen. Using a panel of
monoclonal antibodies (mAbs) directed against the four subclasses of canine IgG
(Mazza and others 1993; Mazza and others 1994b), it was demonstrated that the IgG
response to D. pteronyssinus and D. farinae was dominated by the IgG4 subclass
with significantly greater responders in atopic than normal dogs (Day and others
1996). In addition, significantly higher levels of IgGl, IgG2 and IgG3 antibodies
were produced to D. pteronyssinus in the atopic than in control samples. However,
the allergens involved could not be identified in the ELISA assays used.
The situation in dogs is further complicated by the description of IgGd (Willemse
and others 1985a), a subclass that does not correspond with the 1-4 nomenclature
(Day and others 1996). Experiments performed by Willemse et al in 1985 (Willemse
and others 1985a; Willemse and others 1985b) demonstrated the presence of non-IgE
anaphylactic antibodies, termed IgGd, in the sera of atopic dogs. It was suggested
that this subclass could initiate immediate hypersensitivity. However, the role of
IgGd in atopic diseases is uncertain; IgGd directed against apparently irrelevant
allergens is present in atopic dogs, and there are high levels of IgGd in normal dogs
to the common allergens D. pteronyssinus and D. farinae (Lian and Halliwell 1998).
It is possible that IgGd corresponds to IgGl (Richard Halliwell, personal
communication) but this has not been proven. In contrast, antiserum specific for
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IgGd failed to identify any of the four canine IgG subclasses in purified form in
ELISAs (Day and others 1996). This may reflect the fact that IgGd is a myeloma
protein, and the antiserum may not necessarily recognize native protein.
To date, nothing is known about the individual allergenic proteins targeted by IgG
subclasses in dogs with AD because these have not been evaluated in previous
ELISA assays using crude allergen extracts. Therefore, the aim of this study was to
further develop and validate the semi-quantitative, digital, chemiluminescent western
blot analysis system to evaluate allergen-specific IgG subclass responses to
electrophoretically separated allergens ofDermatophagoides farinae in dogs with
atopic dermatitis. A specific aim was to determine if different subclasses recognised
specific proteins within the separated extract.
4.2 Validation and optimisation ofmethodology
4.2.1 Assessment of purified canine IgG
A commercial preparation of canine IgG purified by ion-exchange chromatography
was used to evaluate the specificity of mAbs against canine IgG subclass antibodies.
10 pg of the purified canine IgG diluted in both reducing buffer and non-reducing
buffer was separated by 10% SDS-PAGE (Chapter 2.4.2). The lane next to the
sample in reducing buffer was not used because the reducing agent, 2-
mercaptoethanol, could possibly diffuse to adjacent lanes and interfere with non-
reducing condition. After electrophoresis, the gel was stained with Coomassie blue
(Chapter 2.4.3).
Purified canine IgG separated in SDS-PAGE is shown in Figure 4.1. 55-kDa (heavy
chain) and 30-kDa (light chain) proteins comprised 93.7% of the total protein content
under reducing conditions, and a 200-kDa protein comprised 81.5% of the total
protein under non-reducing condition. Small traces of other bands were detectable
with the image analysis software, but the purity of this commercial preparation of
canine IgG was considered acceptable for evaluating the specificity of mAbs.
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Figure 4.1 Protein composition of the commercial preparation of canine IgG
Canine IgG was separated under both reducing and non-reducing conditions using
SDS-PAGE. Molecular weight and mass percentage of individual bands are
indicated. R: reducing conditions; NR: non-reducing conditions; M: molecular
weight marker in kDa.
R M NR
21.5
4.2.2 Assessment of the mAbs used in immunoblotting
The mAbs used in this study have previously been evaluated for their specificity
against the four different IgG subclasses (Mazza and others 1993; Mazza and others
1994b). However, in order to characterise the IgG subclass responses to separated
proteins from Dermatophagoidesfarinae, it was essential to demonstrate that the
four different monoclonals could be used in immunoblotting experiments.
Because limited amounts of the four mAbs were available, the highest practical
dilution for these antibodies was 1/200. Assay sensitivity was increased by other
measures, including prolonged incubation times for antibodies and extended and
repeated exposure times in recording the chemiluminescent signals.
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100 pg purified canine IgG diluted in both reducing buffer and non-reducing buffer
was separated by 10% SDS-PAGE using a broad well across the top (Chapter 2.4.2),
transferred onto a PVDF membrane (Chapter 2.5.2) and cut into strips. After
blocking non-specific binding sites with blocking buffer and thorough washing, each
mAb was then added to individual strips at a dilution of 1/200 in dilution buffer and
incubated overnight at room temperature. After further washing, bovine anti-mouse
IgG conjugated with horseradish peroxidase at 1/1000 dilution was added to each
strip before incubation at room temperature for 2 hours. The luminol substrate ECL
was used to develop the chemiluminescent signals. Strips were carefully aligned and
wrapped in cling film and immediately placed protein side down on the image station
along with Coomassie blue stained molecular weight standards (Chapter 2.5.3).
The commercial preparation of purified canine IgG was probed with each of the four
mAbs at a dilution of 1/200. Under non-reducing conditions, IgGl gave the
strongest chemiluminescent signal, followed by IgG4 (Figure 4.2 a). IgG2 and IgG3
could only be detected using less diluted mAbs (1/20) and applying a prolonged
exposure of 2-hours to increase the sensitivity (compared to the 32 minutes used for
IgGl) (Figure 4.2 b). Under reducing conditions, all of the four mAbs gave weak
chemiluminescent signals (Figure 4.3). The reducing conditions seemed to expose
epitopes that were not accessible under non-reducing conditions, and the mAbs could
detect both heavy and light chains of the IgG subclass molecules.
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Figure 4.2 Demonstration of binding between mAbs and purified canine IgG
under non-reducing conditions
A: Purified canine IgG was probed with a panel of four mouse monoclonal
antibodies specific for the subclasses of canine IgG. IgGl gave the strongest
chemiluminescent signal, followed by IgG4. B: IgG2 and IgG3 could only be
detected after a prolonged exposure to increase the sensitivity. M: molecular weight
standards in kDa; 1: IgGl; 2: IgG2; 3: IgG3; 4: IgG4.
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Figure 4.3 Demonstration of binding between mAbs and purified canine IgG
under reducing conditions
Purified canine IgG was probed with a panel of four mouse monoclonal antibodies
specific for the subclasses of canine IgG. The four mAbs were diluted in 1/200 for
IgGl and IgG4„ and in 1/20 for IgG2 and IgG3. A prolonged exposure setting was
applied for IgG2 and IgG3. M: molecular weight standards in kDa; 1: IgGl; 2: IgG2;











4.2.3 Demonstration of D. farinae-specific IgG subclass responses
in immunoblots
After confirming that the four mouse monoclonal antibodies specific for the
subclasses of canine IgG bound to dog IgGl, IgG2, IgG3 and IgG4, it was important
to determine whether the reagents could be used to detect D. farinae-specific IgG
subclass responses. 200 pi (1 mg/ml) crude D. farinae extract (Chapter 2.3) diluted
in reducing buffer was separated by 10% SDS-PAGE (Chapter 2.4.2), transferred
onto a membrane (Chapter 2.5.2) and cut into strips. After blocking non-specific
binding sites with blocking buffer and thorough washing, a non-diluted reference
serum was added and incubated for 3-4 hours. After another round of thorough
washing, each mAb was then added to individual strips at a dilution of 1/100 in
dilution buffer and incubated overnight at room temperature. Bovine anti-mouse IgG
conjugated with horseradish peroxidase at 1/1000 dilution was added to each strip
before incubation at room temperature for another 2 hours. The luminol substrate
ECL was prepared and used to develop the chemiluminescent signals, and the bands
were visualised using the image acquisition system described in Chapter 2.5.3.
When separated proteins from D. farinae were incubated with the reference canine
serum sample and probed with mAbs against IgGl and IgG4, strong signals were
obtained for a protein with a molecular weight of approximately 98 kDa (Figure 4.4
a). Using the above described dilutions, incubation times and 1-2 minute exposure
times, no signals were seen with IgG2 and IgG3 (Figure 4.4 a). D. farinae-specific
IgG2 and IgG3 could only be detected when the assay sensitivity was increased
dramatically by using 1/20 dilution of mAbs, and prolonged 2-hour exposure times
(Figure 4.4 b).
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Figure 4.4 Demonstration ofD.farinae-specific IgG subclass responses under
reducing conditions
A representative set of chemiluminescent blots showing IgG subclass responses to
separated D. farinae antigens. Each strip was incubated with the same reference
serum sample from a healthy dog and probed with mAbs against the four IgG
subclasses, (a) Signals can be seen for IgGl and IgG4 against a 98 kDa protein, but
the IgG4 response is stronger. A low molecular weight band can also be seen with
IgGl. No signal can be discerned with IgG2 or IgG3. (b) After prolonged
incubations using low reagent dilutions, and prolonged exposures, a signal can be
seen at 98 and 66 kDa with IgG2 and IgG3. M: molecular weight standards in kDa; 1:
IgGl; 2: IgG2; 3: IgG3; 4: IgG4.
(a) M 1 2 3 4 (b) M 2 3
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4.2.4 Assessment of assay reproducibility
The purpose of this section was to determine the reproducibility of the
immunoblotting conditions previously determined. D. farinae-specific IgG2 and
IgG3 were not tested here because their levels were below the detection limit using
the standard protocol. 100 pg D. farinae extract diluted 1/1 in reducing sample
buffer were separated in SDS-PAGE and transferred onto a PVDF membrane. The
molecular weight marker was removed from the membrane and stained with
Coomassie blue. Sixteen 4-mm wide strips were obtained and probed with the
reference serum sample diluted 1/20 for 1 hour at room temperature. 8 strips were
then incubated with 1/200 diluted mAb B6 (specific for canine IgGl) and 8 strips
were incubated with 1/200 diluted mAb A5 (specific for canine IgG4) for 1 hour at
room temperature. It was followed by another hour of incubation with 1/1000
bovine anti-mouse IgG conjugated with horseradish peroxidase and luminol solution
ECL was used to visualise the bands.
Results from the eight strips detecting D. farinae-specific IgGl and IgG4
respectively are shown in Figure 4.5 and Figure 4.6. The overall IgGl and IgG4
binding profiles and the number of bands recognised were the same in all strips.
Visual analysis suggested that consistent band intensity could be obtained.
The blotting results analysed by the image analysis software are summarised in Table
4.1 (IgGl) and Table 4.2 (IgG4) where data from 4 representative bands are shown.
The coefficient of variation for IgGl immunoblots ranged from 6 to 30 % for net
intensity and 6 to 22 % for sum intensity. The coefficient of variation for IgG4
immunoblots ranged from 7 to 15 % for net intensity and 5 to 16 % for sum intensity.
These reproducibility figures were considered acceptable for semi-quantitative
analysis.
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Figure 4.5 IgGl chemiluminescent blotting strips showing assay reproducibility
Eight D. farinae strips probed with the same canine reference serum sample, mAb
B6, bovine anti-mouse IgG-HRP and visualised using luminol solution are shown.
The overall pattern was the same in all 8 strips. Band intensity remained consistent.








Table 4.1 Reproducibility of IgGl immunoblotting assay
Net intensity Sum intensity
Band (kDa) p (pixels) a (pixels) Cv (%) p (pixels) a (pixels) Cv (%)
200 92536 16157 17 103584 17935 17
97 88377 9448 11 100150 10535 11
57 22147 1310 6 32140 1941 6
33 28503 8509 30 38965 8638 22
Digital data showing net and sum intensities from 4 representative bands are
summarised. The variation of band strength, measured by net intensity, did not differ
from that measured by sum intensity, p.: mean; o: standard deviation; Cv: coefficient
of variation.
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Figure 4.6 IgG4 chemiluminescent blotting strips showing assay reproducibility
Eight D. farinae strips probed with the same canine reference serum sample, mAb
A5, bovine anti-mouse IgG-HRP and visualised using luminol solution are shown.
The overall pattern was the same in all 8 strips. Band intensity did not differ





Table 4.2 Reproducibility of IgG4 immunoblotting assay
Net intensity Sum intensity
Band (kDa) |j (pixels) a (pixels) Cv (%) p (pixels) a (pixels) Cv (%)
200 148436 18924 13 161535 20765 13
97 78828 8110 10 86408 8325 10
64 30305 4657 15 36124 5684 16
44 35060 2548 7 43906 2411 5
Digital data showing net and sum intensities from 4 representative bands are
summarised. The variation of band strength measured by net intensity did not differ
much from that measured by sum intensity, p: mean; a: standard deviation; Cv:
coefficient of variation.
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4.2.5 Assessment of assay linearity
As with the studies on total IgG conducted in Chapter 3, it was necessary to evaluate
assay linearity. The aim of this section was to determine whether changes in serum
concentration resulted in a linear standard curve.
Blot strips containing separated D.farinae proteins were probed with 3-fold serial
dilutions of the reference serum sample from 1:10 to 1:106. Strips were then
incubated with mAb B6 (for detection of IgG 1 antibody) or mAb A5 (for detection
of IgG4 antibody), followed by bovine anti-mouse IgG-HRP. D.farinae-specific
IgG2 and IgG3 were not tested here because their levels were below the detection
limit using the standard protocol. Luminol solution was used to visualise
chemiluminescent signals.
Results from ten D.farinae immunoblotting strips are shown in Figure 4.7 (IgGl)
and Figure 4.8 (IgG4). It was clear from visual observation that the more diluted the
serum sample, the weaker the band signals were. D.farinae-specific IgGl and IgG4
responses were not detectable in serum samples diluted more than 1000 fold.
For IgGl immunoblots, bands with MWs of 200 kDa, 97 kDa and 34 kDa were
selected and analysed by the image analysis software. For IgG4 immunoblots, bands
with MWs of 200 kDa, 97 kDa and 44 kDa were selected and analysed. Results
showing net intensity and sum intensity are shown in Figure 4.9 and Figure 4.10
respectively for IgGl and IgG4 data. Linear regression could be obtained using data
generated by the software. The R-squared value ranged from 0.9394 to 0.9916 for
IgGl measurements and from 0.9271 to 0.9846 for IgG4 measurements. The
intensity of each band changed in a linear fashion between log serum dilution of 1/10
and 1/1000. Hence, by using serum dilutions of 1/20, the system could be used to
reliably semi quantify IgG concentrations over a range that was 5x higher or 20x
lower than that normally found in serum.
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Figure 4.7 D.farinae-specific blots probed with serial dilutions of a reference
serum sample followed by anti-IgGl
Separated D.farinae antigens transferred onto a PVDF membrane were probed with
a reference canine serum sample at the following dilutions (from strip 1 to 10 in
duplicate): lxlO"1, 3xl0"2, 1x 102, 3xl0~3, and lxlO"3. Strips probed with serum
samples diluted more than 1000 fold were not shown because no signals were
detected. Band signal intensity was reduced when serum concentration was
decreased.









Figure 4.8 D.farinae-specific blots probed with serial dilutions of a reference
serum sample followed by anti-IgG4
Separated D. farinae antigens transferred onto a PVDF membrane were probed with
a reference canine serum sample at the following dilutions (from strip 1 to 10 in
duplicate): lxlO"1, 3xl0~2, lx10"2, 3xl0"3, and lxlO"3. Strips probed with serum
samples diluted more than 1000 fold were not shown because no signals were






Figure 4.9 Demonstration of linear relationship between signal intensity and
serum concentration measuring D. farinae-specific IgGl
The X axis represents serum concentration (pg/ml) in log scale while the Y axis
represents intensity (x 104 pixels). Graphs on the left indicate net intensity and
graphs on the right indicate sum intensity. Logarithmic trend lines and R-squared
values are shown on each graph. Linear regression fit was observed.
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Figure 4.10 Demonstration of linear relationship between signal intensity and
serum concentration measuring D. farinae-specific IgG4
The X axis represents serum concentration (gg/'ml) in log scale while the Y axis
represents intensity (x 104 pixels). Graphs on the left indicate net intensity and
graphs on the right indicate sum intensity. Logarithmic trend lines and R-squared
values are shown on each graph. Linear regression fit was observed.
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4.3 Dermatophagoides farinae-specific IgG subclass
responses in healthy and atopic dogs
The objective of this section was to use the previously validated semi-quantitative
blot analysis system to characterise and quantify the D. farinae-specific IgG subclass
responses both in healthy and atopic dogs.
Serum samples collected from 20 healthy dogs (Chapter 2.1.2) and 20 atopic dogs
(Chapter 2.1.3) were included in this study. 100 pg (1 mg/ml) D. farinae extract
diluted 1/1 in reducing sample buffer was separated in 10% SDS-PAGE gel and
electrophoretically transferred onto a PVDF membrane. The molecular weight
standards were cut off and stained with Coomassie blue. The rest of the membrane
was cut into 16 4-mm wide strips to facilitate subsequent probing with different
serum samples and non-specific binding sites were blocked with 5% skimmed milk
in TBS for 1 hour. To minimise inter-membrane differences, 8 strips were used to
detect D. farinae-specific IgG responses from healthy dogs and another 8 strips from
the same membrane were used to detect that from atopic dogs. For immunoblotting,
1 ml of 1/20 diluted serum samples was added to individual strips for 1 hour at room
temperature. After thorough washing, strips were incubated with 1 ml of 1/200
diluted mAb B6 for IgGl detection or 1ml of 1/200 diluted mAb A5 for IgG4
detection for another hour at room temperature. After another round of thorough
washing with frequent changes of washing buffer, individual strips were incubated
with 1 ml of 1/1000 diluted bovine anti-mouse IgG conjugated with horseradish
peroxidase for 1 hour. Bands were visualised using luminol substrate ECL and
recorded on the image station. The optimal exposure settings were 32 x 1 min
exposures for IgGl blots and 32 x 20 sec exposures for IgG4 blots. Exposure time
was estimated based on the acquired preview image of the blots and repeated
exposure was applied to eliminate potential saturation phenomena.
Results were studied using the Image Analysis software (Chapter 2.5.3), and data
were then exported to MINITAB™ statistical software (Minitab Inc., PA, USA) for
analysis. The Mann-Whitney test was used to compare healthy and atopic dogs for
the number of bands recognised, the molecular weight range of the bands observed,
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the total intensity of the bands in each group and the intensity for the most important
individual bands. A p-value of <0.05 was considered to be significant.
Both healthy and atopic dogs mounted detectable D.farinae-specific IgGl and IgG4
responses (Figure 4.11 and Figure 4.12). Both IgGl and IgG4 recognised multiple
proteins from D. farinae with the most visually obvious bands having molecular
weights of approximately 98 kDa and 18 kDa for IgGl (Figure 4.11) and 98 kDa and
45 kDa for IgG4 (Figure 4.12).
The IgGl chemiluminescent blots of all dog sera from the two groups are shown in
Figure 4.11. The intensity of each band, which represents the magnitude of the IgG
response to that particular protein, is summarised in Figure 4.13. The most
commonly recognised allergen was the 98 kDa protein, followed by a low molecular
weight antigen of 18 kDa. The number of bands recognised per dog did not differ
significantly between the two groups (p—0.99) and varied between 1 and 8 in the
healthy group and 2 and 6 in the atopic group, with median band numbers of 3.5 and
3 respectively. The sum of all the band intensities in each group (i.e. the total IgGl
response to all D.farinae allergens) was 85616 in the healthy group and 65094 in the
atopic group (p=0.6879). The responses to the 98 kDa and 18 kDa antigens were
slightly higher in the healthy group (intensities 21947 and 20197) than in the atopic
group (intensities 19368 and 16344) but the difference did not reach statistic
significance (p=0.5188 for 98 kDa protein andp=0.\ 148 for 18 kDa antigen) (Figure
4.15).
The IgG4 chemiluminescent blots of all dog sera from the two groups are shown in
Figure 4.12, and the data summarised graphically in Figure 4.14. As with IgGl, a 98
kDa protein was commonly detected in both groups, whereas an antigen with a
molecular weight of approximately 45 kDa was also present. The number of bands
recognised did not differ between the two groups (p=0.5975) and varied between 1 to
9 in the healthy group and 1 to 11 in the atopic group, with median band numbers of
6 and 4 respectively. The sum of all the band intensities in each group (i.e. the total
IgG4 response to all D.farinae allergens) was 106700 in the healthy group and
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87813 in the atopic group (/?=0.3123). The responses to the 98 kDa and 44 kDa
antigens were slightly higher in the healthy group (intensities 21242 and 16967) than
in the atopic group (intensities 18758 and 15690) but these were not significantly
different (p=0.1117 for 98 kDa protein andp=0.6893 for 45 kDa antigen) (Figure
4.16).
Figure 4.11 Binding pattern of canine IgGl to separated proteins ofD.farinae
in 20 healthy dogs (a) and 20 atopic dogs (b)
Each strip represents one dog. Similar IgG binding profiles were observed. The
most visually obvious bands were 98 kDa and 18 kDa antigens. M: molecular


















Figure 4.12 Binding pattern of canine IgG4 to separated proteins ofD.farinae
in 20 healthy dogs (a) and 20 atopic dogs (b)
Each strip represents one dog. Similar IgG binding profiles were observed. The
most visually obvious bands were 98 kDa and 44 kDa antigens. M: molecular
weight standards in kDa.
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Figure 4.13 Scatter plot of band molecular weight against D. /anwue-specific
IgGl band intensity in healthy and atopic dogs





lc i?i • I
healthy atopic
:
• • ! . :
• • a t
►i ■ i • i
J •
t •
50 100 150 200 0 50 100 150 200
Molecular weight (kDa)
134
Figure 4.14 Scatter plot of band molecular weight against D. farinae-specific
IgG4 band intensity in healthy and atopic dogs
Each dot represents an IgG4 response to a D. farinae protein in an individual dog.
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Figure 4.15 Intensity of the IgGl response to the two most commonly recognised
antigens in D. farinae
The box and whisker plots summarise the response of 20 atopic and 20 normal dogs
to proteins with molecular weights of 98 kDa and 18 kDa. The middle bar represents
the median, the upper and lower bars represent the 25th and 75th percentiles, and the
whiskers extend to the highest or lowest values that fall within 1.5 times the
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Figure 4.16 Intensity of the IgG4 response to the two most commonly recognised
antigens in D. farinae
The box and whisker plots summarise the response of 20 atopic and 20 normal dogs
to proteins with molecular weights of 98 kDa and 45 kDa. The middle bar represents
the median, the upper and lower bars represent the 25th and 75th percentiles and the
whiskers extend to the highest or lowest values that fall within 1.5 times the
interquartile range.* represents outlier.
atopic normal atopic normal
137
4.4 Discussion
In this chapter we aimed to further develop and validate the semi-quantitative
western blot analysis system to allow us to investigate the IgG subclass responses to
D. farinae allergens in both healthy and atopic dogs. Initially, we determined if the
four mAbs specific for the subclasses could recognise the appropriate antibodies in
immunoblots using a commercially available whole IgG preparation. The signals for
IgGl and IgG4 were much stronger than for IgG2 and IgG3 (Figure 4.2). This does
not reflect the serum levels of the four subtypes as reported by Mazza (Mazza and
others 1994a), where IgGl and IgG2 were shown to have at least nine fold higher
concentrations than IgG3 and IgG4. One explanation for this potential discrepancy is
that the whole IgG used in these validation experiments may have had concentrations
of subclasses within it that do not mirror serum concentrations. Alternatively, the
results may indicate that the monoclonal antibodies used for IgG2 and IgG3 were
less able to bind to immunoblots compared to the ELISA assay used by Mazza
(Mazza and others 1994a) leading to lower signal strengths. This would lower the
sensitivity of the immunoblotting system to detect IgG2 and IgG3 responses.
When the purified canine IgG was denatured by heating in the presence of the
reducing agent P-mercaptoethanol, the non-covalent intra- and inter-molecular
associations, i.e. disulfide bridges, were disrupted and the IgG was effectively
rendered devoid of secondary and tertiary structure. Under denaturing conditions,
two bands corresponding to immunoglobulin heavy chain and light chain were
detected. However, dog IgG2 and IgG3 could only be detected when the assay
sensitivity was dramatically increased by using less diluted mAbs and prolonged
exposure settings (Figure 4.3)
When the immunoblotting system was used to detect IgG subclass responses to
separated D. farinae proteins, strong signals could only be obtained for IgGl and
IgG4. IgG2 and IgG3 responses were virtually undetectable, unless very long
incubation and exposure times were used, together with low dilutions of sera and
reagents. The lack of an IgG2 and IgG3 response could be due to poor binding of
these reagents in this type of system as suggested above. It could also reflect the
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possibility that IgG2 and IgG3 responses are minimal against environmental antigens
such as those from D. farinae, as suggested by Day (Day and others 1996).
Densitometric analysis of chemiluminescent protein signals revealed that the
reproducibility ofD. farinae-specific IgGl and IgG4 responses as assessed by
coefficient of variation ranged from 5 to 30%. Chemiluminescent application was
chosen because of its superior lower detection limit, but reliable measurements were
difficult to obtain because photon emission intensity declined with time, repeated
long exposure was applied in order to capture faint chemiluminescent signals whilst
avoiding potential saturation of strong bands, and minute signal intensity variation
due technical limitation of cooled CCD camera recording system. A coefficient of
variation of below 10% of the detection system was generally considered of high
reproducibility. Despite the substandard repeatability of our chemiluminescence
assay, the coefficient of variation figures was considered acceptable for semi¬
quantitative analysis.
The IgGl and IgG4 responses to D. farinae proteins allowed linear standard curves
to be generated. This allowed semi-quantitative analysis of the antibody
concentrations in serum at concentrations approximately 20 times lower than the
concentrations measured in the reference sample, similar to the results found when
measuring total IgG responses (Chapter 3).
Using the Western blot analysis system, we compared allergen-specific IgGl and
IgG4 subclass responses to various antigens of the house dust mite D. farinae in
healthy dogs and dogs with atopic dermatitis. The profiles of the IgGl and IgG4
responses were similar in the two groups, both in terms of the number of bands
recognised, and their molecular weight. The percentage of individual dogs
recognising these proteins was also similar in the two groups. These results indicate
that D. farinae produces a number of proteins that are recognised by the canine
immune system, both in healthy and atopic dogs, and are in accordance with previous
findings (Lian and Halliwell 1998; Hou and others 2005). However, studies by Day
et al (Day and others 1996) only detected antigen-specific IgG antibodies against D.
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farinae using ELISA in one out of eleven normal dogs. The reason for this
discrepancy is not known but it might arise from technical, geographical,
environmental or gene pool differences in healthy dogs included in the respective
studies.
In terms of the proteins recognised, there was both an IgGl and IgG4 response to an
antigen with a molecular weight of approximately 98 kDa. This is likely to be the
high molecular weight allergen Der f 15 that is recognised by IgE in atopic dogs
(Noli and others 1996; McCall and others 2001; Nuttall and others 2001b). IgGl
also recognised a low molecular weight protein of approximately 18 kDa, whereas
IgG4 commonly recognised an antigen with a molecular weight of approximately 45
kDa. A similar protein is also recognised by IgE in immunoblots (Nuttall and others
2001b). These findings suggest that particular allergens can stimulate different
subclass responses.
The regulatory mechanisms of IgG subclass production to specific allergens has not
yet been fully determined. It has been shown that IgGl and IgG4 antibodies to grass
pollen in allergic patients are synchronised with seasonal variation of IgE antibody in
response to seasonal pollen exposure (Nordvall and others 1986). Studies
investigating IgG subclasses in association with dust mite allergen levels has
suggested that seasonal changes in natural exposure to house dust mite allergen
might lead to concurrent changes in D. farinae-specific IgG4 in mite-sensitive
patients (Nahm and others 1998). In terms of antigen-specific IgG subclass
responses, it has been shown that D. pteronyssinus group II (Der p 2) antigen was
able to elicit increased Der p 2-specific IgG4 responses in patients with mite allergy
(Tame and others 1996). Another study has demonstrated that levels ofD. farinae
group II (Der f 2)-specific IgG2 and IgG4 were higher in the atopic group, but the
reverse was found for the D. farinae group I (Der f l)-specific IgG2, meaning
significantly higher concentration ofDer f 1-specific IgG2 was found in the non-
atopic group (Hong and others 1994). Taken together, the results suggest that
specific proteins in D. farinae are able to stimulate specific subclass responses, but
further studies are required to determine how this happens.
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The strength of the IgGl and IgG4 responses was generally slightly higher in the
healthy controls than in the atopic dogs, both overall and for the most intense bands.
The lack of significant differences between the groups might imply that this
difference was biologically irrelevant. However, a study including a larger number
of dogs in each group might help to clarify whether the difference was genuine and
relevant. Hill et al (Hill and others 1995) reported that total IgG concentrations were
significantly higher in atopic and parasitized dogs compared to healthy controls.
However, this study did not measure allergen-specific IgG, or IgG subclasses, and
the antibody response could have been directed against a range of antigens, including
those derived from staphylococci and Malassezia organisms (Nuttall and Halliwell
2001a; Chen and others 2002a).
Although it is not possible to accurately compare the strength of the IgGl response to
the IgG4 response because we do not know the exact concentration or affinities of
the mAbs, there is some evidence to suggest that the IgG4 response to D. farinae
antigens was stronger. The IgG4 concentration in normal dog serum is 9 times less
than the IgGl response and yet in these experiment, the signals on the blots were
much stronger (Compare Figures 4.11 and 4.12), even when using shorter exposure
times.
Taken together, the results of this and previous studies suggest that D.farinae-
specific IgG and IgG subclasses do not play a major role in the pathogenesis of
canine atopic dermatitis. Such responses occur in both healthy and atopic dogs and




G responses in atopic dogs undergoing allergen-
specific immunotherapy using alum-precipitated or
aqueous vaccines
5.11ntroduction
Allergen-specific immunotherapy (ASIT) is the practice of administering gradually
increasing quantities of an allergen extract to an allergic subject to ameliorate the
symptoms associated with subsequent exposure to the causative allergen (Bousquet
and others 1998; Griffin and Hillier 2001b). The efficacy ofASIT has been well
documented for humans with respiratory atopic diseases and stinging insect allergy,
but its effectiveness seems more controversial for patients with AD. Since Wittich
(Wittich 1941) first reported in 1941 that ASIT could be used successfully in the
treatment of seasonal pollinosis in dogs, many studies, and a large body of clinical
observations by veterinary dermatologists, have suggested that ASIT can be effective
in controlling the signs ofAD in dogs (Nesbitt 1978; Willemse and others 1984;
Scott and Miller 1993c; Mueller and Bettenay 1996; Nuttall and others 1998; Zur and
others 2002b). However, most of these data are either anecdotal or originate from
questionnaire-based studies, and, to date, there has been only one placebo-controlled
study that has investigated this form of treatment in dogs (Willemse and others 1984).
Collectively, this body of information and literature has resulted in efficacy claims
ranging from 50% to 100%, with a response usually being defined as in improvement
in clinical signs of at least 50% (Griffin and Hillier 2001b).
Two main forms ofASIT vaccines are currently used in dogs: aqueous vaccines are
favoured in North America whereas alum-precipitated vaccines are commonly used
and recommended in Europe (Willemse and others 1984). A comparison of the true
efficacy of these vaccine types is not possible because different studies quote
differences in allergen extracts, the number of allergens used, the concentration of
allergens, the frequency of administration, as well as assessment of clinical outcome
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which is highly subjective and easily influenced by other factors such as secondary
infections. One potential advantage of aluminium-adjuvanted vaccines is the more
rapid development of high titre and long-lasting antibody responses after primary
immunisation (Volk and Bunney 1942). The mechanism of action of aluminium
adjuvant likely involves the formation of a depot, increasing targeting of antigens to
antigen-presenting cells, and non-specific activation of the immune response (Gupta
1998). However, in human patients with Hymenoptera venom allergy, the
therapeutic efficacy of specific immunotherapy using aluminium hydroxide adsorbed
vaccines and aqueous preparations did not differ (Rueff and others 2004).
Although the clinical efficacy ofASIT is well documented in humans and dogs, the
molecular and immunological mechanisms involved are incompletely understood.
Current evidence from rodent and human studies suggests that ASIT exerts effects on
several aspects of the immune system, including modulation of allergen-specific B
cells as well as T-cell responses. Studies on the effect ofASIT have demonstrated
reduced basophil reactivity to allergens (Kimura and others 1985; Shim and others
2003), deviation of Th2-cytokine responses to allergens in favour of the Thl
responses (Secrist and others 1993; Jutel and others 1995; McHugh and others 1995;
Akoum and others 1996), and the induction of IL-10-producing regulatory T cells
(Bellinghausen and others 1997; Akdis and others 1998a; Francis and others 2003).
In addition, changes in serum antibody titres in response to ASIT have been
described, mostly as increases in allergen-specific IgG antibodies, particularly of the
IgGl and IgG4 isotypes (Muller and others 1989; McHugh and others 1990).
Allergen-specific IgG produced in response to ASIT has been proposed as "blocking
antibody" by competing with IgE for allergen binding to mast cells, basophils, and
other IgE receptor-expression cells.
To date, only two studies investigating changes in IgG concentrations have been
reported in dogs during ASIT (Hites and others 1989; Fraser and others 2004). Hites
et al reported increases in allergen-specific IgG antibodies to various pollens during
ASIT using aqueous allergens (Hites and others 1989). Fraser et al showed that
concentrations of total IgGl could increase following ASIT using adjuvanted
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vaccines (Fraser and others 2004), but this study did not investigate allergen-specific
responses. However, no studies have reported changes in IgG antibodies specific for
antigens derived from the house dust mite Dermatophagoides farinae, a major cause
of AD in dogs (Noli and others 1996; Hill and DeBoer 2001; McCall and others 2001;
Nuttall and others 2001b).
The aim of these studies was to use the semi-quantitative blot analysis system to
investigate changes in IgG to separated antigens from D. farinae during ASIT with
alum-precipitated and aqueous vaccines. Our hypothesis was that allergen-specific
IgG antibodies would increase after the administration of allergen-specific
immunotherapy in dogs with atopic dermatitis.
5.2 Study 1 - ASIT using alum-precipitated vaccines
5.2.1 Material and methods
5.2.1.1 Serum samples
Serum samples were obtained from 21 dogs with AD taking part in a clinical trial to
evaluate the efficacy of two different ASIT protocols using adjuvanted vaccines
(Colombo and others 2005). All dogs included had a positive reaction to D. farinae
tested by either intradermal test (IDT) or allergen-specific IgE serology (ASIgES)
(Chapter 2.1.4). Details of the inclusion and exclusion criteria, study design, clinical
assessment and scoring, use of concurrent medications and analysis of treatment
efficacy, are reported elsewhere (Colombo and others 2005). Serum samples were to
be collected from each dog before and after 3, 6 and 9 months ofASIT. However,
due to unavoidable logistical and technical circumstances, serum samples could not
be collected at every time point in every dog. All dogs were sampled prior to the
start ofASIT but some only had serum samples taken at one or two of the remaining
three time points. There were 4/24 missing data points in the complete response
group, 5/20 in the partial response group and 5/40 in the no response group.
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All samples were obtained with the owner's consent. As the samples were to be used
for the measurement of allergen-specific antibody responses, which represented
diagnostically and therapeutically useful information; UK Home Office approval was
not required. After collection, serum was separated by centrifugation and stored in
aliquots at -20°C until used (Chapter 2.2.1).
5.2.1.2 Immunotherapy protocol
An alum-precipitated vaccine (Artuvetrin® Therapy, ARTU, The Netherlands)
containing a mixture of allergens specific for each dog and formulated based on the
results of IDT or ASIgES (Chapter 2.1.4), was used in all cases. The dogs were
allocated to two treatment groups according to block randomisation. The control
groups (standard dose, SD) consisted of ten dogs receiving ASIT following the
standard protocol as indicated by the manufacturer (Table 5.1). This involved
administration of an allergen mixture comprising up to eight allergens, at least one of
which was D. farinae which accounted for 2.5-10% v/v of the allergen mixture. The
experimental group (low dose, LD) consisted of eleven dogs treated with ASIT but
receiving 0.1 ml only of the vaccine at the same standard intervals (Table 5.1). The
precise concentration of allergens is not provided by the manufacturer.
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Table 5.1 Protocols of allergen-specific immunotherapy using alum-precipitated
vaccine in the low dose and standard dose groups






1 0 0.2 ml 0.1 ml L Neck
2 2 0.4 ml 0.1 ml R Neck
3 4 0.6 ml 0.1 ml R Flank
4 6 0.8 ml 0.1 ml L Flank
5 9 1.0 ml 0.1 ml L Neck
6* 12 1.0 ml 0.1 ml RNeck
7 16 1.0 ml 0.1 ml R Flank
8 20 1.0 ml 0.1 ml L Flank
9* 24 1.0 ml 0.1 ml L Neck
10 28 1.0 ml 0.1 ml R Neck
11 32 1.0 ml 0.1 ml R Flank
12* 36 1.0 ml 0.1 ml L Flank
SD: standard dose; LD: low dose; *: reinspection at the R(D)SVS and blood sample
collected if possible.
5.2.1.3 Assessment of pruritus
Dogs were assessed for pruritus by the owners using a 0-5 point behaviour-based
scale (Table 5.2) and for skin lesions by a single investigator (S. Colombo) using a
modified canine atopic dermatitis extent and severity index (CADES 1) (Table 5.3)
(Colombo and others 2005). Assessments took place on the day the ASIT was
started and after 3, 6 and 9 months (90, 180 and 270 days) ofASIT. A complete
response to ASIT was defined as a dog whose pruritus score had fallen to zero by the
end of the study without the need for additional anti-pruritic medication. A partial
response to ASIT was defined as a dog whose pruritus score was lower at the end of
the 9-month treatment period compared to the beginning. No response to ASIT was
defined as a dog whose pruritus score was the same or higher after 9 months of
treatment compared to the beginning. Glucocorticoid therapy was permitted for the
first 6 months of the study, but not during the final 3 months ofASIT.
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Table 5.2 0-5 point behaviour-based pruritus scale
Grade Description
0 Normal dog: the dog does not itch more than before the disease began.
1
Occasional episodes of itching (small increase in itch compared with
before the disease began).
2
More frequent episodes of itching, but the itching stops when the dog is
sleeping or eating or playing or exercising or is otherwise distracted.
3
Regular episodes of itching are seen when the dog is awake. The dog
occasionally wakes up because of itching, but the itching stops when the
dog is eating or playing or exercising or is otherwise distracted.
4
Prolonged episodes of itching are seen when the dog is awake. The dog
regularly wakes up because of itching, or itches in its sleep. The itching can
also be seen when the dog is eating or playing or exercising or is otherwise
distracted.
5
Almost continuous itching which does not stop when the dog is distracted,
even in the consulting room (the dog needs to be physically restrained from
itching).
N.B.: Itching includes scratching, biting, licking, chewing and rubbing.
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Table 5.3 Modified canine atopic dermatitis extent and severity index (CADESI)











































Total score: j j j | j
Pruritus score: 0 1 2 3 4 5
Pyoderma: Yes No
Sites checked: Sites affected:
Malassezia dermatitis: Yes No
Sites checked: Sites affected:
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5.2.1.4 Measurement of antibody responses
D. farinae-specific total IgG and D. farinae-specific IgG subclasses were detected
using the methods validated in Chapter 3 and Chapter 4 respectively. Western
blotting was performed according to the methods described in Chapter 2.
5.2.1.5 Statistical analysis
Numerical data derived from the image analysis software were exported to Graphpad
Prism, Version 3.0 for Windows (Graphpad software, San Diego, USA). As
antibody concentrations in dogs are not normally distributed, the Kruskal-Wallis
non-parametric ANOVA was used to compare antibody responses at multiple time
points. If significant differences were detected by Kruskal-Wallis, comparisons
between two individual time points were made by the Mann-Whitney test. A
repeated measures test (Friedman test) was not possible due to the missing data
points. The following comparisons were made: data from four time points (day 0, 90,
180 and 270) when all the dogs were combined as a single group; data from
corresponding time points when dogs were divided into two groups based on those
that showed no response to ASIT versus dogs that showed some response (complete
or partial); data from corresponding time points when dogs were divided into three
groups comprising those that showed a complete, partial or no response to ASIT;
data from the four time points within each response group; and data from eight time
points when dogs were divided into two groups based on those that received the
standard ASIT protocol versus those that received the low-dose ASIT protocol. A p
value of < 0.05 was considered to be significant.
5.2.2 Results
All the dogs had detectable levels ofD. farinae-specific total IgG, IgGl and IgG4
prior to the start of, and during, ASIT (Figure 5.1). Both total IgG, and the
subclasses IgGl and IgG4, recognised multiple proteins from D. farinae including
98- and 44-kDa major allergens and a 66-kDa minor allergen (Nuttall and others
2001b) (Figure 5.1).
149
Visual analysis of the strips from individual dogs showed that the strength of the
bands varied during ASIT. However, there was no clearly obviously trend for the
band intensity to increase or decrease with time. Over the course of 9 months of
ASIT, individual dogs could show an obvious increase in band strength (Figure 5.1
a), a decrease (Figure. 5.1 b), remain relatively static (Figure 5.1 c), or fluctuate. For
each dog, the changes seen with total D. farinae-specific IgG were approximately
mirrored by similar changes in IgGl and IgG4. No consistent induction or
disappearance of specific bands at any molecular weight was observed.
This visual impression was confirmed by the numerical data from the image analysis
software which showed that, during ASIT, there was no consistent increase in the
total antibody response (the sum of all the band intensities on each strip) for IgG,
IgGl or IgG4 (Figure 5.2 a). There was also no consistent change in the response to
the 98-kDa band (Figure 5.2 b) or the 44-kDa band (Figure 5.2 c) for any of the
antibodies.
The statistical analysis of the data is summarised in Tables 5.4, 5.5 and 5.6. When
all the dogs were considered as a single group, there was no significant difference in
the total antibody response to D. farinae (sum of the band intensities on each strip) or
the response to the 98-kDa and 44-kDa proteins at any of the four time points during
ASIT for IgG, IgGl or IgG4 (p > 0.05 for all nine analyses). However, when dogs
that showed no response to ASIT were compared to dogs that showed a response
(partial and complete response groups combined), there was a significant difference
among the time points for total IgG. This difference was attributable to a
significantly greater total IgG response to D. farinae, and the 98-kDa and 44-kDa
proteins, in the group that was non-responsive to ASIT at day 0, compared to the
response group at day 0 (Tables 5.4, 5.5 and 5.6). In the case of the 44-kDa band,
there was also a significantly greater total IgG response in the non-responsive group
at day 90 compared to the response group at day 90 (Table 5.6).
When the dogs were divided into three response groups and compared separately,
there was a significant difference among time points for total IgG responses to D.
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farinae (Table 5.4). This was due to a significantly higher IgG response in the non-
responsive group at day 0, compared to the partial (p = 0.019) and the complete (p =
0.011) response groups. The total IgG responses to the 98-kDa and 44-kDa proteins
were also significantly higher at day 0 in the non-response group compared with the
complete response groups (p = 0.023 andp = 0.042, respectively) (Tables 5.4 and
5.5).
In addition, there was also significant variation among the time points in the
standard- and low-dose ASIT protocols for IgGl against total D. farinae antigens.
This was attributable to significantly lower IgGl levels to D. farinae at day 0 in the
dogs receiving the low-dose protocol compared with those receiving the standard
dose (p = 0.01) (Table 5.4). There were no other significant differences for D.
farinae or the 98-kDa or 44-kDa proteins at any time point for any other antibody
between the standard-dose and low-dose protocol groups.
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Figure 5.1 Examples of immunoblots showing total IgG-, IgGl- and IgG4-
binding profiles to Dermatophagoides farinae extract in dogs undergoing
allergen-specific immunotherapy using alum-precipitated vaccines
Serum samples were collected before and after immunotherapy for 90, 180 and 270
days. The IgG responses to D. farinae allergens varied widely between dogs and
could increase (a), decrease (b), remain the same (c) or fluctuate. Changes in total D.
farinae-specific IgG were usually paralleled by equivalent changes in IgGl and IgG4.
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Figure 5.2 Dermatophagoidesfarinae-specific total IgG, IgGl and IgG4 antibody
responses during 9 months of allergen-specific immunotherapy using alum-
preeipitated vaccines
(a) The total antibody response to D. farinae antigens (calculated as the sum of all
band intensities on each immunoblot strip). The dogs are divided into three groups
categorized by clinical outcome. Dogs that received the standard-dose
immunotherapy protocol are plotted in black. Dogs that received the low-dose
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Figure 5.2 contd. Dermatophagoidesfarinae-specific total IgG, IgGl and IgG4
antibody responses during 9 months of allergen-specific immunotherapy using
alum-precipitated vaccine.
(b) Antibody responses to the 98-kDa band. The dogs are divided into three groups
categorized by clinical outcome.
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Figure 5.2 contd. Dermatophagoidesfarinae-specific total IgG, IgGl and IgG4
antibody responses during 9 months of allergen-specific immunotherapy using
alum-precipitated vaccine.
(c) Antibody responses to the 44-kDa band. The dogs are divided into three groups
categorized by clinical outcome
Group I: Group II: Group III:
(c) No Response Partial Response Complete Response
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5.2.3 Discussion
During ASIT with alum-precipitated vaccines, there was no consistent augmentation
of the total quantity ofD. farinae-specific IgG or IgG subclass antibodies to antigens
from D. farinae. Levels of the antibodies could increase or fall but there was no
significant increase by day 270 compared to day 0. This was the case for the total
response to all the D. farinae proteins (measured by summing all the band intensities
on each strip) as well as the response to the 98-kD and 44-kDa proteins. These latter
proteins were chosen for specific analysis because they were the strongest and most
visually obvious bands on the strips.
Although not exactly parallel, the changes in IgGl and IgG4 tended to mirror the
changes seen with total IgG. The lack of significant increases in levels of allergen-
specific IgG, IgGl and IgG4 is surprising. Previous studies have demonstrated that
increases in allergen-specific IgGl and IgG4 are seen following ASIT in man
(Muller and others 1989; McHugh and others 1990; van Neerven and others 1999).
An increase in total (non-allergen-specific) IgGl was also observed in most dogs that
were given ASIT using alum-precipitated vaccines (Fraser and others 2004). The
reason for the difference in these findings between our study and previous studies is
not clear, but there are a number of possible explanations. First, although
administration of adjuvanted proteins should lead to a marked IgG response, some
studies in humans have shown poor clinical efficacy to alum-precipitated vaccines as
well as a lack of alteration in immune responses (Lichtenstein and others 1968;
Bousquct and others 1985). It is possible that the vaccines used in this study did not
contain sufficient protein to induce an allergen-specific IgG response, even though
they were shown to elicit an increase in total IgGl in most of the dogs in a prior
study (Fraser and others 2004). The allergen manufacturer used in this study does
not provide the specific protein content of allergens within vaccines, so it is not
possible to know the precise amount ofD. farinae that is present. Further, the
quantity ofD. farinae in each vaccine is likely to be different depending on the
number of other allergens included. It is also possible that the amount ofD. farinae
antigens may vary from batch to batch, leading to further variation in specific
immune responses. Evidence for the above possibility is provided by the lack of
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significant differences in IgG, IgGl and IgG4 levels in dogs receiving either the
standard ASIT protocol or the low-dose protocol, which involved administering 1/10
of the recommended dose. It would have been expected that dogs receiving the
higher doses would have mounted a greater antibody response, as long as sufficient
protein was present initially. It is also important that allergen manufacturers work
towards standardisation of allergens so that the precise protein concentrations can be
included in vaccines, allowing direct comparison.
A second possibility for the discrepancy may relate to the different methods
employed in the various studies. In this study we used a validated semi-quantitative
blot analysis system in which the net intensity of bands shows a linear relationship to
log antibody concentration. This system allows a whole range of separated proteins
from D. farinae to be studied simultaneously. This is a major advantage compared
with ELISA assays, which can only measure a single protein at a time. However,
ELISA assays can provide a more accurate measurement of a protein's concentration
in mg/ml and they tend to have lower coefficients of variation, indicating superior
repeatability. Hence, in future studies, a direct comparison of the results obtained by
blot analysis and ELISA warrants investigation.
Thirdly, the increase in total IgG documented in the earlier study (Fraser and others
2004) was quantified using a radial-immuno-diffusion technique. This method
measured the total quantity of IgGl present and did not relate to specific allergens.
Hence, the increase seen in that study could have been due to other allergens or non¬
specific IgG activation and not directly related to D. farinae proteins.
Finally, it is possible that production ofD. farinae specific IgG antibodies is not
induced in dogs with AD undergoing ASIT. This has not previously been studied
and it is not known whether the formulation of the allergens, or the expression of the
epitopes of major allergens in ASIT, is appropriate or sufficient to stimulate this arm
of the immune system. If not, clinical efficacy may be related to some other
mechanism such as down-regulation of cellular function or changes in cytokine
profile.
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An interesting finding arising from this study was that dogs showing no response to
ASIT had significantly higher D.farinae-specific total IgG levels on day 0 compared
with dogs showing a partial or complete response. This was the case both for total D.
farinae antigens, and the 98-kDa and 44-kDa proteins. This suggested that if a dog
with AD had a pre-existing high level of IgG antibodies to D. farinae prior to the
onset ofASIT, it was less likely to respond. This is a potentially exciting finding, as
it may suggest a means by which dogs could be screened prior to initiation ofASIT.
Dogs with a low level of IgG antibodies could be given a better prognosis than those
with a high level. Alternatively, this might allow alterations in dosage schedule to be
predicted in advance. This finding clearly needs to be substantiated using additional
methods and in a larger group of dogs to ensure that it is a repeatable phenomenon.
If so, the discriminatory power of the measurement would have to be carefully
determined.
A statistical quirk that arose in this study was the finding that dogs receiving the
standard-dose ASIT protocol had significantly higher levels of IgGl to total D.
farinae proteins at day 0 compared with those receiving the low-dose protocol. This
can only have arisen by chance, as the dogs were assigned to their relative groups
using block randomisation. This chance occurrence did not seem to have any
bearing on the subsequent efficacy of the ASIT because there were no significant
differences in the response rates between the two groups (Colombo and others 2005).
In summary, this study did not demonstrate the production ofD. farinae-syecific IgG
blocking antibodies in atopic dogs undergoing ASIT based on alum-precipitated
vaccines. However, a high pre-existing level of total IgG to D. farinae antigens,
including the 98-kDa and 44-kDa proteins, suggested that dogs were less likely to
respond to ASIT.
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5.3 Study 2 - ASIT using aqueous vaccines
As a follow-on to the ASIT study using alum-precipitated vaccines, a pilot study was
performed to determine if aqueous vaccines might elicit IgG responses. As this form
of vaccine was not used at the host institution, samples had to be obtained from the
USA. Also, the study design was necessarily different because all aspects of the case
inclusion, monitoring and follow-up could not be controlled.
5.3.1 Material and methods
5.3.1.1 Serum samples
Serum samples from 15 atopic dogs were recruited from the Animal Dermatology
Clinic, San Diego, California, USA. All 15 dogs included had a positive reaction to
D. farinae at a dilution of 1/1000 w/v in an intradermal test. Samples were collected
before the start ofASIT and after 2 to 7.5 months of treatment. The variation in
timing of the post ASIT sample was due to logistical limitations within the study
population. However, as the aim was to determine whether or not there was an
increase in D. farinae specific IgG, and not the magnitude of that response, this was
not considered to be a problem. After collection, serum was separated by
centrifugation and stored at -20°C until use.
5.3.1.2 Immunotherapy protocol
The content ofASIT vaccines was determined based on correlation of the positive
skin test results with the dog's history. All vaccines were prepared with allergen
extracts obtained from Greer Laboratories (Lenoir, NC, USA), and given
subcutaneously. The ASIT protocols used are shown in Table 5.7. The number of
allergens in the treatment sets varied from 6 to 12. All allergens were mixed from
stock solutions that contained between 10,000 and 20,000 protein nitrogen units
(PNU)/ml. Dermatophagoidesfarinae stock solution contained 10,000 PNU/ml. All
dogs underwent an induction phase that consisted of two vials of allergens. Vial one
contained a total of 1,000 - 1,800 PNU/ml and vial two of 10,000 - 18,000 PNU/ml,
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depending on allergen content. The concentration of Dermatophagoides farinae
varied from 83 PNU/ml to 167 PNU/ml in vial 1 and from 833 PNU/ml to 1,667
PNU/m in vial 2. These ASIT schedules were followed unless the dog had an
adverse reaction to an allergen injection, which most commonly consisted of
increased pruritus following injection. If this occurred the volume of allergen
injected was decreased. Final maintenance doses varied from 0.5ml to 1.0ml and
were given at intervals of 5 to 20 days, depending on the patient's response.
Table 5.7 Allergen-specific immunotherapy protocols used in the aqueous
vaccines study
Dog under 201bs Dog over 201bs
Vial Day Volume (ml) Volume (ml)






























In this study, dogs were assessed by means of a pruritus visual analogue scale that
was currently in use at the practice concerned (Figure 5.3).
5.3.1.4 Measurement of antibody responses
D.farinae-specific total IgG was detected using the methods validated in Chapter 3.
Due to insufficient quantities of reagents, IgGl and IgG4 responses could not be
evaluated in this study. Western blotting was performed according to the methods
described in Chapter 2.
5.3.1.5 Statistical analysis
Numerical data derived from the image analysis software were exported to GraphPad
Prism, Version 3.0 for Windows (GraphPad software, San Diego, USA). As in the
alum-precipitated study, results were analysed using a non-parametric test. As only
two time points were available for this study, the Wilcoxon matched-pair signed-
ranks test was used to compare antibody responses before and after ASIT. A p value
of < 0.05 was considered to be significant.
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Figure 5.3 Pruritus visual analogue scale used in the aqueous vaccine
study
Pruritus Visual Analog Scale (PVAS)
During the last 24 hours, my dog was:
01 2 3456789 10
I I I I i i i i i i i
Not Itchy Extremely Itchy
no scratching, chewing scratching, chewing,
rubbing or licking rubbing or licking
observed constantly
5.3.2 Results
As in the alum-precipitated vaccine study, all the atopic dogs included in the study
had detectable levels of D. farinae-specific total IgG prior to the start of, and after,
ASIT (Fig. 5.3). Multiple proteins from D. farinae were recognised, and the most
visually obvious bands had molecular weights of approximately 98 kDa and 44 kDa
(Fig. 5.4). Visual analysis of the strips from individual dogs showed that the strength
of certain individual bands increased after ASIT, and new bands became visible (Fig.
5.4).
This visual impression was confirmed by the numerical data from the image analysis
software which showed that, during ASIT, there was a significant increase in the
total IgG response (the sum of all the band intensities on each strip) to D. farinae
antigens (p=0.015, Fig. 5.5 a). To facilitate further quantitative analysis, three
molecular weight zones were chosen for statistical evaluation: bands with a MW of
98 kDa, bands with MWs between 50-70 kDa and bands with MWs between 30-45
kDa. These zones were selected because most of the visible bands fell within them.
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There was a significant increase in the IgG response to the 98 kDa band (p=0.015,
Fig. 5.5 b), the 50-70 kDa bands (p-0.012, Fig. 5.5 c) and the 30-45 kDa bands
(p=0.035, Fig. 5.5 d).
The severity of pruritus as assessed by the visual analog scale (PVAS) is summarised
in Table 5.8. There was a significant decrease in pruritus scale (p<0.001) after AS1T
using aqueous vaccines (Fig 5.6). In order to correlate the D. farinae-specific IgG
response with clinical improvement, percentage of increased IgG intensity was
plotted against percentage of decreased PVAS score (Fig. 5.7). However, the R-
square value ranged from 0.0537 to 0.1338 and no correlation was found between D.
farinae-specific IgG level and pruritus score (Fig. 5.7).
Figure 5.4 Total IgG binding profile to Dermatophagoidesfarinae extracts
detected by immunoblotting in dogs undergoing allergen-specific
immunotherapy with aqueous vaccines
15 dogs were included. Serum samples were collected before (strip on the left) and
after 2 - 7.5 months (strip on the right) of immunotherapy. In the majority of dogs,
IgG responses to D. farinae allergens visibly increased after immunotherapy, either
in terms of band intensity or number of bands. The molecular weight standards on
the left are in kilo-dalton (kDa).
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Figure 5.5 Significant increases in IgG responses to D.farinae proteins,
measured by digital image analysis of bands on Western blots (shown as net
intensity)
a: The total IgG response to all D.farinae antigens (the sum of all band intensities
on each strip, /?=0.015). b: The IgG response to a 98 kDa band (p=0.015). c: The
IgG response to bands with molecular weights between 50-70 kDa (p=0.012). d:
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Table 5.8 Pruritus visual analog scale scores in dogs undergoing ASIT with
aqueous vaccines
No Breed Sex Age
DfRxin PVAS Score
IDT Pre-ASIT Post-ASIT




MN 2 4 10 6




F 1.5 5 4 2
5 Jack Russell terrier FS 10 4 9 1
6 Jack Russell terrier MN 8 4 7 3
7 Border collie F 1 5 7 4
8 Bichon Frise FS 5 4 10 10
9 Mixed breed FS 5 2 6 6
10 Boston terrier FS 3 4 10 5




M 5 4 7 4
13 German Shepherd M 2 4 5 1




MN 1.5 4-5 7 8
MN: male-neutered; M: male-intact; FS: female-spayed; F: female-intact; PVAS:
pruritus visual analog scale
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Figure 5.6 Significant decrease in pruritus score after ASIT using aqueous
vaccine
The pruritus severity in dogs assessed by a pruritus visual analogue scale is shown.
The pruritus score significantly decreased after ASIT using aqueous vaccines
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5.3.3 Discussion
In this study, we documented allergen-specific total IgG responses to various
antigens of the house dust mite D. farinae in dogs with AD. During ASIT with
aqueous vaccines, there was a significant increase in the quantity of D. farinae-
specific IgG antibodies to various antigens from the mite. This is in contrast to the
results with alum-precipitated vaccines, which documented no significant increase in
IgG concentrations when using exactly the same methodology. The finding that
aqueous vaccines produced a measurable immune response that was not seen with
alum-precipitated vaccines has important implications and raises two important
questions. First, why were the alum-precipitated vaccines not found to elicit such
IgG responses? This would clearly be expected when a foreign protein is injected
into a dog. An increase in total (non-allergen-specific) IgGl was observed in most
dogs that were given ASIT using alum precipitated vaccines (Fraser and others 2004).
This raises the possibility that alum-precipitated vaccines induce a non-specific
augmentation of the IgG response, but do not induce specific antibodies against
major allergens that are relevant in canine atopic dermatitis. Second, does the
antigen-specific IgG response seen with aqueous vaccines represent "blocking
antibodies", and if so, are these antibodies important in the mode of action ofASIT?
If that was the case, it would be expected that the efficacy of aqueous vaccines in
dogs would be superior to alum-precipitated vaccines. Further studies are clearly
warranted to answer these specific questions.
The increase in IgG concentrations was seen to a number of proteins with differing
molecular weights. This resulted in an overall increase in the total IgG response to D.
farinae antigens, as well significant increases in the response to 98 kDa, 50-70 kDa
and 30-45 kDa proteins. This finding provides some support for the hypothesis that
ASIT induces blocking antibodies because the IgG and IgE would be competing for
the same major allergens. It should be emphasised that the relationship between IgG
concentrations and net intensity of the bands on the blots is a log relationship, and
therefore a certain increase in net intensity represents an even greater increase in IgG
concentration. The increase in IgG concentrations to lower molecular weight
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antigens was very apparent in some dogs. This suggests that injection of some D.
farinae proteins induces a specific IgG response that isn't seen in atopic dogs prior to
the start ofASIT. Whether these antibodies are of any clinical relevance, or
contribute to the efficacy ofASIT, remains to be determined.
The significant augmentation of specific antibody responses following ASIT with
aqueous allergens is in accordance with earlier publications. In humans, previous
studies have demonstrated that ASIT results in an increase in the serum
concentration of allergen-specific IgG antibodies with specificity for the injected
antigens (Yunginger 1987; Muller and others 1989; McHugh and others 1990). In
atopic dogs, concentrations of pollen-specific IgG were shown to increase following
at least 6-months ofASIT using aqueous allergens (Hites and others 1989). Our
study is the first to demonstrate an increase in D. farinae specific IgG following
ASIT.
It was not surprising that the correlation between the induced IgG responses and
clinical outcome was poor because most of the dogs were sensitised to multiple
allergens other than D. farinae, and a good or bad response could have been
influenced by other allergens in the vaccine. However, future studies are now
warranted that compare the D. farinae specific IgG response to clinical outcome in a
group of dogs that are mono-sensitised to that allergen.
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Chapter 6
Development of quantitative real-time PCR assays to
assess cytokine gene transcript expression in canine
atopic dermatitis
6.1 Introduction
Recent interest has focused on the role ofCD4+ Thl and Th2 cells in human atopic
dermatitis (Grewe and others 1998; Leung 2000). Several studies have detected Th2
polarisation in the skin and PBMCs of atopic humans (van Reijsen and others 1992;
Leung 1995; Neumann and others 1996; Kimura and others 1998a; Kimura and
others 1998b) and mouse models (Spergel and others 1999; Vestergaard and others
1999). Although Thl cytokines inhibit Th2 differentiation (Mosmann and Coffman
1989), the Thl-type cytokine IFN-y, was found to be highly expressed in eczematous
skin of the vast majority (80%) of human AD patients (Grewe and others 1994),
suggesting that Thl cells also participate in the pathogenesis of chronic atopic
dermatitis. Furthermore, healthy individuals do not develop Thl induced cell-
mediated inflammatory reactions to environmental allergens (Borish and
Rosenwasser 1997). Instead, tolerance in healthy individuals may be mediated by
the immunosuppressive cytokines IL-10 and TGF-P (Muraille and Leo 1998; Koulis
and Robinson 2000).
Imbalances in lymphocyte populations and cytokine production play an important
role in the pathogenesis of human atopic dermatitis. Atopic lesions are dynamic and
sequential activation of the Th2-cell subset during the initiation phase, followed by
the Thl-cell subset has been hypothesized to account for the persistence of the
inflammatory response (Grewe and others 1998). A biphasic pattern of cytokine
expression has also been demonstrated after epi-cutaneous allergen challenge or
atopy patch testing (APT) in humans (Grewe and others 1995; Thepen and others
1996). Using immunohistochemistry, biopsy sections from APT tested atopic
patients were double stained for IL-4 and IFN-y together with different membrane
markers, and a clear dichotomy of the eczematous response to allergen in skin was
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observed (Thepen and others 1996): in the initial phase IL-4 production by Th2 and
ThO cells was predominant over IFN-y production by Thl and ThO cells, and in the
late and chronic phases the situation was reversed and IFN-y production
predominated over IL-4 production (Thepen and others 1996).
To date, there are only a few studies looking at the cytokine profile in dogs with AD.
A study using conventional RT-PCR investigating mRNA transcript expression of
type-1 cytokines (IFN-y, IL-2, IL-12p35, IL-12p40 and TNF-a) and type-2 cytokines
(IL-4, IL-5, IL-6 and IL-10) in lesional and non-lesional skin specimens of atopic
dogs and control skin samples from healthy dogs demonstrated a Th2-type cytokine
pattern in one-fourth of atopic and a Thl-type pattern in one-fourth of healthy canine
skin samples (Olivry and others 1999). Type-2 cytokines IL-4 and IL-5 were
detected in 57.1% of lesional specimens, 40% of non-lesional samples, and in 25%
of normal control specimens, whereas IL-6 and IL-10 transcripts were either rarely or
not detected in atopic and control samples (Olivry and others 1999). Expression of
type-1 cytokine IL-2 mRNA was less frequently detected in non-lesional atopic
samples versus normal control specimens, and IL-12p40 transcripts were detected
significantly more often in normal control than lesional atopic skin specimens
(Olivry and others 1999).
Studies using semi-quantitative RT-PCR looking at the expression of Th2 cytokines
(IL-4, IL-6), Thl cytokines (IFN-y, IL-2 and TNF-a) and immunosuppressive
cytokines (TGF-P and IL-10) indicated an over-expression of IL-4 and under-
expression of TGF-P in the skin of atopic dogs (Nuttall and others 2002a; Nuttall and
others 2002b). Significantly higher levels of IL-4 mRNA were detected in both
lesional and non-lesional atopic skin compared with healthy skin, whereas levels of
TGF-P mRNA were significantly higher in healthy compared with atopic skin
(Nuttall and others 2002a). A similar pattern of transcription for the type-1 cytokines
IFN-y, IL-2 and TNF-a was found and significantly higher levels ofmRNA for each
cytokine were detected in lesional atopic skin compared with either non-lesional
atopic or healthy skin (Nuttall and others 2002a). Levels of IL-12p35 and IL-12p40
mRNA were highly variable in both atopic and healthy skin, and no difference was
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found between the three groups of samples (Nuttall and others 2002a; Nuttall and
others 2002b).
Another study using semi-quantitative RT-PCR examining IFN-y, IL-4, IL-5 and IL-
10 in the PBMCs of atopic and healthy dogs also demonstrated a Th2 cytokine
pattern (Hayashiya and others 2002). In this study, The average IL-5 mRNA
expression in atopic dogs was significantly higher than in control group, and levels
of IL-4 mRNA tended to be higher in the atopic dogs as well (Hayashiya and others
2002). The IFN-y mRNA expression level in atopic dogs was significantly lower
than in control dogs, but expression of IL-10 did not differ between the groups
(Hayashiya and others 2002).
A further study researching cytokine profiles ofPBMCs from dogs experimentally
sensitised to Japanese cedar pollen showed a Th2 polarisation and PBMC
proliferation in response to the sensitising antigen (Fujiwara and others 2003). The
expression level of cytokines IL-1(3, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IFN-y,
TGF-P and TNF-a were quantified using a real-time RT-PCR system, and
significantly increased levels of TNF-a and IL-8 were detected in the experimentally
sensitised group compared to the control group in the primary PBMCs, but IFN-y
was found to be decreased in the experimental group (Fujiwara and others 2003).
The cytokine profile changed after PBMCs were stimulated with the crude Japanese
cedar pollen antigen; the levels of IL-6 and TNF-a were expressed at greater
quantities in the control group compared to the experimentally sensitised group, and
the level of IL-2 mRNA in the PBMCs from the experimentally sensitised dogs was
significantly higher than that in the PBMCs from the control dogs (Fujiwara and
others 2003). The amount of IL-4 mRNA was below the lower detection limit in all
of the sensitised and control dogs in primary PBMCs, but the amount of IL-4 mRNA
was found to be markedly increased after PBMC stimulation with the offending
antigen (Fujiwara and others 2003).
The most recent study investigated a panel of fourteen Thl, Th2, pro-inflammatory
cytokines and chemokines in APT-tested high-IgE beagles experimentally sensitised
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to house dust mites (Marsella and others 2006). The cytokine profiles analysed by
real-time RT-PCR were studied before and after 6, 24, 48 and 96 hours of atopy
patch testing. It was shown that IL-6 plays a role in early reactions followed by an
increase of IL-13 and thymus and activation regulated chemokine (TARC), while IL-
18 progressively increases in later reactions (Marsella and others 2006). The results
support the hypothesis that, similar to human AD, there is varying skin expression of
cytokine genes depending on lesion age.
Taken together, these studies suggest that a Th2 type cytokine profile may be
apparent in canine atopic dermatitis, but the expression of Th2-type and Thl-type
cytokines in AD is not mutually exclusive, suggesting that both Th-cell subsets
contribute to the pathogenesis of canine atopic dermatitis. It can be argued that in
both dogs and man, Thl- and Th2-type cytokines contribute to different stages of the
development of skin lesions in atopic dermatitis patients. In such a model, a key
element is the sequential activation of the Th2-cell subsets during the initiation phase,
followed by the Thl-cell subset to account for the persistence of the inflammatory
responses (Grewe and others 1994).
In addition to T-cell derived cytokines, other mediators may be involved in
inflammatory skin diseases. Inducible nitric oxide synthase (iNOS) is involved in
the generation of nitric oxide (NO), a dynamic molecule utilised through the animal
kingdom as a signalling or toxic agent between cells. NO exhibits complex functions,
and is also involved in innate immunity as a toxic agent towards infectious organisms
and can induce or regulate death and function of host immune cells, thereby
regulating specific immunity (Coleman 2001). Expression of iNOS mRNA was
found to be decreased in AD, as compared with psoriasis (Nomura and others 2003),
but the immunoreactivity of iNOS was significantly more extensive in AD skin than
in contact dermatitis skin (Rowe and others 1997). However, the role of iNOS in the
context ofAD is far from fully understood.
Many cellular decisions concerning survival, growth and differentiation are reflected
in altered patterns of gene expression and the ability to quantify transcription levels
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of specific genes has always been central to research into gene function and its role
in disease pathogenesis (Zamorano and others 1996). The fluorescence-based kinetic
real-time RT-PCR procedure significantly simplifies the process of producing
reproducible quantification ofmRNA, and is an excellent tool in investigating the
expression of various genes actively involved in the immunopathogenesis of atopic
dermatitis. Although it would have been ideal to include all potential immune
response genes in this study, it was not practical due to logistical, funding and time
limitations. Therefore, one representative gene from each subset of the immune
system was chosen for real-time RT-PCR. Based on the findings of previous studies,
cytokines shown to differ between atopic and control groups were selected as key
examples, and they were the Thl-type cytokine IFN-y, the Th2-type cytokine IL-4,
and the immunosuppressive regulatory cytokine TGF-p. iNOS was also included as
a representative of the innate immune response.
The aim of this study was to further explore, using new methodologies, the
possibility that canine atopic dermatitis is associated with polarised Thl/Th2
responses as seen in humans, and to investigate the role of iNOS in AD.
6.2 Development, validation and optimisation ofmethodology
The purpose of this section was to develop, validate and optimise quantitative real¬
time reverse transcription mediated polymerase chain reaction (qRT-PCR) to detect
mRNA for the four cytokines mentioned in 6.1, including interleukin-4 (IL-4),
interferon-y (IFN-y), transforming growth factor-P (TGF-p), inducible nitric oxide
synthase (iNOS) as well as the housekeeping gene 18S ribosomal RNA (rRNA).
Conventional PCR was used to amplify the target gene first. The PCR product was
then cloned and DNA sequencing was used to confirm its identification. The cloned
cytokine fragment was then used to generate a standard curve in real-time PCR
experiments in order to calculate the absolute copy number of the cytokine transcript
being examined.
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6.2.1 Canine cytokine amplification using positive control samples
The primer sequences used to amplify target canine cytokine transcripts were
designed using an online primer design program Primer3 (Chapter 2.8.1). For real¬
time PCR, primer pairs were designed with optimal amplicon size of 100 bp. A pair
of outer primer flanking target sequences for real-time PCR was also obtained for
each cytokine. The amplification products of the outer primers were used for cloning.
Positive template DNA samples expressing IL-4, IFN-y and TGF-[3 were selected
using primers previously designed by Nuttall (Nuttall and others 2002a; Nuttall and
others 2002b). Screening of iNOS template positive samples was done using newly
designed outer primers. The published primer pairs specific for the housekeeping
gene 18S rRNA was used to detect template containing samples.
RNA extracted from the popliteal lymph nodes of healthy dogs was reverse
transcribed into complementary DNA using random hexamer primer (Chapter 2.7.5).
The lymph nodes are secondary lymphoid organs that function through adult life.
These organs are rich in macrophages and dendritic cells that trap and process
antigens, and in T and B lymphocytes, which mediate the immune responses. They
were therefore likely to be a good source of the cytokines that were of interest.
Standard PCRs were performed in 50 pi volumes containing 2 pi cDNA, 400 nM
forward and reverse primers, 2.5 units Taq DNA polymerase in a reaction buffer
composed of 10 mM Tris-FlCl, 2 mM MgCl2, 0.2 mM each dNTPs (Chapter 2.8.2).
The reaction conditions consisted of initial denaturing at 94°C for 2 min, then cycles
of denaturing at 94°C for 30 sec, primer annealing for 30 sec and elongation at 72°C
for 30 sec, before a final elongation at 72°C for 10 min (Chapter 2.8.2). Results of
standard PCRs were visualised in agarose gel containing 0.5 pg/ml ethidium bromide
and recorded on the image station (Chapter 2.8.3).
6.2.2 Conventional PCR optimisation
Factors influencing the performance of a real-time PCR include divalent metal
(magnesium ion, Mg2+) concentration, primer concentration, dNTP concentration,
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buffer pH and annealing temperature. Two of the most important ingredients
influencing the results of a PCR reaction are the buffer and the magnesium
concentration. A panel of 16 buffers (PCR optimisation kit, Roche) comprising
different magnesium concentrations and pH was used to evaluate appropriate
reaction conditions for each pair of primers.
16 reactions differing only in the composition ofmagnesium concentrations (ranging
from 1.0 mM to 2.5 mM) and buffer pH (ranging from 8.3 to 9.2) (Table 6.1) were
set up for each set of primers and the results are shown in Figure 6.1.
Reactions with expected amplicon size showing a band with strong intensity and
reactions without non-specific amplification were chosen for each pair of primers.
For IL-4 (Figure 6.1 a) only a weak band with MW of 400 bp in lane 4 was visible.
A magnesium concentration of 2.5 mM with buffer pH of 8.3 was chosen for the
amplification of canine IL-4. For IFN-y (Figure 6.1 b), the reaction conditions in
lane 11 comprising buffer with 2.0 mM Mg2+ and pH 8.9 yielding the strongest band
intensity was selected. For TGF-p (Figure 6.1 c), designed primers amplified non-
specifically under most buffer conditions. However, the reaction conditions in lane
10 were chosen because a band with the expected amplicon size was present and
non-specific binding was minimal. Buffer with a magnesium concentration of 1.5
mM and pH of 8.9 was used for the amplification of canine TGF-p. Several reaction
conditions yielded specific amplification of iNOS (Figure 6.1 d). The buffer
comprising a magnesium concentration of 1.5 mM and pH of 8.9 yielded the
strongest signal and was therefore selected.
Table 6.1 Concentrations ofMgCh and pH-value for buffers 1-16
pH
MgCh concentration (mM)
1.0 1.5 2.0 2.5
8.3 1 2 3 4
8.6 5 6 7 8
8.9 9 10 11 12
9.2 13 14 15 16
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Figure 6.1 PCR optimisation experiment evaluating reaction MgCh
concentration and buffer pH
16 buffers, each containing 100 mM Tris-HCl, 500 mM KC1, 1-2.5 mM MgCh-
Detailed concentrations ofMgChand pH-value for each buffer are listed in Table 6.1.
Expected amplicon size is 403 bp for IL-4 (a); 863 bp for IFN-y (b); 1000 bp for
TGF-J3 (c); and 1062 bp for iNOS (d). M: molecular weight marker; bp: base pairs.
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6.2.3 Cloning of canine cytokine gene fragments
Freshly amplified PCR products were cloned into the linear plasmid vector pCR®4-
Topo® and re-introduced into chemically competent E. coli (Chapter 2.6.6). The E.
coli transformant cells harbouring target inserts were then plated onto LB agar plates
and incubated overnight at 37°C in an incubation chamber. A single colony was then
inoculated into 5 ml LB medium and incubated overnight at 37°C with vigorous
shaking at 250 rpm. Purified plasmid DNA was digested with EcoK I to release the
inserted fragment and assessed with gel electrophoresis. After confirming that the
insertion had occurred, DNA sequencing was performed to confirm the identity of
the inserted sequence.
DNA fragments of canine IL-4 (403 bp), iNOS (1062 bp), TGF-p (1000 bp) and
IFN-y (863 bp) were cloned and analysed (Figure 6.2). Plasmid DNA (3956 bp) and
inserted fragments were separated and visualised on the gel. IFN-y, TGF-P and
iNOS appeared to be cloned into the plasmid whereas IL-4 fragment was not inserted
in the vector (Figure 6.2). DNA sequencing ofpurified plasmid DNA with IFN-y or
iNOS insertions confirmed their identity, whereas the sequencing result of the TGF-P
clone revealed a segment of the E. coli genome.
The cloning of the 403-bp canine IL-4 was not successful. The problem could have
arisen from poor primer design even though known design criteria were met. In the
IL-4 PCR optimisation experiment, a weakly visible band was detected when the
reaction was performed in 2.5 mM MgCb with buffer pH 8.3 (Figure 6.la). It was
obvious that the amplification efficiency was not ideal, therefore the resultant PCR
product was not suitable for cloning. Gel-purification of the target PCR fragment
was also performed prior to cloning, but possible dilution of the DNA was likely,
making successful cloning even more difficult to achieve. Therefore, another pair of
primers targeting the canine IL-4 flanking 114-bp fragment was chosen for attempted
cloning.
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Cloning of the 1000-bp canine TGF-P was unsuccessful the first time it was
attempted. The sequencing result revealed that the identity of the insert belonged to
the E. coli genome. Chemically competent E. coli were used as transformants, but
how and when contamination occurred remained unknown.
Limited sequence data of dog 18S rRNA was available, and only a set of primers
designed to amplify canine 18S rRNA with an amplicon size of 96 bp has been
published to date. Therefore, the same primer pair used in real-time RT-PCR was
used for cloning.
A second attempt at cloning and sequencing was performed for IL-4, TGF-P and 18S
rRNA. After the standard cloning procedure and bacterial cultural expansion,
plasmid DNA was purified and analysed by £coR I digestion and gel electrophoresis.
A 1000-bp band was seen for TGF-P clones (Figure 6.3) whilst the 96-bp and 114-bp
inserts for canine 18S rRNA and IL-4 were not visualised in the gel. It was possible
that those small fragments had migrated out of the gel. Although the expected
cloned fragments were not seen on the gel electrophoresis analysis, DNA sequencing
of these clones was performed, and sequencing results confirmed the identity of
inserted sequences to be canine TGF-P (1000 bp), 18S rRNA (96 bp) and IL-4 (114
bp) (Table 6.2).
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Figure 6.2 Evaluation of canine IL-4, IFN-y, TGF-p and iNOS clones
Purified plasmid DNA was analysed by EcoR I digestion and agarose gel
electrophoresis. 4 randomly selected single colonies expanded in LB broth overnight
were chosen for each gene clone. The 3956-bp plasmid vector as well as the insert of
interest were seen in IFN-y (b), TGF-p (c) and iNOS (d) clones, whereas insertion of
the IL-4 (a) gene fragment did not occur. M: molecular weight marker; kb: kilo
bases; bp: base pairs.
(a) IL-4 (c) TGF-p
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Figure 6.3 Evaluation of canine TGF-p, 18S rRNA and IL-4 clones
Purified plasmid DNA was analysed by EcoR I digestion and agarose gel
electrophoresis. 4 randomly selected single colonies expanded in LB broth overnight
were chosen for each gene clone. The 3956-bp vector was present in every well,
whilst excessive amount of plasmid DNA was loaded in lanes 1-3. The expected
target insert of 1000-bp for TGF-P was seen in lanes 1-3 and absent in lane 4. The
96-bp and 114-bp inserts of 18S rRNA and IL-4 could not be visualised in the gel.
M: molecular weight marker; kb: kilo bases; bp: base pairs.
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6.2.4 Optimisation of PCR annealing temperature
Factors influencing the performance of a real-time PCR include divalent metal (i.e.
2+
Mg ) concentration, primer concentration, dNTP concentration and annealing
temperature. Non-specific amplifications can be reduced by increasing annealing
temperature; therefore, annealing temperature was first optimised for each canine
gene transcript of interest. The optimised temperature of each PCR reaction was
determined using the temperature gradient function of the thermal cycler
(GeneAmp® PCR system 2400; Perkin-Elmer, Cambridge, UK). Eight reaction
tubes, using the same dilution of cloned DNA fragment as template, were run at a
range of annealing temperatures between 55 and 65°C. The highest annealing
temperature with successful PCR amplification is chosen for qRT-PCR because of
reduced mis-priming events and non-specific amplifications. The results indicated
that 65°C of annealing temperature was suitable for all cytokines in real-time
amplification (Figure 6.4).
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Figure 6.4 Annealing temperature optimisation of real-time PCR primers
Eight reactions were run at different annealing temperature ranging from 55°C (lane
1) to 65°C (lane 8) for the primers for canine IL-4 (a), IFN-y (b), TGF-P (c), iNOS (d)
and 18S rRNA. The annealing temperature is 56.4°C, 57.8°C, 59.3°C, 60.7°C,
62.1°C and 63.6°C in lanes 2 to 7. Amplification results were analysed by agarose
gel electrophoresis and visualised in UV light. The results indicated that 65°C
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Figure 6.4 contd. Annealing temperature optimisation of real-time PCR primers
(c) TGF-p
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6.2.5 Optimisation of magnesium chloride concentration
2+ - 2"t" ** -i
Mg and dNTP concentrations require strict control, because Mg affects enzyme
activity, and imbalanced dNTP mixtures will reduce polymerase fidelity (Eckert and
Kunkel 1991). In addition, Mg2+ increases the melting temperature (Tm) of double-
stranded DNA, and forms soluble complexes with dNTPs to produce the actual
substrate that the polymerase recognises. Therefore, high concentration of dNTPs
interferes with polymerase activity and affects primer annealing by reducing free
Mg2+.
4 duplicate reactions differing only in the composition of magnesium concentrations
(ranging from 2.5 mM to 4.0 mM) were set up for each set of primers. 105 copies of
the cloned template for each cytokine were used as template for real-time
optimisation experiments. The optimal Mg2+ concentration was 3.0 mM for 18S
rRNA, TGF-(3 and IL-4, and 4.0 mM for IFN-y and iNOS. The representative results
of 18S rRNA optimisation are shown in Figure 6.5.
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Figure 6.5 Magnesium chloride concentration optimisation for 18S rRNA using
SYBR Green dye and a melting curve analysis of the resulting products
(a) A representative experiment in which the total fluorescence was measured at the
end of each cycle. The negative control contains no input cDNA. All samples were
amplified simultaneously for 45 cycles and the fluorescence was measured at the end
of each extension step, (b) A melting curve analysis in which melting peaks were
determined by plotting the negative derivative of fluorescence emitted by each
sample during a melting curve analysis in which PCR products were slowly melted
and fluorescence was determined continuously. The product of interest of 18S rRNA
had a Tm of 82.8°C. dF: change in fluorescence; dT: change in temperature; NC:
negative control.
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6.2.6 Generation of real-time RT-PCR standard curves
The standard curve for each individual amplicon was constructed from purified
plasmid dsDNA of known concentration. This curve was then used as a reference
standard for extrapolating quantitative information for mRNA targets of unknown
concentrations. Ideally RNA standards should be used for absolute quantification of
mRNA; however, in vitro transcribed RNA standards are difficult to accurately
quantify and their stability could be a source ofvariability in the final analysis.
Therefore, plasmid DNAs were used to construct a standard curve for quantification.
The variation introduced due to variable RNA inputs was corrected by normalisation
to a housekeeping gene 18S rRNA.
The concentration of the plasmid was measured using a spectrophotometer,
converted to g/pl by multiplying a factor of 10"9, and the corresponding copy number
was calculated using the following equation:
6.02 x 1023 (copies/mol) x DNA concentration (g/pl)
copy number (copies/pi) =
molecular weight of plasmid DNA (g/mol)
where molecular weight = (insert bp + vector 3956 bp) x 660 (dalton/bp)
The concentrated DNA was then diluted over several orders ofmagnitude by
accurate pipetting. The stability of the diluted standards was important, so diluted
standards were divided into small aliquots, stored at -70°C, and thawed only once
before use. A hundred-fold dilution series of cloned cytokine fragments was
produced in duplicate for each cytokine assay. The reaction efficiencies were
calculated from the slope of the threshold cycle vs. copy number graphs and were
96.99 %, 95.14 %, 96.32 %, 93.58 % and 97.07 % with correlation coefficients of
0.9981, 0.9995, 0.9982, 0.9996 and 0.9901 for 18S rRNA (Figure 6.6), TGF-P




The intercalating dye SYBR Green used in real-time PCR fluoresces intensely when
associated with double stranded DNA. However, any double stranded product,
including primer-dimers, is detected and false positives could occur. A melting
curve was used to identify formation of primer-dimer and non-specific signals.
A melting curve was produced by heating the samples from 65°C to 95°C in 0.3°C
increments with a dwell time at each temperature of 10 seconds during which the
fluorescence data were collected. The melting temperatures of the product was
determined with the Rotor-Gene Software (version 6: Corbett Research) using a rate
of change of fluorescence (dF/dT) vs. temperature graph (Figures 6.6-6.10 b).
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Figure 6.6 Amplification of canine 18S rRNA gene in 100-fold dilutions of
template
(a) Amplification plot showing the change in fluorescence of SYBR® Green I dye
plotted versus cycle number, (b) Melt curve analysis of online PCR signals. The
18S rRNA amplicon had a Tm of 82-83°C. (c) Standard curve was generated.
Reaction efficiency and correlation coefficient (R2) values were noted. NC: negative
control; Norm. Fluoro.: normalised fluorescence; dF: change in fluorescence; dT:
change in temperature; deg.: degree in °C.
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Figure 6.7 Amplification of canine TGF-p gene in 100-fold dilutions of template
(a) Amplification plot showing the change in fluorescence of SYBR* Green I dye
plotted versus cycle number, (b) Melt curve analysis of online PCR signals. The
TGF-P amplicon had a Tm of 85-86°C. Non-specific signals were detected in
reactions with 104 and 102 copies of template, (c) Standard curve was generated.
Reaction efficiency and correlation coefficient (R2) values were noted. NC: negative
control; Norm. Fluoro.: normalised fluorescence; dF: change in fluorescence; dT:
change in temperature; deg.: degree in °C.
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Figure 6.8 Amplification of canine IL-4 gene in 100-fold dilutions of template
(a) Amplification plot showing the change in fluorescence of SYBR® Green I dye
plotted versus cycle number, (b) Melt curve analysis of online PCR signals. The IL-
4 amplicon had a Tm of 79-80°C. (c) Standard curve was generated. Reaction
efficiency and correlation coefficient (R2) values were noted. NC: negative control;
Norm. Fluoro.: normalised fluorescence; dF: change in fluorescence; dT: change in









































Figure 6.9 Amplification of canine IFN-y gene in 100-fold dilutions of template
(a) Amplification plot showing the change in fluorescence of SYBR® Green I dye
plotted versus cycle number, (b) Melt curve analysis of online PCR signals. The
IFN-y amplicon had a Tm of 81-82°C. (c) Standard curve was generated. Reaction
efficiency and correlation coefficient (R2) values were noted. NC: negative control;
Norm. Fluoro.: normalised fluorescence; dF: change in fluorescence; dT: change in















































Figure 6.10 Amplification of canine iNOS gene in 100-fold dilutions of template
(a) Amplification plot showing the change in fluorescence of SYBR* Green I dye
plotted versus cycle number, (b) Melt curve analysis of online PCR signals. The
iNOS amplicon had a Tm of 81-82°C. (c) Standard curve was generated. Reaction
efficiency and correlation coefficient (R2) values were noted. NC: negative control;
Norm. Fluoro.: normalised fluorescence; dF: change in fluorescence; dT: change in
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6.2.8 Cytokine copy number calculation
When assaying the canine skin samples for cytokine expression, the corresponding
standard series was run under the same conditions. The absolute copy numbers for
the cytokine in question and the housekeeping gene (18S rRNA) was determined
automatically by the real time machine software by inputting the Ct value of the
sample into the standard curve. Comparing samples requires normalisation to
compensate for difference in the amount of biological material in the tested samples.
rRNAs, which constitute 85-90% of total cellular RNA, are useful internal controls,
as the various rRNA transcripts are generated by a distinct polymerase and their
levels are less likely to vary under conditions that affect the expression of mRNAs
(Barbu and Dautry 1989). It has also been shown that rRNAs are more reliable than
other commonly used housekeeping genes, i.e. P-actin and GAPDH in human and
murine cells (de Leeuw and others 1989; Mansur and others 1993; Bhatia and others
1994; Zhong and Simons 1999). 18S rRNA was therefore selected as the internal
control.
The variation introduced due to variable RNA inputs was corrected by normalisation
to 18S rRNA using the following equation:
Adjusted absolute copy number
= target copy number / 18S rRNA copy number * 1,000,000
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6.3 Results
6.3.1 Archive sample RNA quality assessment
RNAs extracted from skin samples from atopic and healthy dogs were collected by
Dr. Nuttall during 2000-2001 and had been stored at -70°C (Chapter 2.2.1). The
Agilent 2100 Bioanalyzer was used to assess the quality of archived sample RNAs
(Chapter 2.7.4). In this assay, RNA is combined with a sample buffer containing a
fluorescent dye that intercalates into the RNA and is excited by an internal 635 nm
diode laser. Data output is in the form of an electropherogram, which graphically
depicts spikes in fluorescence over time; the larger the peak, the more intact
ribosomal subunits are in the sample. If a sample is degraded, subunits will show a
smaller degree of fluorescence that is spread out over a longer period of time,
indicating a greater variety of sizes in the sample.
Two representative results ofRNA quality assessment illustrated in
electropherograms are shown in Figure 6.11. The big peak seen at 22-24 seconds is
the marker. The peaks appearing at 24-29 seconds could be 5S RNA and transfer
RNA. The trizol RNA extraction method used does not remove 5S and tRNA in
contrast to many column-based RNA extraction kits that do remove these small RNA
species. Distinct peaks for 18S and 28S rRNA were detected in 25 of the 35 samples
and degradation was more evident in 10 samples. However, the archived RNA
samples were not of the highest quality and some degradation had occurred because
rRNA peaks did not dominate the fluorescence of these samples and various other
peaks were also present. Several reasons for unexpected peaks other than RNA
degradation include contamination of dust in the working environment,
contamination of particles from the cell during RNA extraction, bubbles forming
during pipetting or during heating of the gel through the electrical current and
inappropriate gel filtration. These results indicated that the archived RNA samples
used for the real-time RT-PCR assays were partially degraded and interpretation of
real-time results would therefore require caution.
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Figure 6.11 RNA quality assessment measured by the Agilent 2100 Bioanalyzer
Representative electropherograms showing good quality (a) and poor quality (b)
RNA. Clear peaks for 18S and 28S rRNA were seen in most RNA samples. In the
lower part of the graph, 5S RNA and transfer RNA can also be seen. Various
unexpected bands were present in most samples, indicating possible RNA























6.3.2 Cytokine transcript expression in healthy and atopic dogs
Graphical illustrations of real-time fluorescent RT-PCR reactions are shown in
Figure 6.12 for 18S rRNA, Figure 6.13 for TGF-P, Figure 6.14 for IL-4, Figure 6.15
for IFN-y and Figure 6.16 for iNOS. The absolute copy numbers of cytokine
transcripts were automatically derived by the real-time PCR software from the
standard curves, consisting of known copy numbers of plasmid DNA as calculated
using the equation in Chapter 6.2.6. The raw data obtained from the real time
machine are shown in the appendix at the back of this thesis. Levels of cytokine
mRNA were quantified in most of the samples collected in this study (Table 6.3).
Biopsies from all dogs were found to express 18S rRNA, TGF-p, IL-4, IFN-y and
iNOS. The most abundant transcripts were those encoding 18S rRNA and iNOS, and
the least abundant transcripts were those encoding IL-4, TGF-P and IFN-y.
Descriptive statistics of the normalised absolute copy numbers are summarised in
Table 6.4, and illustrated in Figure 6.17. Overall, the results tended to show trends
rather than statistically significant differences, and there was marked variation in
copy numbers between samples. For TGF- P, copy numbers tended to be higher in
healthy and non-lesional atopic skin compared to lesional skin, but the difference did
not reach statistical significance (y?=0.1052 and 0.0664 respectively). Expression of
IL-4 was generally low in all three groups, although when it was present, higher
levels were observed in atopic skin. For IFN-y, copy numbers were higher in atopic
skin compared to the controls and a significant difference was seen between lesional
and healthy skin (p=0.0338); expression of IFN-y was also higher in non-lesional
atopic skin compared to healthy controls (p=0.0710). With iNOS, copy numbers
were highest in healthy and non-lesional skin but appeared to be lower in lesional
atopic skin.
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Figure 6.12 Detection and quantisation of 18S rRNA by real-time RT-PCR
PCR cycle numbers were plotted against normalised fluorescence intensities on a
logarithmic scale, for better illustration of the exponential phase of the PCR (a).
Slopes of the exponential amplification phases are highly reproducible and
independent of template concentration. The horizontal red line indicates the
fluorescence threshold of amplification detection at normalised fluorescence =
0.0802, set within the exponential phase and determined by real-time software.
Absolute copy numbers of unknown samples (dots in red) were derived from data of
standards (dots in blue) (b). The value ofCt ranges from 4.97 to 21.07 with a mean
of 8.683. The copy number per pi ranges from 75,984,061 to 3,190 with a mean of
17,201,548.
(a) Norm. Fluoro.
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Figure 6.13 Detection and quantification of TGF-p mRNA by real-time RT-PCR
Normalised fluorescence intensities were plotted against PCR cycle number (a). The
horizontal red line indicates the fluorescence threshold of amplification detection at
normalised fluorescence = 0.052, set within the exponential phase and determined by
real-time software. Absolute copy numbers of unknown samples (dots in red) were
derived from data of standards (dots in blue) (b). The value ofCt ranges from
27.150 to 42.580 with a mean of 32.352. The copy number per pi ranges from 3,783
to 0 with a mean of 941.
(a)
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Figure 6.14 Detection and quantification of IL-4 mRNA by real-time RT-PCR
Normalised fluorescence intensities were plotted against PCR cycle number (a). The
horizontal red line indicates the fluorescence threshold of amplification detection at
normalised fluorescence = 0.2844, set within the exponential phase and determined
by real-time software. Absolute copy numbers of unknown samples (dots in red)
were derived from data of standards (dots in blue) (b). The value of Ct ranges from
27.78 to 41.04 with a mean of 34.329. The copy number per p.1 ranges from 521 to 0
with a mean of 50.4.
(a)
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Figure 6.15 Detection and quantification of IFN-y mRNA by real-time RT-PCR
Normalised fluorescence intensities were plotted against PCR cycle number (a). The
horizontal red line indicates the fluorescence threshold of amplification detection at
normalised fluorescence = 0.0164, set within the exponential phase and determined
by real-time software. Absolute copy numbers of unknown samples (dots in red)
were derived from data of standards (dots in blue) (b). The value ofCt ranges from
28.748 to 36.06 with a mean of 30.203. The copy number per pi ranges from 150 to
0 with a mean of 19.
(a)





Figure 6.16 Detection and quantification of iNOS mRNA by real-time RT-PCR
Normalised fluorescence intensities were plotted against PCR cycle number (a). The
horizontal red line indicates the fluorescence threshold of amplification detection at
normalised fluorescence = 0.0152, set within the exponential phase and determined
by real-time software. Absolute copy numbers of unknown samples (dots in red)
were derived from data of standards (dots in blue) (b). The value of Ct ranges from
24.79 to 35.68 with a mean of 27.068. The copy number per pi ranges from 429 to 0
with a mean of 85.5.
(a)






Table 6.3 Undetected mRNA transcript expressions in samples
18S rRNA TGF-p IL-4 IFN-y iNOS
Undetected 0 5 7 3 0
Lesional (n=5) 0 1 3 1 1
Non-Lesional (n=20) 0 3 3 2 1
Healthy (n=10) 0 1 3 2 0
Table 6.4 Descriptive statistics of normalised absolute copy numbers












































































































































N: number of samples; N*: number of missing values; SE mean: standard error of
mean; St Dev: standard deviation; Ql: 25th quartile; Q3: 75th quartile; L: lesional;
NL: non-lesional; H: healthy.
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Figure 6.17 Cytokine expression measured by qRT-PCR
Absolute copy numbers of TGF-P, IL-4, IFN-y and iNOS mRNA transcripts
normalised against 18S rRNA by dividing target copy number by 18S rRNA copy
number and multiply by a factor of 1,000,000 in the three groups of skin samples:
lesional atopic skin (L), non-lesional atopic skin (NL) and healthy controls (H) are
shown as a scatter plot (a) and box plot (b). The box represents the 25th and 75th
quartiles with the horizontal bar indicating the median. The whiskers indicate the
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6.4 Discussion
6.4.1 Quantification of mRNA expression
Four methods are in common use for the quantification of transcription: Northern
blotting, in situ hybridisation, RNAse protection assays and reverse transcription
polymerase chain reaction (RT-PCR). A fifth method, cDNA arrays, is still limited
in its use by cost considerations. RT-PCR is an in vitro method for enzymatically
amplifying defined sequences ofRNA and permits the analysis of samples
containing very little starting material. It is the most exquisitely sensitive and the
most flexible of the quantification methods and can be used to compare the levels of
mRNAs in different sample populations, to characterise patterns ofmRNA
expression, and to discriminate between closely related mRNAs (Bustin 2000).
Any PCR reaction can be divided into four different kinetic stages (Freeman and
others 1999; Wilhelm and Pingoud 2003). First, there is a lag phase where
exponential amplification is already ongoing within the PCR tube, but no
fluorescence signal above the background level is measurable. Secondly, in the
logarithmic (log) phase the exponential growth of PCR product - ideally, there is a
doubling of PCR product every cycle - is measurable as fluorescent signal. Thirdly,
in the retardation phase, accumulation of PCR inhibiting factors and loss of enzyme
and substrates for the PCR decelerates the reaction. Fourthly, the PCR reaches a
steady state in the stationary phase, and no more amplicons are produced (Pannetier
and others 1993; Freeman and others 1999). Theoretically, during the exponential
growth phase, there is a quantitative relationship between amount of starting target
sequence and amount of PCR product at any given cycle, and a linear relationship
exists between the number of amplification cycles and the logarithm of the number
ofmolecules. However, the efficiency of amplification is decreased because of
contaminants (inhibitors), competitive reactions, substrate exhaustion, inactivation of
the polymerase and target reannealing. As the number of cycles increases, the
amplification efficiency decreases, eventually resulting in a plateau effect.
The conventional RT-PCR utilising end-point product analysis is not able to
determine the initial quantity of template molecules for a gene-specific PCR, because
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at the end of the amplification cycles the amount of amplicon depends not only on
the input amount but also technical variations occurring during the reaction (Liu and
Saint 2002). Quantitative PCR requires the measurement to be taken prior to the
reaction plateau. Some applications are designed to include an endogenous internal
standard, i.e. housekeeping gene, to monitor the efficiency of amplification.
Amplification of housekeeping genes verifies that the target nucleic acid and reaction
components were of acceptable quality but does not account for differences in
amplification efficiencies due to differences in product size or primer annealing
efficiency between the internal standard and target being quantified.
Analysis of PCR product by gel electrophoresis can be at best semi-quantitative
because amplification efficiencies are not known. Real-time PCR instruments detect
amplicons as they accumulate, by measuring an increase in fluorescence resulting
from DNA synthesis (Higuchi and others 1992).
To date, published studies investigating the cytokine expression in dogs with atopic
dermatitis have used basic RT-PCR (Olivry and others 1999), semi-quantitative RT-
PCR (Hayashiya and others 2002; Nuttall and others 2002a; Nuttall and others 2002b)
and relative quantification using real-time RT-PCR (Fujiwara and others 2003). In
this study, by cloning, transformation, plasmid preparation, linearisation, verification
and exact determination of standard concentration, it was possible to generate very
stable and highly reproducible standard curves for each target gene. This
information was then used to calculate the absolute copy number of target transcripts.
This is the first time the use of such standard curves has been reported in the
veterinary literature. This method is superior to conventional RT-PCR and should
yield more accurate and reliable data.
When this method was applied to the measurement of cytokines in canine skin, in
general, major significant differences were not observed between the different skin
groups. As with any biological experiment, the first question is whether or not this is
a true biological finding or if it could reflect lack of statistical power or technical
issues (false positive or negative results). In this study, the group size in the lesional
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skin group was small which would have a negative impact on statistical power. This
is always a problem when dealing with samples obtained from clinical cases,
especially when such research samples have to be obtained under home office
licence and with owner's consent. Obviously, a larger group size would have been
desirable but it was not possible due to logistical reasons.
Technical factors also come into play when interpreting data from RT-PCR reactions.
In general, real time PCR can only be used to reliably detect a minimum of a two
fold difference in DNA levels between samples. This essentially represents one
cycle (because the amount ofDNA approximately doubles in each cycle). In this
study, the use of standard curves and normalisation to a housekeeping gene should
have minimised inaccuracies due to technical issues but, despite this, the method
would still not have been able to detect more subtle differences between groups if
those differences were less than two fold.
A further technical issue relates to the quality of the RNA in the archived samples.
Results from the electropherograms indicating that partial degradation ofRNA had
occurred in some of the samples which might have influenced the final analysis.
Despite the general lack of significant statistical differences, there were some trends
in the data that warrant further comment and comparison to existing literature.
6.4.2 Th2 and Th1 cytokine expression in canine atopic dermatitis
Studies in humans and experimental mouse models suggest that IL-4 expression is a
hallmark of atopic dermatitis (Leung 2000). No significant difference was found in
IL-4 mRNA expression between the groups in our study, but there was a tendency
for higher levels to be seen in atopic skin. In Nuttall's study (using the same
samples), this difference was significant (Nuttall and others 2002a; Nuttall and others
2002b). In Marsella's study, using genetically predisposed high-IgE Beagles, no
increase in IL-4 mRNA was recorded after epi-cutaneous allergen challenge (atopy
patch testing). An earlier study using non-quantitative methods found that IL-4
mRNA was expressed in both atopic and healthy skin samples (Olivry and others
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1999) whereas in another study using quantitative RT-PCR, IL-4 mRNA was not
detected in any of the skin samples from either atopic or healthy dogs examined
(Maeda and others 2002). Possible explanations for these discrepancies are
discussed at the end of this section.
Studies evaluating IL-4 mRNA expression in PBMCs have showed similar results.
Levels of IL-4 in resting PBMCs were similar in both atopic and healthy dogs
whereas significantly higher levels of IL-4 mRNA were detected in D. farinae
stimulated atopic PBMCs compared to healthy PBMCs in a semi-quantitative study
using samples from naturally occurring atopic dogs (Nuttall 2003). In another study,
the amount of IL-4 mRNA was below the lower detection limit in all of the sensitised
and control dogs in primary PBMCs but was markedly increased after stimulation
with the sensitising antigen in a quantitative study using experimentally sensitised
dogs (Fujiwara and others 2003). These findings suggest that Th2 responses in
atopic dogs are the result of interaction with specific allergens rather than the result
of global Th2 polarisation. It has also been confirmed in humans that the Th2
responses in atopic patients are allergen specific and are not associated with non-
sensitising antigens (Jenmalm and others 2001).
It is likely that other Th2-type cytokines such as IL-13, IL-6 and IL-5 could be
associated with Th2 polarisation and IgE production in atopic disease but their
expression was not investigated in this study. Further studies should examine a
wider range of cytokines over a dynamic period in order to elucidate the complex
orchestration of the cytokine milieu in canine atopic dermatitis.
Higher levels ofmRNA for the Thl cytokine IFN-y were seen in atopic dog skin as
compared with healthy controls in this study. This result is consistent with previous
findings. Studies using skin samples from naturally occurring atopic dogs have
shown that significantly higher levels of IFN-y mRNA were detected in lesional
compared with non-lesional and healthy skin (Maeda and others 2002; Nuttall and
others 2002a; Nuttall and others 2002b), and mRNA expression of IFN-y also
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significantly increased during epi-cutaneous allergen challenge in high-IgE Beagles
(Marsella and others 2006).
The increase of IFN-y in atopic group in our study is, however, contrary to other
reports (Hayashiya and others 2002; Fujiwara and others 2003) in which the
expression of IFN-y mRNA in primary PBMCs both in naturally occurring AD and
in experimentally sensitised dogs was significantly lower than that in the healthy
dogs. Several studies in humans have shown an increased frequency of allergen-
specific T cells producing little IFN-y in the peripheral blood and skin lesions of
patients with AD (van der Heijden and others 1991; van Reijsen and others 1992).
After stimulation with sensitising antigen, the expression level of IFN-y mRNA in
the PBMCs from sensitised dogs was similar to that in PBMCs from the healthy dogs
(Fujiwara and others 2003). However, one unpublished report showed that similar
levels of IFN-y mRNA were present in both atopic and healthy dogs in resting
PBMCs, but significantly greater levels of IFN-y transcription were seen in
stimulated healthy PBMCs compared to atopic PBMCs (Nuttall 2003). In Nuttall's
study, canine immunological responses to the antigens from house dust mite D.
farinae in naturally occurring atopic dogs were investigated whilst Fujiwara studied
the immune responses to antigens from Japanese cedar Cryptomeria japonica in
experimentally sensitised dogs. It is not known whether different antigens activate
different immunological pathways in disease development. Further studies to
identify the cells producing these cytokines and to compare the mRNA expression
with the protein production are needed to make a complete interpretation.
Thl and Th2 cytokines contribute to the pathogenesis of skin inflammation in human
AD with the relative contribution of each cytokine dependent on the duration of the
skin lesion (Leung 2000). Controlled studies evaluating cytokine expression in
relation to lesion development would provide more genuine information. It has been
shown in humans that acute T-cell infiltration in AD is associated with a
predominance of IL-4 and IL-13 expression, whereas maintenance of chronic
inflammation is associated with increased IL-5, IL-12 and IFN-y expression
accompanied by the infiltration of eosinophils and macrophages (Hamid and others
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1994; Hamid and others 1996). The biphasic pattern of T-cell activation has also
been demonstrated in studies on allergen patch testing (Grewe and others 1998).
Increased expression of IL-4 mRNA and protein is observed 24 hours after allergen
application to the skin, after which IL-4 expression declines to baseline levels. In
contrast, IFN-y mRNA expression is not detected in 24-hour patch-test lesions but is
strongly over-expressed at the 48- and 72-hour time points (Grewe and others 1998).
Atopy patch testing in dogs has recently been performed (Marsella and others 2006)
and the authors concluded that early lesions are overall associated with high
transcription and translation of pro-inflammatory cytokines (e.g. IL-6) and Th2
cytokines (e.g. IL-13), while later lesions are accompanied by progressive increase of
Thl cytokines (e.g. IL-18) (Marsella and others 2006). In the same study, IFN-y
mRNA showed a biphasic response with an early peak at 6-hour; the early rise of
INF-y could be potentially explained by the presence of some T-cell infiltration even
prior to any allergen challenge, as indicated by the presence of a mononuclear
infiltrate in both baseline and 6 h biopsies (Marsella and others 2006).
Thl cytokines appear to be important in the establishment and maintenance of
chronic lesions, but the trigger for Thl cytokine expression in chronic lesions is not
fully understood. Skin lesions in human and canine atopic dermatitis include
erythema, papular eruptions, alopecia, scaling, crusting, hyperpigmentation and
lichenification (Rothe and Grant-Kels 1996; Scott and others 2001). Flowever,
clinically uncomplicated canine atopic dermatitis is largely a pruritic and
erythematous disease and most lesions result from self-trauma and microbial
colonisation (Rothe and Grant-Kels 1996; Griffin and DeBoer 2001a). Self-trauma
induced by scratching or rubbing severely pruritic skin can induce inflammatory
cytokines (e.g. IL-1, TNF-a and GM-CSF) from keratinocytes and result in the
recruitment of mononuclear cells and ultimately the development of chronic lesions
(Robert and Kupper 1999). Bacterial activation of Toll-like receptors by cutaneous
bacteria and increased expression of MHC II, IL-1 and IL-12, up-regulated
endothelial ICAM-1 and VCAM-1, as well as increased CLA expression on T-cells
induced by staphylococcal superantigens also contribute to the development of
chronic skin lesions.
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The Thl-type cytokines IL-2, IFN-y and TNF-a are associated with cell-mediated
inflammation and inhibition of Th2 differentiation (Fiorentino and others 1989).
APC derived IL-12 is a critical factor in Thl differentiation, IFN-y production and
CLA expression on circulating T-cells (Snijders and others 1998). Studies using
microarray investigating thousands of genes at the same time would provide more
information regarding the intricate interaction between various cytokines and cells
involved in the pathogenesis of atopic dermatitis.
There are various explanations for the discrepancies and conflicting data in relation
to the role of Th2 and Thl cytokines in canine atopic dermatitis. First, there may be
differences due to varying methodologies. Conflicting results relating to different
methods used to quantify cytokine gene transcripts have been shown in another study
in dogs suffering from chronic diarrhoea. Using basic semi-quantitative RT-PCR,
increased concentration of IL-2, IL-5, IL-12p40, TNF-a and TGF-[3 mRNA
transcripts were reported in the duodenal mucosa ofGerman Shepherd dog with
chronic enteropathies compared with control dogs (German and others 2000).
However, no difference in expression of these cytokines was found in a follow-up
study using real-time quantitative RT-PCR (Peters and others 2005). Real-time RT-
PCR provides a more accurate representation of tissue mRNA concentration over
conventional RT-PCR because the latter does not differentiate exponential
amplification and plateau reaction, and therefore the intensity of the gel band may
bear little relation to the starting template quantity. Hence, cautious interpretation
should be exercised when comparing results from various studies in which different
methodologies were employed.
Second, the varying results obtained by different authors who have assessed Th2 and
Thl cytokine profiles in healthy and atopic dogs could be explained by obtaining
"snapshots" of the cytokine milieu at a particular point in time, whereas in reality,
the situation is in a constant state of flux. As the precise "age" of lesions in clinical
cases is not known at the time of biopsy, the particular cytokine in question may or
may not be present in abnormal amounts.
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Taken together, the balance of evidence from this and previous studies suggests that
IL-4 may be increased in the skin of atopic dogs throughout the pathological
continuum, but its level may be very variable depending on the exact age of the
lesion and the particular cyto-humoral milieu at a particular point in time. It has
been reported in the human literature that IL-13 rather than IL-4 is released by
peripheral T cells of patients with AD and in lesional skin (Akdis and others 1999b;
Aleksza and others 2002). In contrast, IFN-y appears to increase as the chronic
inflammatory reaction develops. Unfortunately, due to the limited availability of
antibodies suitable for immunohistochemical staining of cytokines, all studies
investigating the cytokine milieu in atopic dogs have so far had to use PCR
techniques. In the future, immunohistochemistry and proteomic analysis might
confirm whether or not there is genuine over-expression of these specific proteins in
atopic canine skin.
6.4.3 Immunosuppressive cytokines in canine atopic dermatitis
The TGF-P family of proteins are a set of pleiotropic secreted signalling molecules
with unique and potent immuno-regulatory properties. TGF-P is known to affect T
cell proliferation, differentiation, apoptosis, antigen presentation, effector functions
ofmacrophages, the expression of MHC I, MHC II, CD40 and IL-12 (Jutel and
others 2003). It can also modulate expression of adhesion molecules, provide a
chemotactic gradient for leukocytes and other cells participating in an inflammatory
response, and inhibit them once they have become activated (Letterio and Roberts
1998). However, the role TGF-p plays in the canine immune system is less well
understood.
In this study, higher levels of TGF-P mRNA were detected in healthy and non-
lesional skin compared to lesional atopic skin. These results are in general
agreement to those ofNuttall who used the same tissue samples, although in his
study, lower levels of TGF-P mRNA were found in both non-lesional and lesional
atopic skin (Nuttall and others 2002b). These results suggest that the expression of
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TGF- p might be down-regulated in lesional atopic skin, and the lack of its
immunosuppressive effect might be one factor that allows the inflammatory reaction
to progress..
TGF-P, and IL-10, mediate certain aspects of peripheral immune tolerance to
environmental allergens. Both CD4+ and CD8+ suppressive T cell subsets that
secrete active TGF-P have been identified following induction of oral tolerance
(Chen and others 1995), and the protective function of these cells both in vitro and in
vivo can be blocked by antibodies to TGF-P (Chen and others 1994). Furthermore,
TGF-P and IL-10 have been shown to cooperate in suppression of the immune
response to aeroallergens and control allergic inflammation due to allergen exposure
in healthy individuals as well as in allergen-specific immunotherapy for house dust
mite allergic patients (Jutel and others 2003). The low levels of cutaneous TGF-p
mRNA in lesional skin found in this study could, therefore, reflect a breakdown of
suppressive mechanisms. In contrast, constitutive expression of TGF-P in non-
lesional and healthy skin could inhibit inappropriate inflammatory responses to
environmental allergens. The balance of anti-inflammatory and stimulatory activity
of TGF-P may depend on the degree of differentiation or activation of a target cell as
well as the overall cytokine and cellular milieu (Ling and Robinson 2002)
6.4.4 Inducible nitric oxide synthase expression
Nitric oxide (NO) is a highly diffusible intercellular signalling molecule involved in
a wide range of biological effects (Anggard 1994). It is generated by the enzyme
nitric oxide synthase (NOS), and three genetically distinct NOS isoforms have been
characterised in humans. Two isoforms are constitutively expressed (cNOS,
including endothelial NOS or eNOS and neuronal NOS or nNOS), whereas one
isoform is an inducible enzyme (iNOS, NOS2). The cNOS isoforms are active only
after binding of calcium-calmodulin complexes and produce NO for short periods of
time (seconds to minutes), and NO synthesised by the cNOS isoforms usually acts as
an intercellular signalling molecule mediating time-restricted events such as
neurotransmission or vasorelaxation (Lowenstein and Snyder 1992; Knowles and
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Moncada 1994). It has been suggested that the cNOS pathway provides regulatory
and homeostatic functions in the skin (Bruch-Gerharz and others 1998). In contrast
to the cNOS isoforms, iNOS is transcriptionally regulated and requires de novo
messenger RNA and protein synthesis for its activity (Kroncke and others 1995).
Once induced, iNOS is active for comparatively long periods of time (hours to days),
thereby producing large amounts ofNO, which can display non-specific host
protective functions and immuno-regulatory and cytotoxic activities (Liew and Cox
1991; Nathan 1992). It has been shown that the transcriptionally regulated induction
of iNOS can be inhibited by glucocorticosteroids, cyclophilins, and retinoids as well
as TGF-P, IL-4 and IL-10 (Becherel and others 1996). It has been found in most
cells of the skin, including keratinocytes, Langerhans cells, fibroblasts and
endothelial cells (Bruch-Gerharz and others 1998). Research from experiments with
mice lacking a functional iNOS gene showed that NO generated from iNOS activity
may also be involved in the regulation of Thl cell population expansion and Thl-
mediated immune responses (MacMicking and others 1995; Wei and others 1995).
The expression of iNOS in cells of the skin is predominantly associated with
inflammatory processes early in cutaneous immune responses (Bruch-Gerharz and
others 1998).
Using immunohistochemistry, eNOS and iNOS have been measured in skin from
human patients with AD, allergic contact dermatitis (CD) and psoriasis (Rowe and
others 1994; Rowe and others 1997). Expression of iNOS mRNA was found to be
decreased in AD, as compared with psoriasis, skin using GeneChip microarrays
(Nomura and others 2003), but the immunoreactivity of iNOS was significantly more
extensive in AD skin than in CD skin using immunohistochemistry (Rowe and others
1997). Induction of iNOS in the dermal endothelium and in perivascular
inflammatory cells may be significant with respect to the roles ofNO in both the
vasodilatory component of the inflammatory response and in the modulation of
immune responses in the skin (Rowe and others 1997). However, the potential role
of iNOS in the context ofAD is not fully understood.
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In this study, the expression of iNOS mRNA transcripts was lower in lesional
compared with non-lesional skin samples from atopic dogs although the difference
did not reach statistical significance. These results were unexpected. The primers
used in RT-PCR were designed to specifically amplify transcripts of iNOS, and
amplification of neuronal NOS (NOS1) or endothelial NOS (NOS3) was not likely, if
not impossible.
It has been shown that iNOS expression is found in a number of inflammatory skin
conditions including psoriasis, atopic dermatitis, irritant and allergic contact
dermatitis (Kolb-Bachofen and others 1994; Rowe and others 1997; Ormerod and
others 1997; Ormerod and others 1998). The mRNA or protein levels of iNOS are
usually the highest in lesional skin followed by clinically uninvolved skin, and the
expression of iNOS is often minimal in healthy skin (Rowe and others 1997;
Ormerod and others 1998). iNOS is not usually found in normal resting cells, but
induced in response to inflammatory cytokines or a combination of cytokines (i.e.
IFN-y, IL-ip, IL-2, IL-8 and TNF-a) and bacterial polysaccharides (Cals-Grierson
and Ormerod 2004). However, these cytokines are either absent or only present at
low levels in AD lesions, and some of the cytokines that are present (such as IL-4)
may have inhibitory effects on iNOS expression. It is possible that the cytokine
milieu in AD prevents the induction of iNOS due to lower levels of pro¬
inflammatory cytokines such as TNF-a or IFN-y and the increased Th2 cytokines
(Nomura and others 2003).
In summary, the levels of iNOS mRNA in canine atopic skin appeared to be lower





7.1 D. farinae-specific IgG responses in canine atopic
dermatitis
This thesis describes the immunological features of dogs with atopic dermatitis.
Until very recently little was known of the pathogenesis of this disease. Although
the presence of circulating and cutaneous mast cell bound allergen-specific IgE was
well recognised, the role of IgG is not clear and remains paradoxical. The most
common allergens are the house dust mites Dermatophagoidesfarinae and D.
pteronyssinus, but the major allergen for atopic dogs is a 98-kDa chitinase (Der f 15)
rather than group 1 or 2 allergens (Noli and others 1996; McCall and others 2001).
By developing and validating a digital image analysis method for Western blots, we
were able to study and semi-quantify global antibody responses against various D.
farinae antigens simultaneously without operator's bias. The technique has its
superiority over existing antibody study methods, i.e. ELISA, in that comprehensive
antigen-specific antibody response can be investigated and distinguished
contemporaneously. The methodology we developed provides a powerful
surveillance capacity in identifying major antigens of crude allergen extract when
studying novel allergens. It is also ideal for monitoring different specific antibody
responses in allergic patients undergoing treatment, i.e. ASIT, and should be used in
initial investigation stage identifying potential target antigens responsible for
successful therapy.
The profile of IgG binding against D. farinae antigens was similar in dogs with
atopic dermatitis and healthy dogs, and the responses were generally stronger in
atopic dogs although the specific antibody levels did not differ significantly. The
generation of specific antibody response to ubiquitous environmental allergen seem
to merely represent the recognisition of foreign antigen by canine immune system,
and a reciprocal interaction of other factors including predisposed genetic
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background, early immunisation of the offending allergen, vigorous vaccination
programme, etc has a prominent influence on the development of atopic disease than
the downstream antibody response.
The D. farinae-specific IgG responses were consisted predominantly of the subclass
IgGl and IgG4, and D. farinae specific IgG2 and IgG3 were not detected in atopic
dogs. This finding is in consistent with the previous study showing a degree of IgG
subclass restriction in the humoral immune response of canine atopy which may be
dependent upon the nature of the allergen (Day and others 1996). However, the
function of dog IgG subclass antibodies has not been examined due to limited
availability of suitable specific reagents, and further study is warranted to establish
the functionality of IgG subclasses in the context of allergic disease.
Taken together, the results of these studies suggest that D. farinae-specific IgG and
IgG subclasses do not play a major role in the pathogenesis of canine atopic
dermatitis. Such responses occur in both healthy and atopic dogs and do not appear
to be either protective or pathogenic. These findings would fit with a hypothesis in
which the production of IgG, and its subclasses, against D. farinae antigens was
merely a result of recognition of a foreign protein that was presented to the immune
system in relatively large quantities. This would also fit with the concept ofD.
farinae antigens acting as 'danger' signals to the immune system, thus provoking an
antibody response even though the molecules themselves appear to be harmless. In
view of this, it seems likely that the production of IgE and the activation of allergen-
specific T lymphocytes are the most important immunological events in canine
atopic dermatitis.
7.2 D. farinae-specific IgG responses in atopic dogs
undergoing allergen-specific immunotherapy
In atopic dogs undergoing allergen-specific immunotherapy using alum-precipitated
vaccines or aqueous vaccines, D. farinae-specific IgG responses were also
investigated. Whilst specific antibody responses did not change in relation to the
outcome of treatment or dosage of vaccine in atopic dogs using alum-precipitated
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vaccines, D. farinae-specific IgG levels were shown to increase significantly after 2
month ofASIT using aqueous vaccines. If specific IgG antibody was not induced
after ASIT, the beneficial effect of successful ASIT might be accounted for by other
mechanism such as down-regulation of cellular function, induction of regulatory T
cells or changes in immuno-suppressive/immuno-regulatory cytokine profile. On the
other hand, the study using aqueous vaccines demonstrated a dramatic increase in D.
farinae-specific IgG level, and supported the hypothesis of blocking antibody theory.
Although clinical improvement did not correspond well with D. farinae-specific IgG
response because most of the atopic dogs included in the study were sensitised to
multiple allergens in addition to house dust mite, the induction of IgG antibody
demonstrated a possible role of IgG in the pathogenesis of canine atopic dermatitis.
Further studies comparing the D. farinae-specific IgG response to clinical outcome
in dogs that are mono-sensitised to dust mite allergen would yield an explicit picture
of the role of D. farinae-specific IgG.
A potentially exciting finding was noticed in that atopic dog with a pre-existing high
level of IgG antibodies to D. farinae prior to the onset ofASIT was less likely to
respond to the treatment. This may suggest a means by which dogs could be
screened prior to initiation ofASIT; alternatively, this might allow alterations in
dosage schedule to be predicted in advance. Additional methods are required to
substantiate this finding in a larger group of dogs. If this is a repeatable phenomenon,
D. farinae-specific IgG level could be used as a prognostic indicator in clinical
settings to assist the assessment of whether to engage ASIT.
7.3 Cytokine responses in canine atopic dermatitis
Upon exposure to most foreign antigens, the usual humoral immune response results
in production of IgG antibody rather than IgE. A major determinant of which
antibody class predominates is which one of the two subsets of helper T lymphocytes
(Thl and Th2) is dominant. The factors that determine whether a Thl or a Th2
response will predominate are complex but include both genetic and environmental
influences.
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Previous studies using semi-quantitative RT-PCR had demonstrated that the skin of
dogs with AD over expressed IL-4 mRNA and under expressed TGF-P compared
with healthy dog skin, which indicated a Th2-biased response (Nuttall and others
2002b). We investigated the four arms of immune responses - the Thl type, the Th2
type, the regulatory and the innate immune responses - by studying one representing
cytokine for each response using quantitative real-time RT-PCR. The system was
validated using plasmid DNA constructs containing the sequences of interest, and the
generation of absolute quantity of target gene mRNA transcripts normalised to
endogenous internal control 18S rRNA provided superior quantitative accuracy as
compared with the conventional RT-PCR techniques. The immunoregulatory
cytokine TGF-P tended to be suppressed in lesional skin samples, whilst the innate
immune response cytokine iNOS expression was somehow lower in healthy skin as
compared to atopic skin. IL-4 was not significantly expressed in the skin of atopic
dogs throughout the pathological continuum, whereas IFN-y appeared to increase as
the chronic inflammatory reaction developed.
It is interesting to note that the level of IL-4 mRNA transcripts in atopic dog skin and
primary PBMC was often below the detection limit in real-time RT-PCR despite its
supreme sensitivity (Maeda and others 2002; Fjuiwara and others 2003; Marsella
and others 2006). Also, statistical significant differences in mRNA expression were
not often reached using real-time RT-PCR methodology as compared with semi¬
quantitative RT-PCR in studying dog with bowel disease (German and others 2000;
Peters and others 2005), as well as in our study. The biological meaning of such
finding remains to be determined. Future cytokine profile studies should combine
with immunohistochemistry, proteometic and microarray analysis, and also to
investigate a lesion age-related cytokine milieu to characterise potential dynamic and
sequential activation of different T cell subsets. Advances in our understanding of
this complex disease will no doubt continue to provide us with additional therapeutic
solutions in the future.
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7.4 Future studies
In order to understand why allergen-specific immunotherapy benefits some atopic
dogs but not others, it is necessary to elucidate how ASIT modulates the immune
system. D. farinae-sensitised atopic dogs with a pre-existing high level of D.
farinae-specific IgG antibody prior to ASIT responded poorly to the treatment.
Further studies are required to confirm this finding in a larger group of dogs, and to
evaluate whether other isotypes of allergen-specific antibody are potential prognostic
indicators. Allergen-specific IgE has been used for diagnostic purpose in canine
atopic dermatitis despite poor assay specificity, and D. farinae-specific IgE was more
prevalent in normal dogs than in atopic dogs. Semi-quantitative analysis ofD.
farinae-specific IgE in normal and atopic dogs using immunoblotting technique
should be carried out to clarify its function. The role of blocking antibody needs to
be pursued further because significant augmentation of D. farinae-specific IgG was
recorded after ASIT using an aqueous vaccine, although the level of specific IgG did
not correlate with clinical outcome. Epitope specificity of IgG antibody also needs
to be investigated because it could be one of the missing puzzles in the mechanism of
ASIT. In addition, further cytokine response studies are also required and studies
should combine cytokine expression experiments with immunohistochemistry,
proteomic and microarray analysis in order to identify the key functioning cells
and/or cytokines in the complex interaction of various immune components. A
thorough understanding ofASIT will hopefully provide us new therapeutic options to











18S 108 Standard 5.82 100000000 92052925
18S 108 Standard 5.75 100000000 96008355
18S 106 Standard 12.28 1000000 1129371
18S 106 Standard 12.45 1000000 1007881
18S 104 Standard 19.36 10000 9141
18S 104 Standard 18.93 10000 12232
18S 102 Standard 26.66 100 64
18S 102 Standard 25.50 100 140
NL1 Non-lesional skin 6.78 24385644
NL2 Non-lesional skin 6.78 24385644
NL3 Non-lesional skin 6.01 39557785
NL4 Non-lesional skin 6.37 31631510
NL5 Non-lesional skin 7.07 20372447
NL6 Non-lesional skin 7.35 17141700
NL7 Non-lesional skin 12.41 719625
NL8 Non-lesional skin 7.60 14574054
NL10 Non-lesional skin 7.67 13978857
NL11 Non-lesional skin 8.22 9910283
NL12 Non-lesional skin 21.07 3190
NL13 Non-lesional skin 8.01 11323225
NL14 Non-lesional skin 6.66 26337178
NL15 Non-lesional skin 7.98 11501821
NL16 Non-lesional skin 7.22 18546602
NL17 Non-lesional skin 7.88 12295082
NL18 Non-lesional skin 8.24 9808800
NL19 Non-lesional skin 6.24 34303139
NL20 Non-lesional skin 9.60 4182282
NL21 Non-lesional skin 11.94 964345
L1 Lesional skin 10.17 2922969
L2 Lesional skin 9.16 5492067
L3 Lesional skin 9.28 5116187
L4 Lesional skin 10.60 2235485
L5 Lesional skin 12.56 655405
N1 Healthy skin 7.14 19448309
N2 Healthy skin 5.99 40131101
N3 Healthy skin 7.09 20165948
N4 Healthy skin 13.82 298694
N5 Healthy skin 6.69 25881970
N6 Healthy skin 5.29 61944595
N7 Healthy skin 4.97 75984061
N8 Healthy skin 8.91 6423797
N9 Healthy skin 8.40 8863361
N10 Healthy skin 12.79 567033
water Control
Given Cone.: given concentration; Calc Cone.: calculated concentration.
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TGF-p 108 Standard 5.80 100000000 103482053
TGF-p 108 Standard 5.96 100000000 92442478
TGF-p 106 Standard 12.67 1000000 1026606
TGF-p 106 Standard 12.46 1000000 1183095
TGF-p 104 Standard 19.61 10000 9702
TGF-p 104 Standard 19.90 10000 7981
TGF-p 102 Standard 26.44 100 99
TGF-p 102 Standard 26.26 100 112
NL1 Non-lesional skin 28.52 1900
NL2 Non-lesional skin 33.71 141
NL3 Non-lesional skin 29.52 1153
NL4 Non-lesional skin 31.80 368
NL5 Non-lesional skin 27.15 3783
NL6 Non-lesional skin 32.81 222
NL7 Non-lesional skin 42.55 2
NL8 Non-lesional skin 30.13 850
NL10 Non-lesional skin 29.02 1478
NL11 Non-lesional skin 32.04 327
NL12 Non-lesional skin
NL13 Non-lesional skin 28.41 2009
NL14 Non-lesional skin 28.80 1652
NL15 Non-lesional skin 32.04 327
NL16 Non-lesional skin 31.14 512
NL17 Non-lesional skin 32.26 292
NL18 Non-lesional skin 31.84 361
NL19 Non-lesional skin 27.16 3761
NL20 Non-lesional skin 42.58 2
NL21 Non-lesional skin 38.24 15
L1 Lesional skin 39.12 9
L2 Lesional skin 33.70 142
L3 Lesional skin 33.61 149
L4 Lesional skin 38.23 15
L5 Lesional skin
N1 Healthy skin 29.66 1075
N2 Healthy skin 27.77 2774
N3 Healthy skin 29.96 927
N4 Healthy skin
N5 Healthy skin 30.99 552
N6 Healthy skin 28.72 1720
N7 Healthy skin 27.52 3132
N8 Healthy skin 31.70 386
N9 Healthy skin 35.12 70
N10 Healthy skin 39.43 8
water Control
Given Cone.: given concentration; Calc Cone.: calculated concentration.
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Raw data of IL-4 quantification using qRT-PCR
Name Type Ct
Given Cone. Calc Cone.
(copies/pl) (copies/gl)
IL-4 108 Standard 5.66 100000000 81050289
IL-4 108 Standard 5.59 100000000 85201561
IL-4 106 Standard 11.80 1000000 1257116
IL-4 106 Standard 11.67 1000000 1377034
IL-4 104 Standard 19.11 10000 8780
IL-4 104 Standard 18.71 10000 11541
IL-4 102 Standard 26.21 100 71
IL-4 102 Standard 25.48 100 117
NL1 Non-lesional skin 31.94 54
NL2 Non-lesional skin 35.28 9
NL3 Non-lesional skin 34.08 17
NL4 Non-lesional skin 34.71 12
NL5 Non-lesional skin 27.78 521
NL6 Non-lesional skin 37.79 2
NL7 Non-lesional skin
NL8 Non-lesional skin 31.64 64
NL10 Non-lesional skin 32.11 49
NL11 Non-lesional skin 34.61 13
NL12 Non-lesional skin
NL13 Non-lesional skin 34.17 16
NL14 Non-lesional skin 31.96 53
NL15 Non-lesional skin 34.80 11
NL16 Non-lesional skin 34.06 17
NL17 Non-lesional skin 33.82 19
NL18 Non-lesional skin 34.84 11
NL19 Non-lesional skin 30.07 150
NL20 Non-lesional skin
NL21 Non-lesional skin 37.54 3
L1 Lesional skin 41.04
L2 Lesional skin 40.67
L3 Lesional skin 31.25 79
L4 Lesional skin 40.02 1
L5 Lesional skin
N1 Healthy skin 34.52 13
N2 Healthy skin 31.33 75
N3 Healthy skin 35.41 8
N4 Healthy skin
N5 Healthy skin 36.00 6
N6 Healthy skin 33.04 30
N7 Healthy skin 31.48 69




Given Cone.: given concentration; Calc Cone.: calculated concentration
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IFN-Y IOB Standard 7.48 100000000 94764659
IFN-Y 10S Standard 7.51 100000000 93373222
IFN-Y 106 Standard 14.31 1000000 1029381
IFN-Y 106 Standard 14.26 1000000 1063273
IFN-Y 104 Standard 21.03 10000 11925
IFN-Y 104 Standard 21.28 10000 10104
IFN-Y 102 Standard 28.14 100 108
IFN-Y 102 Standard 28.59 100 80
NL1 Non-lesional skin 30.95 4
NL2 Non-lesional skin 29.01 15
NL3 Non-lesional skin 30.29 6
NL4 Non-lesional skin 29.81 9
NL5 Non-lesional skin 25.37 150
NL6 Non-lesional skin 32.65 1
NL7 Non-lesional skin 33.10 1
NL8 Non-lesional skin 27.66 35
NL10 Non-lesional skin 26.64 67
NL11 Non-lesional skin 27.27 44
NL12 Non-lesional skin 36.06
NL13 Non-lesional skin 29.29 12
NL14 Non-lesional skin 27.46 39
NL15 Non-lesional skin 27.47 39
NL16 Non-lesional skin 28.72 18
NL17 Non-lesional skin
NL18 Non-lesional skin 29.10 14
NL19 Non-lesional skin 30.98 4
NL20 Non-lesional skin 31.72 3
NL21 Non-lesional skin 33.85 1
L1 Lesional skin 31.89 2
L2 Lesional skin 31.29 3
L3 Lesional skin 31.59 3
L4 Lesional skin 30.19 7
L5 Lesional skin 35.66
N1 Healthy skin 29.91 8
N2 Healthy skin 28.84 16
N3 Healthy skin 30.60 5
N4 Healthy skin
N5 Healthy skin 29.92 8
N6 Healthy skin 27.76 33
N7 Healthy skin 28.83 16
N8 Healthy skin 30.52 6
N9 Healthy skin 32.09 2
N10 Healthy skin
water Control
Given Cone.: given concentration; Calc Cone.: calculated concentration.
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iNOS 108 Standard 6.26 100000000 108789213
iNOS 108 Standard 6.31 100000000 105497928
iNOS 10® Standard 12.79 1000000 1283984
iNOS 10® Standard 12.67 1000000 1393835
iNOS 104 Standard 20.49 10000 6800
iNOS 104 Standard 21.67 10000 3037
iNOS 102 Standard 26.02 100 158
iNOS 102 Standard 26.10 100 150
NL1 Non-lesional skin 24.63 121
NL2 Non-lesional skin 28.58 12
NL3 Non-lesional skin 25.36 79
NL4 Non-lesional skin 26.90 32
NL5 Non-lesional skin 24.26 151
NL6 Non-lesional skin 25.31 81
NL7 Non-lesional skin 28.61 11
NL8 Non-lesional skin 24.79 110
NL10 Non-lesional skin 24.87 105
NL11 Non-lesional skin 24.99 98
NL12 Non-lesional skin 34.60
NL13 Non-lesional skin 25.22 85
NL14 Non-lesional skin 22.50 429
NL15 Non-lesional skin 24.56 127
NL16 Non-lesional skin 26.16 49
NL17 Non-lesional skin 25.18 88
NL18 Non-lesional skin 26.70 35
NL19 Non-lesional skin 23.38 254
NL20 Non-lesional skin 32.15 1
NL21 Non-lesional skin 29.16 8
L1 Lesional skin 35.68
L2 Lesional skin 27.27 25
L3 Lesional skin 30.48 4
L4 Lesional skin 28.58 12
L5 Lesional skin 33.29 1
N1 Healthy skin 26.85 32
N2 Healthy skin 24.50 131
N3 Healthy skin 25.26 83
N4 Healthy skin 32.80 1
N5 Healthy skin 27.22 26
N6 Healthy skin 25.43 75
N7 Healthy skin 22.90 340
N8 Healthy skin 26.74 35
N9 Healthy skin 24.09 167
N10 Healthy skin 28.37 13
water Control
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antigens from Dermatophagoidesfarinae in healthy and atopic dogs. Veterinary
Immunology and Immunopathology. 106: 121-128.
In this study, we used a semi-quantitative electrophoresis and immunoblotting
technique to characterise the IgG response to antigens from Dermatophagoides
farinae in 20 healthy and 20 atopic dogs. Both groups mounted an IgG response to
multiple antigens from the mite. There was no significant difference in the number
of bands recognised, or the molecular weights of the bands, between the two groups.
The two most obvious bands in both groups were proteins with molecular weights of
98Kd (likely to be the high molecular weight allergen Der f 15) and 44 Kd, although
dogs in both groups recognised a similar pattern of other antigens. The magnitude of
the IgG response was greater in the atopic group although this was not statistically
significant. The results indicate that the immune system of both healthy and atopic
dogs generates an IgG response to multiple antigens from Dermatophagoides farinae.
As some of these antigens (such as the 98Kd and 44Kd proteins) are also targeted by
IgE in atopic dogs, immunoglobulin class switching in response to Th2 cytokines
may not be as dominant a process as has been proposed.
2. Hou C, Day MJ, Nuttall TJ, and Hill PB. (2006) Evaluation of IgG subclass
responses against Dermatophagoides fairnae allergens in healthy and atopic dogs.
Veterinary Dermatology. 17: 103-110.
A semi-quantitative chemiluminescent western blot analysis system was developed
and validated to evaluate allergen-specific IgG subclass responses to
electrophoretically separated allergens of Dermatophagoidesfarinae in 20 healthy
and 20 atopic dogs.
Both groups mounted IgGl and IgG4 responses to multiple antigens from the mite
while D. farinae-specific IgG2 and IgG3 levels were undetectable using standard
blotting conditions. The profiles of the IgGl and IgG4 responses were similar in the
two groups, both in terms of the number of bands recognised, and their molecular
weights. The most commonly recognised bands in both healthy and atopic groups
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were 98 kDa and 18 kDa antigens for IgGl and 98 kDa and 45 kDa antigens for
IgG4. The number of bands recognised per dog did not differ significantly between
the two groups. The overall D. farinae-specific IgGl and IgG4 responses were
slightly higher in the healthy group but were not significantly different. The IgGl
responses to the 98 kDa and 18 kDa antigens and the IgG4 responses to the 98 kDa
and 45 kDa were slightly higher in the healthy group but again the differences were
not statistically significant. These results suggest that different allergens produced
by Dermatophagoidesfarinae can induce different subclass responses. However, as
these responses are seen in both healthy and atopic dogs, they are likely to merely
represent recognition of foreign proteins that are presented to the immune system,
rather than being involved in the pathogenesis of atopic dermatitis.
3. Hou C, Nuttall TJ, Day MJ, and Hill PB. (2005) Dermatophagoides farinae-
specific IgG subclass responses in atopic dogs undergoing allergen-specific
immunotherapy. In: Hillier A, Foster AP, and Kwochka KW eds. Advances in
Veterinary Dermatology, Vol 5. Oxford: Blackwell Publishing. 70-81.
The molecular and immunologic mechanisms involved with successful allergen-
specific immunotherapy (ASIT) have not been completely elucidated. The aim of
this study was to characterize the changes in Dermatophagoides^/hrwae-specific
total IgG and IgG subclasses during ASIT of dogs with atopic dermatitis. Twenty-
one dogs with D. farinae hypersensitivity were treated with alum-precipitated
vaccines for 9 months. Serum samples were collected before and after 3, 6, and 9
months of therapy and used to probe western blots containing separated proteins ofD.
farinae. IgG responses were detected using a polyclonal antibody and a
colourimetric substrate whereas IgG subclasses were detected using a panel of
monoclonal anti-IgG antibodies and chemiluminescence. The blots were analysed
using a semi-quantitative digital image analysis system that provided the number and
molecular weight of bands, as well as their intensity, which was related to IgG
concentration. Prior to ASIT, all dogs showed an IgG, IgGl and IgG4 response to
multiple proteins of different molecular weights, the most common being 98Kd and
44Kd. There was virtually no detectable IgG2 or IgG3 response. During ASIT, the
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total IgG, IgGl and IgG4 response to D.farinae antigens varied widely between
dogs and could increase, decrease, fluctuate, or remain the same, but there was no
induction of IgG2 or IgG3 antibodies. There were no significant increases in total
IgG or IgG subclass responses in dogs showing a complete or partial response to
ASIT. However, dogs showing no response to ASIT had significantly higher D.
farinae-specific total IgG levels prior to the start of therapy, compared to dogs that
responded to ASIT.
4. Hou C, Griffin CE, and Hill PB. (2007) Changes of Dermatophagoides farinae-
specific immunoglobulin G in atopic dogs undergoing allergen-specific
immunotherapy using aqueous vaccines. Submitted to Veterinary Dermatology.
The molecular and immunologic mechanisms involved with successful allergen-
specific immunotherapy (ASIT) have not been completely elucidated. The aim of
this study was to characterize the changes in Dermatophagoides farinae (D. farinae)-
specific total IgG in atopic dogs undergoing ASIT using aqueous vaccines. Fifteen
dogs with D. farinae hypersensitivity were treated with aqueous vaccines for a
minimal of 2 months. Serum samples were collected before and after therapy and
used to probe western blots containing separated proteins of D.farinae. IgG
responses were detected using a polyclonal goat anti-canine IgG antibody and a
chromogenic substrate 3,3'-diaminobenzidine (DAB). The blots were analysed using
a semi-quantitative digital image analysis system that provided the number and
molecular weight of bands, as well as their intensity, which was related to IgG
concentration. Prior to and during ASIT, all dogs showed an allergen-specific IgG
responses to various antigens of the house dust mite D.farinae. During ASIT with
aqueous vaccines, there was a significant augmentation in the quantity of D. farinae-
specific IgG antibodies to various antigens from the mite (£>=0.015). The significant
increase in the IgG response to the 98-kDa band (£>=0.015), the 50-70 kDa bands
(/?=0.012) and the 30-45 kDa bands (£>=0.035). This finding provides some support
for the hypothesis that ASIT induces blocking antibodies because of possible
competition of IgG with IgE for antigen binding sites on effector cells.
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Abstract
In this study, we used a semi-quantitative electrophoresis and immunoblotting technique to characterise the IgG response to
antigens from Dermatophagoides farinae in 20 healthy and 20 atopic dogs. Both groups mounted an IgG response to multiple
antigens from the mite. There was no significant difference in the number of bands recognised, or the molecular weights of the
bands, between the two groups. The two most obvious bands in both groups were proteins with molecular weights of 98 kDa
(likely to be the high molecular weight allergen Der f 15) and 14 lcDa, although dogs in both groups recognised a similar pattern
of other antigens. The magnitude of the IgG response was greater in the atopic group although this was not statistically
significant. The results indicate that the immune system of both healthy and atopic dogs generates an IgG response to multiple
antigens from D. farinae. As some of these antigens (such as the 98 and 44 kDa proteins) are also targeted by IgE in atopic dogs,
immunoglobulin class switching in response to Th2 cytokines may not be as dominant a process as has been proposed.
© 2005 Elsevier B.V. All rights reserved.
Keywords: Atopic dermatitis; Dermatophagoides farinae\ IgG; Dogs
1. Introduction
Atopic dermatitis (AD) is one of the most common
pruritic skin diseases in the canine population and is
characterised by an imbalance in the response of the
immune system upon allergen-recognition (Hill and
DeBoer, 2001; Hill and Olivry, 2001). Since Wittch
* Corresponding author. Tel.: +44 131 650 7650;
fax: +44 131 650 7652.
E-mail address: pbhill@ed.ac.uk (P.B. Hill).
(1941) first described a dog suffering from AD, much
research has been performed to elucidate the patho¬
genesis of the disease, yet the exact mechanisms are
still unknown. One key aspect of the pathogenesis is
the production of allergen-specific IgE in response to
innocuous environmental allergens (Halliwell and
DeBoer, 2001). This is thought to result from initial
polarisation of the Th2 cytokine profile leading to
increased production of interleukin 4 and immuno¬
globulin class switching (Olivry et al., 1999; Nuttall
et al., 2002). Recent studies have shown that a high
0165-2427/$ - see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.vetimm.2005.01.011
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molecular weight chitinase derived from the house
dust mite Dermatophagoides farinae (D. farinae),
termed Der f 15, is the most important allergen in
dogs, whereas the low molecular weight group I
proteases appear to be less involved (Noli et al., 1996;
McCall et al., 2001; Nuttall et al., 2001).
The role of IgG in canine atopic dermatitis is less
well understood. Hill et al. (1995) showed that total
IgG concentrations were significantly higher in atopic
dogs compared to healthy controls. Willemse et al.
(1985) also demonstrated that IgGd was capable of
inducing an anaphylactic reaction and suggested that
IgGd might be important in the pathogenesis of canine
atopic dermatitis. However, Lian and Halliwell (1998)
showed that significantly higher levels of Dermato¬
phagoides pteronyssinus-specific IgGd were present
in normal dogs compared to atopic dogs, which argues
for a protective role for IgGd. In contrast, Fraser et al.
(2004) have recently shown that concentrations of
total IgGl are higher in atopic dogs than in healthy
dogs, suggesting that the atopic state also leads to
activation of IgG subclass production in addition to
IgE. A role for IgG has also been proposed in the
mechanism of action of allergen-specific immuno¬
therapy (ASIT). Hites et al. (1989) detected IgG
antibodies with specificity for various allergens in the
majority of non-atopic individuals and in all atopic
subjects, but concentrations were highest in atopic
dogs receiving allergen-specific immunotherapy.
Furthermore, Fraser et al. (2004) have shown that
concentrations of total IgGl can increase following
allergen-specific immunotherapy.
To date, compared to IgE, there is limited informa¬
tion on the specific IgG response to D. farinae antigens
in atopic dogs. The aim of this study, therefore, was to
develop and validate a semi-quantitative blot analysis
system and use it to characterise and quantify the
IgG response using sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting.
2. Materials and methods
2.1. Serum samples
Client-owned dogs suffering from atopic dermatitis
(n = 20) were recruited from the Dermatology Clinic
at the University of Edinburgh Hospital for Small
Animals. The diagnosis of atopic dermatitis was based
on a combination of a compatible history and clinical
signs (Willemse, 1986), exclusion of other pruritic
skin diseases (e.g., ectoparasite infestation and
adverse food reaction), and the presence of at least
one positive reaction either in an intradermal test or a
commercially available allergen-specific IgE assay
(Heska Corporation, CO, US). Coat brushings, skin
scrapings and trial therapy were used to rule out
ectoparasites. A 6-week home-cooked diet trial was
conducted to eliminate the possibility of adverse food
reactions. Seborrhoea, staphylococcal pyoderma and
Malassezia infections that occurred secondarily to
atopic dermatitis were managed appropriately. No
anti-inflammatory medication was given for at least 3
weeks prior to intradermal skin testing. All serum
samples were collected prior to the initiation of
allergen-specific immunotherapy.
Control samples were taken from healthy dogs
(n = 20), either belonging to clients or staff members,
or dogs presented from a local rescue centre. None of
the healthy dogs had a history or clinical signs of
pruritic skin disease or systemic conditions likely to
affect immune function. All procedures were per¬
formed with UK Home Office approval.
2.2. D. farinae extracts
A freeze-dried crude extract from D. farinae (Greer
Laboratories, Lenoir, USA) was reconstituted in
sterile phosphate-buffered saline (PBS) (pH 7.4) to
a final concentration of 1 mg/ml and 200 p.1 aliquots
were stored at —70 °C.
2.3. SDS-PAGE and protein transfer
SDS-PAGE was performed according to Laemmli's
method (Laemmli, 1970) using a 10% Tris-glycine
polyacrylamide resolving gel and a 4% stacking gel in
a discontinuous buffer system containing 25 mM Tris-
HC1, 0.2 M glycine and 0.1% SDS, pH 8.3. D. farinae
extract (50 p,g) and molecular weight standards were
diluted 1:1 and 1:20, respectively, with reducing
sample buffer (125 mM Tris-HCl, 4% SDS, 20%
glycerol, 0.005% bromophenol blue and 10% 2-
mercaptoethanol) and heated at 95 °C for 5 min. The
extract was then loaded into a single broad well with
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the molecular weight marker alongside and the
electrophoresis was run at 200 V for 40 min.
Separated proteins were transferred to polyvinylidene
fluoride (PVDF) membranes (Millipore Immobi-
lon™-P Transfer Membrane, Millipore Corporation,
Bedford, MA, USA) in a Bio-Rad Trans-Blot® SD
Semi-Dry Electrophoretic Transfer Cell using 0.3 M
Tris-HCl/10% methanol (pH 10.4) on the lower
anode, 25 mM Tris-HCl/10% methanol (pH 10.4) on
the upper anode and 25 mM Tris-HCl/40 mM 6-
amino-n-hexonic acid/10% methanol (pH 9.4) on the
cathode according to the manufacturers instructions.
The transfer was run at 80 mA per minigel for 1 h.
Membranes were then dried and stored at 4 °C.
2.4. Immunoblotting
The molecular weight markers (Bio-Rad Labora¬
tories Ltd., Hertfordshire, UK) and a strip to identify
protein bands were removed from the edge of the
membrane and stained with 0.25% Coomassie
Brilliant Blue R-250 (BDH, Dorset, UK). The
remainder of the membrane was then cut long¬
itudinally into 4-mm strips and placed into individual
lanes of an incubation tray, blocked with 5% skimmed
milk/Tris-buffered saline (TBS)/0.1% Tween-20
(TTBS) for 1 h at room temperature and washed with
washing buffer (TTBS) three times for 5 min.
Preliminary experiments were performed to determine
the optimal dilution of sera and the primary antibody
to yield strong bands against a clear background (data
not shown). Serum samples were diluted to 1:100 in
dilution buffer (1% skimmed milk/TTBS) and 1 ml
was added to each lane and incubated for 1 h at room
temperature. After washing as described above, the
strips were incubated with 1 ml of 1:1000 horseradish
peroxidase-conjugated goat anti-dog IgG (Bethyl
Laboratories Inc., Montgomery, TX, USA) diluted
in dilution buffer for another hour at room tempera¬
ture, and washed thoroughly with washing buffer. One
millilitre of 3,3'-diaminobenzidine (DAB; Vector
Laboratories Inc., Burlingame, CA, USA), prepared
according to the manufacturers recommendations,
was finally added to each strip for 1 min and then
removed by washing in distilled water. The strips were
air-dried overnight prior to analysis.
The specificity of the binding of the anti-canine IgG
to dog IgG and not D. farinae proteins was confirmed
by performing experiments in which serum samples
were omitted. No bands were visible in these
experiments (data not shown). The specificity of the
anti-canine IgG is verified by the manufacturer, but
any potential cross-reactivity of the reagent with
canine IgE would not be relevant in these experiments
because serum concentrations of allergen-specific IgE
are so low that they cannot be detected using
colorimetric blots, even when employing specific
anti-canine IgE reagents (Chen et al., 2002b).
2.5. Digital image analysis
The strips, along with the molecular weight
standard, were aligned and digitally scanned using a
flatbed scanner (Epson 1650, Hemel, Hempstead, UK)
set at 8-bit grey scale. The bands were analysed by
importing the scanned images into an image analysis
software (Kodak Digital Science™ ID Image
Analysis Software, Kodak, Rochester, NY, USA).
Band sensitivity was set at 0 and the net intensity of
individual bands was calculated automatically in
pixels. This system allowed measurement of both band
molecular weight and density without operator bias.
Bands with molecular weights >200 or < 10 kDa were
not analysed because they were outwith the molecular
weight marker range. Numerical data was exported to
MINITAB™ statistical software (Minitab Inc., PA,
USA) for analysis.
2.6. Validation of semi-quantitative analysis system
In order to validate the immunoblotting and image
analysis system for semi-quantitative measurements,
experiments were performed to determine linearity,
sensitivity, saturation effects and repeatability. To
confirm that changes in serum concentration resulted
in a linear standard curve, blots containing separated
D. farinae proteins were probed with 3-fold serial
dilutions of a standard serum sample from 1:10 to
1:106. The standard serum sample was chosen because
it gave a positive response to a number of protein
bands in preliminary experiments. Fig. 1 shows
representative curves for a high molecular weight
band (98 kDa) and a lower molecular weight band
(44 kDa). The intensity of each band changed in a
linear fashion between log serum dilutions of 1:10
and 1:1000, which represented the lower limit of
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Serum dilution (ul/ml)
Fig. 1. Effect of serum dilution on net intensity of bands. Serum was
diluted 3-fold between 1:10 and 1:106 and used to probe blots
containing separated D. farinae proteins. (A) Curve for a 98 kDa
band; (B) curve for a 44 kDa band. Linearity was obtained over the
whole molecular weight range with serum dilutions ranging between
1:10 and 1:1000, the lower limit of sensitivity.
sensitivity. Hence, by using serum dilutions of 1:100,
the system could be used to reliably semiquantify IgG
concentrations over a range that was 10 x higher or
lOx lower than those normally found in serum.
To ensure that band intensity was not affected by
colorimetric saturation, identical strips containing
separated D. farinae proteins probed with canine sera
were incubated with the DAB substrate for different
periods of time ranging between 10 s and 20 min.
Linear development of colour intensity occurred
between 10 s and 5 min, after which a plateau was
reached (data not shown). Hence, routine development
of the blots for 1 min did not affect the semi¬
quantitative assessment of IgG responses.
To determine the repeatability of the system, 15
identical strips, all probed with the same serum sample
at a dilution of 1:100, were assayed as described
above. The coefficients of variation of net intensity for
bands over the whole molecular weight range was
typically around 10%, with a maximum of 15%. These
were considered satisfactory for semi-quantitative
analysis.
2.7. Statistical analysis
The Mann-Whitney test was used to compare
healthy and atopic dogs for the number of bands
recognised, the molecular weight range of the bands
observed, the total intensity of the bands in each group
and the intensity of the most important individual
bands. A p-value of <0.05 was considered to be
significant.
3. Results
A representative set of IgG immunoblots of
individual dog sera from the two groups is shown
in Fig. 2. Both healthy and atopic dogs mounted an
IgG response to multiple antigens from D. farinae.
The two most visually obvious bands in both groups
were seen at molecular weights of approximately 98
and 44 kDa (Fig. 2). The number of bands recognised
did not differ significantly between the two groups
(p = 0.6652; Fig. 3) and varied between 3 and 12 in
the healthy group and 2 and 10 in the atopic group,
with median band numbers of 6.5 and 6, respectively.
The percentage of dogs recognising antigens of
various molecular weights is shown in Fig. 4. In both
the healthy and atopic groups, two peaks of frequency
were seen. The first occurred at around 100 kDa and
predominantly comprised responses to the 98 kDa
antigen. The second occurred between 30 and 60 kDa,
a major proportion of which represented responses to
the 44 kDa antigen. However, IgG responses were
seen to multiple other bands ranging in molecular
weights from 20 to 180 kDa (Figs. 2 and 4).
The intensity of each band, and therefore, the
magnitude of the IgG response to that particular
protein(s), was provided by the digital analysis
software. The intensity of response in each dog to
proteins of various molecular weights is shown in
Fig. 5. The most intense bands were seen at molecular
weights clustered around 100 and 44 kDa. Hence, not
only were these proteins the most commonly
recognised (as seen in Fig. 4), they also resulted in
the greatest IgG response. The average of the total
band intensity in each strip (i.e., for each dog) was
8335 in the healthy group and 9997 in the atopic
group; this difference approached statistical signifi¬
cance (p = 0.0697). The total response to the 98 kDa
protein was similar in the atopic group (net intensity
18411) and healthy groups (net intensity 16953) and
was not significantly different {p = 0.4094). However,
the total response to the 44 kDa antigen in the atopic
group (net intensity 11088) was almost double that
seen in the healthy group (net intensity 6410). Based
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Fig. 3. Number of D. farinae bands recognised by canine IgG in
healthy and atopic dogs. Each box and whisker plot summarises the
response of 20 dogs. The box represents the 25th and 75th quartiles
with the horizontal bar indicating the median. The whiskers indicate
the range.
on the standard curve for this protein, this actually
represented a 6-fold increase in serum concentration,
but the difference between groups was again not
statistically significant (p - 0.2689).
4. Discussion
In this study, we compared the D. farinae-specific
IgG responses in healthy dogs and dogs with atopic
dermatitis. The profile of IgG binding was similar in
the two groups, both in terms of the number of bands
recognised and their molecular weights. The percen¬
tage of individual dogs recognising these proteins was
also similar in the two groups. These results indicate
that D. farinae produces a number of proteins that are
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Fig. 4. Proportion of healthy (A) and atopic (B) dogs recognising D.
farinae allergens. Antigens are grouped in lOkDa intervals and
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Fig. 5. Plot of band molecular weight against band net intensity in
healthy (A) and atopic (B) dogs. Each dot represents an IgG
response to a D. farinae protein in an individual dog. Note the
two peaks of intensity around 100 and 44 kDa.
recognised by the canine immune system, both in
healthy and atopic dogs.
The strength of the IgG response appeared to be
greater overall, and for the 44 kDa band, in the atopic
dogs than in the healthy controls. The lack of
significant differences between the groups might
imply that this difference was biologically irrelevant
but this must be interpreted with caution. A larger
number of dogs in each group would have increased
the statistical power, which might have yielded a
significant difference.
These results are in accordance with previous
findings that demonstrated the presence of antigen-
specific IgG antibodies in both healthy and atopic dogs
using ELISAs (Willemse et al., 1985; Hites et al.,
1989; Day et al., 1996; Lian and Halliwell. 1998).
Furthermore, the increased antigen-specific IgG
response in the atopic group would be consistent
with previous reports that showed higher concentra¬
tions of total IgG (Hill et al., 1995) and total IgGl
(Fraser et al., 2004) in atopic dogs. However, it must
be born in mind that these two previous studies
measured total, and not antigen-specific, antibody
concentrations. The total IgG responses seen in these
studies could be directed at antigens other than D.
farinae such as additional environmental allergens or
proteins produced by Malassezia or staphylococcal
organisms. Secondary infection with these pathogens
is common in dogs with atopic dermatitis and previous
studies have shown significantly greater IgG responses
in atopic dogs to both Malassezia antigens (Nuttall
and Halliwell, 2001; Chen et al., 2002a) and
staphylococcal proteins (Halliwell, 1987; Morales
et al., 1994; Shearer and Day, 1997).
The most important D. farinae antigens recognised,
both in terms of frequency and magnitude, were 98
and 44 kDa proteins. We, and others, have shown
previously that bands with the same molecular weights
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are recognised in IgE blots (Noli et al., 1996; McCall
et al., 2001; Nuttall et al., 2001), although the 44 kDa
protein is only seen when reducing buffers are used
(Nuttall et al., 2001), suggesting that it might be a part
of a bigger antigen. It is likely that the 98 kDa protein
is the same as the high molecular weight chitinase that
has recently been designated Der f 15 (McCall et al.,
2001). This protein is the most important allergen in
atopic dogs that is recognised by IgE. However, the
substantial IgG response to this protein indicates
that distinct immune responses dominated by either
isotype do not occur. Hence, although IgE responses
are a critical component in the pathogenesis of canine
atopic dermatitis, the concept of Th2 cytokine
controlled class switching is clearly not an absolute
phenomenon.
Taken together, the results of this and previous
studies suggest that dogs mount an IgG response to
multiple environmental antigens, including house dust
mites. This response is similar in healthy and atopic
dogs, but is possibly greater in magnitude in atopic
dogs. Hence, the presence of D.farinae antigens in the
environment does not appear to be ignored by the
canine immune system in healthy dogs and yet the IgG
response does not appear to be protective against the
development of clinical atopic disease. Whether the
IgG response plays any role in the pathogenesis of the
disease remains to be determined.
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A semiquantitative chemiluminescent Western
blot analysis system was developed and validated
to evaluate antigen-specific IgG subclass responses
to electrophoretically separated proteins of Dermat¬
ophagoides farinae in healthy and atopic dogs.
Both groups mounted similar D. far/'nae-specific
lgG1 and lgG4 responses to multiple antigens, but lgG2
and lgG3 responses were difficult to detect. The most
commonly recognized bands in both groups were 18
and 98 kDa antigens for IgGI and 18,45,66,98,130 and
180 kDa for lgG4. The number of bands recognized per
dog did not differ significantly, but significantly more
atopic dogs had an lgG1 response to a 180 kDa protein.
The overall D. farinae-specific IgGI and lgG4 responses
were slightly higher, but not significantly different, in
the healthy group. The results suggest that some
antigens produced by D. farinae can induce different
subclass responses. However, asmost of these responses
are seen in both healthy and atopic dogs, they are
likely to merely represent recognition of foreign pro¬
teins presented to the immune system, rather than
involvement in the pathogenesis of atopic dermatitis.
The role of the 180 kDa antigen warrants further study.
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Introduction
Atopic dermatitis (AD) is a genetically predisposed inflam¬
matory and pruritic allergic skin disease with characteristic
clinical features.1 Affected individuals mount an aberrant
immune response against innocuous environmental aller¬
gens, most commonly to house dust mite antigens from
Dermatophagoides farinae and Dermatophagoides ptero-
nyssinus2'8 Much research has been performed to elucidate
the mechanisms underlying AD in dogs, especially in relation
to the role of IgE which plays an important role in the devel¬
opment of immediate hypersensitivity. It has been shown
that serum allergen-specific IgE antibodies are usually
elevated both in humans9-10 and in dogs11-12 with atopic
diseases. However, the role of IgG remains controversial and
paradoxical. In humans, IgG concentrations are elevated in
various allergic conditions.13"15 Both total serum IgG16 or
allergen-specific IgG can be raised in dogs suffering from AD,
although dogs with no apparent clinical sensitivity to a particular
allergen can also have elevated allergen-specific IgG.17"19
IgG is not a homogenous molecule. In humans, there
are four IgG subclasses, distinguished by differences in
y-chain sequence and electrophoretic mobility. They are
numbered according to their decreasing mean serum
concentrations as IgGI, lgG2, lgG3 and lgG4. In dogs, four
IgG subclasses have also been identified20 and similarly
named: IgGI (mean serum concentration 8.17 mg mL"1),
lgG2 (8.15 mg mL"1), lgG4 (0.95 mg mL"1) and lgG3
(0.36 mg mL"1). Non-lgE anaphylactic antibodies have
been identified as lgG4 in man21 and guinea pigs,22 IgGI
in mice,23 lgG2a in rats24 and lgG2 in sheep.25 Studies by
Day17 suggested that IgGI and lgG4 were involved in
canine AD, depending on the allergen. Using a panel of
monoclonal antibodies (mAbs) directed against the four
subclasses of canine IgG,20-26 it was shown that the IgG
response to D. farinae was dominated by the lgG4 sub¬
class.17 However, the specific proteins involved could not
be identified in the ELISAs used.
The situation in dogs is further complicated by the
description of IgGd,27 a subclass that does not correspond
with the 1-4 nomenclature.17 Willemse ef a/.19-27 demon¬
strated the presence of non-lgE anaphylactic antibodies,
termed IgGd, in the sera of atopic dogs and suggested
that this subclass could initiate immediate hypersensitiv¬
ity. However, its role in atopic diseases is uncertain; IgGd
directed against apparently irrelevant allergens is present
in atopic dogs, and there are high levels of IgGd in normal
dogs to the common allergens D. pteronyssinus and
D. farinae.u It is possible that IgGd corresponds to IgGI
(R. Halliwell, personal communication), but this has not
been proved. In contrast, antiserum specific for IgGd
failed to identify any of the four canine IgG subclasses in
purified form in ELISAs.17 This may reflect the fact that
IgGd is a myeloma protein, and the antiserum may not
necessarily recognize native protein.
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Nothing is known about the individual allergenic proteins
targeted by IgG subclasses in dogs with AD because
these have not been evaluated by ELISAs and the crude
allergen extracts used previously. Therefore, the aim of
this study was to develop and validate a semiquantitative,
digital, chemiluminescent Western blot analysis system
to evaluate the allergen-specific IgG subclass response
to electrophoretically separated allergens of D. farinae in
dogs with atopic dermatitis.
Materials and methods
Dogs and serum samples
Dogs suffering from AD (n = 23) were recruited from the dermatology
clinic at the Royal (Dick) School of Veterinary Studies, Edinburgh. The
diagnosis of AD was based on a combination of compatible history
and clinical signs,28 exclusion of other pruritic skin diseases (e.g.
ectoparasite infestation and adverse food reaction), and the presence
of at least one positive reaction (including D. farinae) in either an intra¬
dermal test or a commercially available allergen-specific IgE assay
(Allercept®, Heska Corporation, Fort Collins, CO, US). Coat brushings,
skin scrapings and trial therapy were used to rule out ectoparasites
and a 6-week home-cooked diet trial was conducted to eliminate the
possibility of adverse food reactions. Concurrent seborrhoea, staphy¬
lococcal pyoderma and Malassezia infections were managed appro¬
priately with systemic and topical medications. No glucocorticoids or
antihistamines were given for at least 3 weeks prior to intradermal
testing. All serum samples were collected prior to the initiation of
allergen-specific immunotherapy.
Control samples were taken from healthy dogs (n = 20) pre¬
sented for euthanasia from a local rescue centre with no history or
clinical signs of skin disease or conditions likely to alter immune
function.
Blood samples were collected from atopic dogs (n = 23) by jugular
venepuncture and from healthy dogs by cardiac puncture immediately
after euthanasia. Serum was separated by centrifugation and stored
at -20 °C.
Dermatophagoides farinae extract
Lyophilized whole-body D. farinae crude extract (Greer Laborato¬
ries, Lenoir, NC, USA) was reconstituted to 1 mg mL"1 in sterile
phosphate-buffered saline (PBS, pH 7.5) and 200 pL aliquots were
stored at -20 °C.
Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE)
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) was performed according to the method of Laemmli29 using a
10% Tris-glycine polyacrylamide (ProtoGel®, National Diagnostics,
UK) separating gel and 4% stacking gel in a discontinuous buffer
system containing 25 mmol L~1 Tris-HCI (Trizma® hydrochloride; Sigma-
Aldrich, Dorset, UK), 200 mmol L"1 glycine (Fisher Scientific, Lough¬
borough, UK) and 0.1% SDS (Fisher Scientific, UK), pH 8.3. 100 pL
of D. farinae extract and molecular weight markers were diluted 1 : 1
and 1 : 20, respectively, with reducing sample buffer containing125
mmol L"1 Tris-HCI, 4% SDS, 20% glycerol (BDH Chemicals, Poole, UK),
0.005% bromophenol blue (BDH, UK) and 10% 2-mercaptoethanol
(Sigma-Aldrich, UK) and then heated at 95 °C in a water bath for 5 min.
The extract was then loaded into one broad well across the top of the
gel and the electrophoresis run at 200 V for 40 min (Mini-Protean II®,
Biorad, Hercules, USA).
Western blots
Separated D. farinae proteins were transferred to polyvinylidene
fluoride (PVDF) microporous membranes (Millipore lmmobilon™-P
Transfer Membrane, Millipore Corp.. Bedford, MA, USA) in a semidry
electrophoretic transfer cell (Trans-Blot® SD, Bio-Rad, Atlanta, GA,
USA) using 300 mmol L"1 Tris-HCI/10% methanol (pH 10.4) on the
lower anode. 25 mmol L"1 Tris-HCI/10% methanol (pH 10.4) on the
upper anode and 25 mmol L"' Tris-HCI/40 mmol L"1 6-amino-n-
hexonic acid/10% methanol (pH 9.4) on the cathode. The transfer was
run at 80 mA per minigel for 1 h. Membranes were dried and stored
at 4 °C. Transfer quality was checked by staining gels and molecular
weight standards blotted onto the membrane with 0.25% Coomassie
Brilliant Blue R-250 (BDH Chemicals, UK).
Monoclonal antibodies
A panel of four mouse monoclonal antibodies specific for the sub¬
classes of canine IgG were used:20'26-30,3' mAb B6 with restricted
specificity for canine IgG 1 and lgG3, but specifically reactive with IgG 1
in serological and immunohistochemical assays; mAb E5 specific
for canine lgG2; mAb A3G4 specific for canine lgG3; mAb A5 with
restricted specificity for canine lgG2 and lgG4 but reactive specifically
with lgG4 in serological and immunohistochemical assays. The spe¬
cific activity of the subclass-restricted mAbs B6 and A5 is probably
due to conformational differences between the target IgG subclasses
in solid-phase assay vs. other serological and immunohistochemical
techniques.30-31 The mAbs A5, E5 and B6 were used as 45% ammo¬
nium sulphate precipitates of tissue culture supernatants, and A3G4
was used as undiluted tissue culture supernatant as it was in lower
supply.
Assessment of the mAbs used in immunoblotting
To determine if the monoclonal antibodies against IgG subclasses
would work in immunoblotting, a commercial preparation of canino
IgG purified by ion-exchange chromatography (Sigma-Aldrich, Dorset,
UK) was used. One hundred micrograms purified canine IgG diluted
in both reducing buffer and nonreducing buffer was separated by
SDS-PAGE, transferred to a PVDF membrane and cut into strips. After
blocking and thorough washing, each mAb was added to individual
strips at a dilution of 1/200 in buffer and inoubatod overnight at room
temperature (RT). After further washing, bovine antimouse IgG
conjugated with horseradish peroxidase (Bethyl Laboratories, Mont¬
gomery, TX, USA) at 1/1000 dilution was added to each strip before
incubation at RT for 2 h. The luminol substrate ECL (ECL, Amersham-
Pharmacia Biotech, Little Chalfont, UK) was used to develop the
chemiluminescent signals, and the bands were visualized using an
image acquisition system as described below. Preliminary experi¬
ments showed that strong signals could be obtained for IgG 1 and
lgG4, but not for lgG2 or lgG3. lgG2 and lgG3 responses could only
be detected after prolonged exposures (2 h) to increase the sensitivity
(compared to 32 min for IgG 1 and 10.6 min for lgG4).
Immunoblotting of serum samples against
Dermatophagoides farinae proteins
Blotting membranes with transferred separated D. farinae proteins
were cut longitudinally into 4-mm wide strips to allow probing with
serum samples from different dogs. Strips were inserted into individ¬
ual lanes of an eight-channel incubation tray (Bio-Rad, UK), blocked
with 5% skimmed milk (Marvel, Sainsbury, UK) in Tris-buffered saline
(TBS, pH 7.5) containing 0.02 mol L"1 Tris-HCI and 0.5 mol L_1 NaCI
(Sigma-Aldrich, UK) for 1 h at RT, and washed with 0.1 % Tween 20
(Fisher Scientific, UK)/TBS (TBS/T) three times for 5 min. For effective
immunoblotting, it was important that each mAb was used at a dilu¬
tion that gave a high signaknoise ratio. After a series of titrations, the
optimum dilutions were found to be 1/20 for serum samples, 1/200
for the mABs, and 1/1000 for bovine antimouse IgG. All reagents
were diluted in dilution buffer (1 % skimmed milk/TBS/T).
After blocking, strips were probed with individual dog sera (1/20
dilution) for 1 h at RT, followed by a 1 -h incubation with one of the four
mAbs (1/200) with specificity for each canine IgG subclass. Horseradish
peroxidase-conjugated bovine antimouse IgG (Bethyl Laboratories,
USA) at 1/1000 was added for another hour. Incubation steps were
accompanied by gentle agitation, with frequent changes of washing
buffer between each step. The protein surface of each strip was then
covered with the luminol solution (ECL, Amersham-Pharmacia Biotech,
Little Chalfont, UK) for 1 min and visualized on an image station as
described below.
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Digital image acquisition and analysis
The chemiluminescent substrate ECL was used for blot visualization
because of its higher sensitivity than colourimetric substrates. Higher
sensitivity was required because the concentrations of IgG sub¬
classes are obviously lower than total IgG,30 and the concentrations
of allergen-specific IgG subclasses lower still. After draining off
excess liquid, the strips were wrapped in cling film and placed protein
side down on a Kodak Digital Science™ Image Station 440CF (Kodak,
Rochester, NY, USA) along with Coomassie blue-stained molecular
weight standards Images were obtained with a charge coupled
device (CCD) camera using multiple exposures to eliminate the pos¬
sibility of image saturation (see below). Kodak Digital Science™ 1D
Image Analysis software was used to detect the bands on the blots
and to determine the signal magnitude of individual bands and their
molecular weights by analysing their positions relative to the molecu¬
lar weight standards. This system allowed measurements of both
band molecular weight and density without operator bias. Data were
then exported to minitab™ statistical software (Minitab Inc., PA, USA)
for analysis.
Validation of the semiquantitative, chemiluminescent
analysis system
To validate the chemiluminescent immunoblotting and image analysis
system for semiquantitative measurements, experiments were car¬
ried out to determine linearity, sensitivity, saturation effects and
repeatability. To confirm that changes in serum concentration resulted
in a linear standard curvo, blots containing soparotod D. farinao pro
teins were probed with threefold serial dilutions of a reference serum
sample (from a healthy dog which gave a positive signal in preliminary
experiments) from 1 : 10 to 1 : 105 in duplicate. To ensure that band
intensity was not affected by saturation, strips containing separated
D. farinae proteins probed with canine sera and antibodies were
imaged using different exposure and capture times. To determine
system repeatability, 1G identical strips ull piobcd with the SuiViC
serum sample were assayed as described above and imaged
simultaneously.
Statistical analysis
The Mann-Whitney test was used to compare healthy and atopic
dogs for the number of bands recognized, the total intensity of the
bands in each group and the intensity of the most important individual
bands. The frequency with which a particular band was recognized
within the twu giuups was compared by Fisher's exact test. A f-value
of < 0.05 was considered to be significant.
Results
Validation of the semiquantitative, chemiluminescent
analysis system
Using the standard dilutions, incubation times and exposure
times, no signals were seen with lgG2 or lgG3. As in the
preliminary experiments using whole IgG, D. farinae-
cpocific lgG2 and lgG3 could only bo dotoctod when assay
sensitivity was increased dramatically by using low dilu
tions of sorum and mAbs, and prolongod incubation and
exposure times. Even then, the bands were very weak. As
the lgG2 and lgG3 responses were so low, it was not
possible to generate standard curves for semiquantitative
analysis. For IgG 1 and lgG4, linear standard curves were
obtained using serial serum dilutions. Figure 1 shows
curves generated using a reference serum sample from
a healthy dog. In Fig. 1A, linear standard curves can be
seen for two proteins recognized by IgG 1 with molecular
weights of 98 and 18 Kd. In Fig. 1B, linear standard curves
can be seen for the lgG4 response. The linearity of each
curve extended over a range of serum dilutions from 1:10
to 1 : 1000, which represented the lower limit of detec¬
tion. By using serum dilutions of 1 : 20, the system could
therefore be used to reliably ocmiquantify IgC 1 and IgG 1
concentrations over a range that was 5x higher or 20x
lower than those normally found in serum. The imaging
system also allowed detection of bands that appeared
poorly resolved to the naked eye.
With the image acquisition of the chemiluminescent
signals, longer exposure timos were found to incroaso tho
sensitivity but also the likelihood of image saturation. To
overcome this problem, short exposure times were used
but repeatedly. This increased the sensitivity while keep¬
ing background noise to a minimum. The optimal expo¬
sure settings were 32 x 1 min exposures for IgG 1 blots
and 32 x 20 s exposures for lgG4 blots.
The coefficients of variation for repeated measurement
of bandc ovor tho wholo molecular woight rango was
typically around 10%, with a maximum of 15% and a
© 2006 The Authors. Journal compilation © 2006 European Society of Veterinary Dermatology.
0.001 0.010 0.100




Figure 1. Effect of serum dilution on band >,
intensity. A reference serum sample from a '<2
healthy dog was used and the intensity of -2
each band was measured using image
analysis software. (A) Standard curves
generated for IgG 1 against two commonly
detected proteins with molecular weights
of 98 and 18 kDa. (B) Standard curves
generated for lgG4 against two commonly
detected proteins with molecular weights of
98 and 45 kDa. Linearity was obtained with
serum dilutions ranging between 1:10 and
1 : 1000.
0.001 0.010 0.100
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Figure 2. Binding of canine IgG 1 to separated proteins of D. farinae
in 20 healthy dogs (A) and 23 atopic dogs (B). Each strip represents
one dog. The most common bands observed in both groups had
molecular weights of approximately 18 and 98 kDa. A band at
approximately 180 kDa was more prevalent in the atopic group.
minimum of 3%. These were considered satisfactory for
semiquantitative analysis.
of approximately 18 and 98 kDa, but some lesswell resolved
higher molecular weight proteins were also seen. The inten¬
sity and molecular weight data from these blots, derived
from the image analysis software, is shown in Fig. 3. The
intensity of each band represents the magnitude of the IgGI
response to that particular protein. The most commonly
recognized allergen was the 98 kDa protein, followed by
the low molecular weight 18 kDa antigen. In addition, a
protein with an approximate molecular weight of 180 kDa
was also seen in both groups, but was significantly more
prevalent in the atopic group (P = 0.005). The total number
of bands recognized per dog did not differ significantly
between the two groups (P= 0.99) and varied between
one and eight in the healthy group and two and six in the
atopic group, with median band numbers of 3.5 and 3,
respectively. The sum of all the band intensities in each group
(i.e. the total IgG 1 response to all D. farinae allergens) was
85 616 in the healthy group and 65 094 in the atopic group,
but this difference was not significant (P = 0.6879). There
were no significant differences between the groups in band
intensities for the 18, 98 and 180 kDa proteins.
The lgG4 chemiluminescent blots of all dog sera from
the two groups are shown in Fig. 4, with the image analy¬
sis data graphed in Fig. 5. A larger number of bands were
seen compared to IgG 1, with proteins ranging in molecular
weights from 18 to 180 kDa. The number of bands recog¬
nized did not differ between the two groups (P = 0.5975)
and varied between one and nine in the healthy group and
one to 11 in the atopic group, with median band numbers
of six and four, respectively. The sum of all the band inten¬
sities in each group (i.e. the total lgG4 response to all D.
farinae allergens) was 106 700 in the healthy group and 87
813 in the atopic group (P= 0.3123). There were no sig¬
nificant differences in band intensity for individual proteins
between the two groups.
Dermatophagoides farinae-specific lgG1 and lgG4
subclass responses in atopic and healthy dogs
The IgG 1 chemiluminescent blots of all dog sera from the
two groups are shown in Fig, 2. In both healthy and atopic
dogs, two main bands were visible with molecular weights
Discussion
The semiquantitative Western blot analysis system devel¬
oped and validated for investigation of D. farinae-specific
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Figure 3. Plot of band molecular weight
against band intensity in healthy and atopic
dogs, as measured by the image analysis
software. Each dot represents an IgG 1
response to a D. farinae protein in an
individual dog. The most commonly
recognized proteins in both groups had
molecular weights of approximately 18 and
98 kDa. A protein with a molecular weight
of approximately 180 kDa was significantly
more prevalent in the atopic group.
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Figure 4. Binding of canine lgG4 to separated proteins of D. farinae
in 20 healthy dogs (A) and 23 atopic dogs (B). Each strip represents
one dog. Bands with molecular weights of 18, 45, 66, 98, 130 and
180 kDa were recognized; any above 200 kDa could not be evaluated
because they were outwith the range of the molecular weight
markers.
antibodies specific for the IgG subclasses could recognize
the appropriate antibodies in immunoblots using a whole
IgG preparation. The much stronger signals obtained for
IgG 1 and lgG4 than for lgG2 and lgG3 do not reflect the
serum levels of the four subtypes as reported by Mazza,30
where IgG 1 and lgG2 were shown to have at least nine¬
fold higher concentrations than lgG3 and lgG4. One expla¬
nation for this potential discrepancy is that the whole IgG
used in these validation experiments may have had con¬
centrations of subclasses within it that do not mirror
serum concentrations. Alternatively, the results may
indicate that the monoclonal antibodies used for lgG2 and
lgG3 were less able to bind to immunoblots compared
to the ELISAs used by Mazza,30 leading to lower signal
strengths. This would lower the sensitivity of the immu-
noblotting system to detect lgG2 and lgG3 responses.
Further studies using ELISAs to precisely quantify the
subclass concentrations in the whole IgG preparation are
required to clarify this issue.
When the monoclonal antibodies were used to detect
D. farinae-specific subclass responses, a similar, very low
sensitivity was obtained for lgG2 and lgG3. This could be
due to poor binding of the reagents in this type of system
as suggested above, or it could reflect the possibility that
lgG2 and lgG3 responses are minimal against environ¬
mental antigens such as those from D. farinae, as sug¬
gested by Day.17 Further evaluation of the reagents is
required to answer this question.
The generation of linear standard curves from the IgG 1
and lgG4 responses to D. farinae proteins allowed semi¬
quantitative analysis of the antibody concentrations in
canine serum. It has been shown previously that this type
of image analysis system can be used to measure the total
IgG response to antigens in Western blots,32 but this is the
first report of such a system being used to measure IgG
subclass responses.
The IgG 1 and lgG4 subclass responses to various
antigens of the house dust mite D. farinae were similar in
healthy and affected dogs, both in terms of the number of
bands recognized and of their molecular weights. The only
significant difference detected between the two groups
was the increased frequency of recognition of a 180 kDa
protein in the atopic dogs. These results indicate that D. fari¬
nae produces a number of proteins that are recognized by
the canine immune system, both in healthy and in atopic
dogs, and are in accordance with previous findings.12,32
However, studies by Day et a/.17 detected antigen-specific
IgG antibodies against crude D. farinae extracts in only
one of 11 normal dogs. The reason for this discrepancy is
unknown but it could be due to greater sensitivity of the
chemiluminescent method compared to ELISAs. It might
also reflect technical, geographical, environmental or
Figure 5. Plot of band molecular weight
against band intensity in healthy and atopic
dogs, as measured by the image analysis
software. Each dot represents an lgG4
response to a D. farinae protein in an
individual dog. The most commonly
recognized proteins had molecular weights
of 18, 45, 66, 98, 130 and 180 kDa. No
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gene pool differences in the healthy dogs included in the
respective studies.
In terms of the proteins recognized, the IgG 1 and lgG4
response to an antigen with a molecular weight of approx¬
imately 98 kDa is likely to be the high molecular weight
allergen Der f 15 that is recognized by IgE in atopic
dogs.33-35 IgG 1 also recognized a low molecular weight
protein of approximately 18 kDa, whereas lgG4 more
commonly recognized an antigen with a molecular weight
of approximately 45 kDa. A protein of the same molecular
weight is also recognized by IgE in immunoblots.35 These
findings suggest that some allergens can stimulate dif¬
ferent subclass responses in individual dogs. The signifi¬
cance of this finding is currently unknown but it warrants
further study.
The identity of the 180 kDa protein recognized more
commonly in atopic dogs is currently unknown. However,
proteins of similar high molecular weight have been
reported as allergens in canine atopic dermatitis.36 The role
of this protein requires further investigation and it would
be premature to conclude a role of it in the pathogenesis
of atopic dermatitis.
The strength of the IgG 1 and lgG4 responses was gen¬
erally slightly higher in the healthy controls than in the
atopic dogs, both overall and for the most intense bands.
Although there was no significant difference between the
groups, suggesting no biological relevance, a study with a
larger number of dogs in each group is required to estab¬
lish that no genuine and relevant difference exists. Hill
ef a/.16 reported that total IgG concentrations were signif¬
icantly higher in atopic and parasitized dogs compared to
healthy controls. However, that study did not measure
allergen-specific IgG, or IgG subclasses, and the antibody
response could have been directed against a range of
antigens, including those derived from staphylococci and
Malassezia organisms.37,38
Although it is not possible to accurately compare the
strength of the IgG 1 response to the lgG4 response because
the exact concentrations and affinities of the monoclonal
antibodies were unknown, there is some evidence to sug¬
gest that the lgG4 response to D. farinae antigens was
stronger. The lgG4 concentration in normal dog serum is
nine times less than lgG1 and yet in the current experiments,
the signals on the blots were much stronger (compare
Figs 2 and 4), even when using shorter exposure times.
Taken together, the results of this and previous studies
suggest that D. farinae-specific IgG and IgG subclasses do
not play a major role in the pathogenesis of canine atopic
dermatitis. Such responses occur in both healthy and
atopic dogs to the vast majority of antigens and do not
appear to be either protective or pathogenic. Some of the
proteins recognized (98 kDa, 45 kDa) are regarded as
major allergens in relation to IgE production and yet were
found in both the healthy and the atopic groups in equal
numbers and intensity. Whether the 180 kDa protein has
a more specific role remains to be determined. These find¬
ings fit a hypothesis in which the production of IgG, and its
subclasses, against the majority of D. farinae antigens is
merely a result of recognition of a foreign protein presented
to the immune system in relatively large quantities. They
also accord with the concept of D. farinae antigens acting
as 'danger' signals to the immune system, thus provoking
an antibody response even though the molecules them¬
selves appear to be harmless. In view of this, it seems
likely that the production of IgE, and the activation of allergen-
specific T lymphocytes, are the most important immunological
events in canine atopic dermatitis.
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Resume Un systbme semi-quantitatif de western blot a bte developpe et valide pour evaluer les sous-
classes d'lgG spbcifiques observees au niveau de proteines de Dermatophagoides farinae sbparees par
electrophorese chez des chiens sains et des chiens atopiques,
Les deux groupes ont montrb des rbponses IgG 1 et lgG4 similaires mais il a etb difficile de detecter des
rbponses lgG2 et lgG3. Les bandes les plus facilement reconnues dans les deux groupes etaient des
antigenes de 18 et 98 kDa pour les IgG 1 et de 18, 45, 66, 98, 130 et 180 kDa pour les lgG4. Le nombre de
bandes reconnues par chien n'etait pas statistiquement significatif, mais plus de chiens atopiques prbsen-
taient une reponse IgG 1 b la protbine de 180 kDa protein. Les rbponses IgG 1 et lgG4 btaient un peu plus
elevees dans le groupe sain, mais sans difference significative. Ces resultats suggerent que certains
antigbnes produits par Dermatophagoides farinae peuvent provoquer la synthese de differentes sous-
classes d'anticorps. Cependant, comme la plupart de ces anticorps sont retrouves chez les chiens sains et
les chiens atopiques, il s'agit probablement une reconnaissance de proteines btrangeres par le systeme
immunitaire plutot qu'ils jouent un role dans la pathogbnie de la dermatite atopique. Le role joue par
I'antigene de 180 kDa nbcessite des etudes supplementaires.
Resumen Se desarrollo un analisis semi-cuantitativo de western blot utilizando quemoluminiscencia y
se demostrb su eficacia para evaluar la respuesta en subclases de inmunoglobulinas especificas de
antigeno en perros sanos y atopicos, frente a proteinas de Dermatophagoides farinae separadas mediante
electroforesis.
Ambos grupos respondieron de forma similar con IgG 1 e lgG4 especificas frente a D. farinae para multiples
antigenos, pero lgG2 e lgG3 fueron diflciles de detectar. Las bandas mas comunmente reconocidas en
ambos grupos fueron antigenos de 18 y 98 kDa para la IgG 1 y de 18, 45, 66, 98, 130 y 180 kDa para la
lgG4. El numero de bandas reconocido no vario de forma significativa entre los perros, pero significativamente
un mayor numero de perros atopicos desarrollo una respuesta de IgG 1 frente a la protelna de 180 kDa. En
conjunto, las respuestas de IgG 1 e lgG4 especificas frente a D. farinae fueron ligeramente mas pronunciadas,
pero no significativamente diferentes, en el grupo sano. Los resultados sugieren que algunos antigenos
producidos en D. farinae pueden inducir respuestas con diferentes subclases de inmunoglobulinas. Sin
embargo, como la mayorla de las respuestas se observaron tanto en perros sanos como atopicos, es
presumible que representen simplemente el reconocimiento de proteinas extraiias presentadas al sistema
inmune, mbs que estar implicadas en la patogenia de la dermatitis atbpica. El papel de la protelna de 180
kDa merecerla un estudio mbs detallado.
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Zusammenfassung Ein semi-quantitatives Chemilumineszenz Western-Blot Analyse System wurde
entwickelt und validiert, um die Antwort von antigen-spezifischen IgG Unterklassen auf elektrophoretisch
separierte Proteine von Dermatophagoides farinae bei gesunden und atopischen Hunden zu evaluieren.
Beide Gruppen entwickelten ahnliche D. far/'nae-spezifische IgG 1 und lgG4 Antworten auf multiple Antigene,
wahrend lgG2 und lgG3 Antworten schwierig festzustellen waren. Die am haufigsten erkannten Banden
entsprachen in beiden Gruppen 18 und 98 kDa Antigenen fur IgG 1 und 18, 45, 66, 98, 130 und 180 kDa fur
lgG4. Die Anzahl der Banden, die von jedem Hund erkannt wurden, war nicht signifikant unterschiedlich;
allerdings zeigten signifikant mehr atopische Hunde eine IgG 1 Antwort auf ein 180 kDa Protein. Die gesamten
D. far/nae-spezifischen IgG 1 und lgG4 Antworten waren in der gesunden Gruppe etwas hoher, aber nicht
signifikant unterschiedlich. Die Ergebnisse weisen darauf hin, dass einige Antigene, die von Dermatophagoides
farinae produziert werden, Antworten verschiedener Unterklassen induzieren konnen. Da jedoch die
Mehrheit dieser Immunantworten bei gesunden wie auch bei atopischen Hunden gesehen werden, ist es
wahrscheinlicher, dass diese nur die Erkennung von Fremdproteinen durch das Immunsystem reprasen-
tieren anstatt einen Einfluss der Pathogenese der atopischen Dermatitis. Die Rolle des 180 kDa Antigens
sollte weiter untersucht werden.
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Summary
The molecular and immunologic mechanisms involved in successful
allergen-specific immunotherapy (ASIT) have not been completely
elucidated. The aim of this study was to characterise the changes in
Dermatophagoides farinae-specific total IgG and IgG subclasses during
ASIT of dogs with atopic dermatitis.
Twenty-one dogs with D. farinae hypersensitivity were treated with
alum-precipitated vaccines for 9 months. Serum samples were collected
before and after 3,6 and 9 months of therapy and used to probeWestern
blots containing separated proteins of D. farinae. IgG responses were
detected using a polyclonal antibody and a colorimetric substrate,
whereas IgG subclasses were detected using a panel of monoclonal
anti-IgG antibodies and chemiluminescence. The blots were analysed
using a semi-quantitative digital image analysis system that provided
the number and molecular weight of bands, as well as their intensity,
which was related to IgG concentration. Prior to ASIT, all dogs showed an
IgG, IgG 1 and lgG4 response to multiple proteins of different molecular
weights, the most common being 98 kDaand 44 kDa. There was virtually
no detectable lgG2 or lgG3 response, During ASIT, the total IgG, IgG 1 and
lgG4 response to D. farinae antigens varied widely between dogs and
could increase, decrease, fluctuate or remain the same, but there was no
induction of lgG2 or lgG3 antibodies. There were no significant increases
In total IgG or IgG subclass responses in dogs showing a complete or
partial response to ASIT. However, dogs showing no response to ASIT had
significantly higher D. farinae-specific total IgG levels prior to the start of
therapy, compared to dogs that responded to ASIT.
Introduction
Allergen-specific immunotherapy (ASIT) is the prac¬
tice ofadministeringgradually increasing quantities of
an allergen extract to an allergic subject to ameliorate
the symptoms associated with subsequent exposure to
the causative allergen.1,2 Since the first reports ofASIT
in humans3 ,1 and in the dog,5 many studies, and a large
body ofclinical observations by veterinary dermatolo¬
gists, have suggested that ASIT can be effective in con¬
trolling the signs ofatopic dermatitis (AD) in dogs.2,6,7
Most of these data are either anecdotal or originate
from questionnaire-based studies and, to date, there
has been only one placebo-controlled study that has
investigated this form of treatment in dogs.8 Collec¬
tively, this body of information and literature has re¬
sulted in efficacy claims ranging from 50% to 100%,
with a response usually being defined as an improve¬
ment in clinical signs of at least 50%.2
Two main forms of ASIT vaccines are currently
used in dogs: aqueous vaccines are favoured in North
America whereas aluminium-adsorbed vaccines are
commonly used in Europe. A comparison between
these vaccine types of their true efficacy is not pos¬
sible because different studies quote differences in
allergen extracts, the number of allergens used, the
concentration of allergens, the frequency of admin¬
istration, as well as symptom scores which are easily
influenced by other factors such as infections. How¬
ever, one potential advantage of aluminium-adju-
vanted vaccines is the more rapid development of
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high titre, and long-lasting, antibody responses after
" primary immunisation.9 The mechanism of action of
aluminium adjuvants likely involves the formation of
a depot, increasing targeting of antigens to antigen-
presenting cells, and non-specific activation of the
immune response.10
Although the clinical efficacy of ASIT is well doc¬
umented in humans and dogs, the molecular and
immunological mechanisms involved are incom¬
pletely understood. Current evidence from rodent
and human studies suggests that ASIT exerts effects
on several aspects of the immune system, including
modulation of allergen-specific B cells as well as T-
cell responses. Studies on the effect ofASIT have dem¬
onstrated reduced basophil reactivity to allergens,"
deviation of Th2-cytokine responses to allergens in
favour of a Thl response,12"15 and the induction of
IL-10-producing regulatory T cells.16"18 In addition,
changes in serum antibody titres in response to ASIT
have been described, mostly as increases in allergen-
specific IgG antibodies, particularly of the IgGl and
IgG4 isotypes.19,20 Allergen-specific IgG produced in
response to ASIT has been termed 'blocking antibody'
because it has been proposed that competition with
IgE may prevent successful activation ofmast cells.
To the authors' knowledge, only two studies investi¬
gating changes in IgG concentrations have been report¬
ed in dogs.21,22 In the first of these reports, increases in
allergen-specific IgG antibodies to various pollens were
reported during ASIT with aqueous allergens.21 The
second report showed that concentrations of total IgGl
(i.e. not allergen-specific) could increase followingASIT
using adjuvanted vaccines.22 However, no studies have
reported changes in IgG antibodies specific for antigens
derived from the house dust mite Dermatophagoides
farinae, a major cause ofAD in dogs.23"26
The aim of this study was to use a semi-quantita¬
tive blot analysis system27 (C. Hou, M.J. Day, T.J. Nut-
tall, P.B. Hill, unpublished data) to investigate the
changes in total IgG, and the subclasses IgGl, IgG2,
IgG3 and IgG4, to separated antigens from D. farinae,
during ASIT with aluminium-adsorbed vaccines. Our
hypothesis was that allergen-specific IgG antibodies
would increase after the administration of allergen-
specific immunotherapy in dogs with AD.
Materials and methods
Study population
Serum samples used in this study were obtained from
21 dogs with AD taking part in another study to evalu¬
ate the efficacy of two different allergen-specific im¬
munotherapy (ASIT) protocols. Details of the inclu¬
sion and exclusion criteria, study design, clinical as¬
sessment and scoring, use of concurrent medications
and analysis of treatment efficacy, will be reported
elsewhere.28 Briefly, the diagnosis of AD was based
on a combination of a compatible history and clinical
signs,29 exclusion of other pruritic skin diseases (e.g.
ectoparasite infestation and adverse food reaction),
and the presence of at least one positive reaction ei¬
ther in an intradermal test or a commercially available
allergen-specific IgE assay (Allercept™, Heska Corpo¬
ration, Fort Collins, CO, USA). All dogs included in
the present study had a positive reaction to D. farinae
at a dilution of 1/1000 w/v on an intradermal test; test
sites were scored from 0 to 4 compared to the positive
(1/100 000 w/v histamine) control and the negative
(diluent) control, with reactions > 2 being considered
positive. Multiple coat brushings and skin scrapings
were used to eliminate the possibility of an ectopara¬
site infestation.All dogs were also placed on a rigorous
flea and sarcopticmange control programme using se-
lamectin (Stronghold® spot-on, Pfizer Animal Health,
Sandwich, UK) for 6weeks before the start of the study
and at monthly intervals throughout the study. Dogs
that experienced complete resolution of clinical signs
after treatment were excluded. A 6-week novel ingre¬
dient home-cooked diet trial was conducted to elimi¬
nate the possibility of adverse food reactions. Concur¬
rent staphylococcal pyoderma was managed with oral
cephalexin and topical treatment with either benzoyl
peroxide (Paxcutol®, Virbac, UK) or 10% ethyl lactate
(Etiderm®, Virbac). Concurrent Malassezia infection
was treated with 2% miconazole/2% chlorhexidine
shampoo (Malaseb®, Leo Animal Health, UK). No
glucocorticoids were given for 3 months prior to the
initiation ofASIT.
Ten dogs received a standard immunotherapy pro¬
tocol (Artuvetrin® Therapy, ARTU, The Netherlands),
as used in the dermatology clinic at the Royal (Dick)
School of Veterinary Studies in Edinburgh (Table
1.9.1). This involved administration of an allergen
mixture comprising up to eight allergens, at least one
of which was D. farinae which accounted for 2.5-10%
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Table 1.9.1 Standard-dose and low-dose protocols
for allergen-specific immunotherapy using aluminium-
adsorbed allergens administered by subcutaneous
injection
Dose of allergen extract (ml)









Every 4 weeks 1.0 0.1
v/v of the allergen mixture. Eleven dogs received an al¬
ternative protocol in which the frequency of injections
was identical but the maintenance dose of allergen was
only 1/10 that of the standard protocol (Table 1.9.1).
The precise concentration of allergens is not provided
by the manufacturer.
Dogs were assessed for pruritus by the owners using
a 0-5 point behaviour-based scale and for skin lesions
by a single investigator using a modified canine atopic
dermatitis extent and severity index (CADESI).28 As¬
sessments took place on the day the ASIT was started
and after 3, 6 and 9 months (90, 180 and 270 days) of
ASIT.A complete response toASIT was defined as a dog
whose pruritus score had fallen to zero by the end of
the study without the need for additional anti-pruritic
medication. A partial response to ASIT was defined
as a dog whose pruritus score was lower at the end of
the 9-month treatment period compared to the begin¬
ning. No response to ASIT was defined as a dog whose
pruritus score was the same or higher after 9 months
of treatment compared to the beginning. Glucocorti¬
coid therapywas permitted for the first 6months of the
study, but not during the final 3 months ofASIT.
Serum samples
Serum samples were to be collected from each dog be¬
fore and after 3,6 and 9 months ofASIT. However, due
to unavoidable logistical and technical circumstances,
serum samples could not be collected at every time
point in every dog. All dogs were sampled prior to the
start ofASIT but some only had serum samples taken
at one or two of the remaining three time points. There
were 4/24missing data points in the complete response
group, 5/20 in the partial response group and 5/40 in
the no response group.
All samples were obtainedwith the owner's consent.
As the samples were to be used for measurement of al¬
lergen-specific antibody responses, which represented
diagnostically and therapeutically useful information;
UK Home Office approval was not required. After col¬
lection, serum was separated by centrifugation and
stored in aliquots at -20°C until used.
D. farinae extract
Lyophilised whole-body D. farinae crude extract
(Greer Laboratories, Lenoir, NC, USA) was reconsti¬
tuted to 1 mg/ml in sterile phosphate-buffered saline
(PBS,pH 7.5) and 200-pl aliquots were stored at-20°C
until used.
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE)
SDS-PAGE was performed according to the method
of Laemmli30 using a 10% Tris-glycine polyacrylamide
(ProtoGel®, National Diagnostics, UK) separating gel
and 4% stacking gel in a discontinuous buffer system
containing 25 mM Tris-HCl (Trizma® hydrochloride;
Sigma-Aldrich, Dorset, UK), 0.2M glycine (Fisher Sci¬
entific, Loughborough, UK) and0.1%SDS (Fisher Sci¬
entific), pH 8.3. A total of50 pi (for total IgG colorimet-
ric blots) or 100 pi (for IgG subclass chemiluminescent
blots) ofD. farinae extract, and 0.5 pi of the molecular
weight markers, were diluted 1:1 and 1:20, respectively,
with reducing sample buffer containing 125 mM Tris-
HCl, 4% SDS, 20% glycerol (BDH Chemicals, Poole,
UK), 0.005% bromophenol blue (BDH) and 10% 2-
mercaptoethanol (Sigma-Aldrich) and heated at 95°C
for 5 minutes. The extract was then loaded into one
broad well across the top of the gel alongside a lane
containing the molecular weight markers and the elec¬
trophoresis was run at 200 V for 40 minutes according
to the manufacturer's recommendations (Mini-Pro¬
tean II®; Biorad, Hercules, USA).
Western blots
Separated D. farinae proteins were transferred to poly-
vinylidene fluoride (PVDF) microporous membranes
(Millipore Immobilon™-P Transfer Membrane, Mil-
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lipore Corporation, Bedford, MA, USA) in a semi-dry
electrophoretic transfer cell (Trans-Blot® SD, Biorad)
using0.3 M Tris-HCl/10% methanol (pH 10.4) on the
lower anode, 25 mM Tris-HCl/10% methanol (pH
10.4) on the upper anode and 25 mM Tris-HCl/40 mM
6-amino-n-hexonic acid/10% methanol (pH 9.4) on
the cathode according to the manufacturer's instruc¬
tions. The transfer was run at 80 mA per minigel for
1 hour, after which the membranes were dried and
stored at 4°C. The quality of transfer was checked by
staining gels and molecular weight standards blotted
onto the membrane with Coomassie brilliant blue R-
250 (BDH).
Antibodies
To assess total IgG responses to separated antigens
from D. farinae, a polyclonal horseradish peroxidase-
conjugated goat anti-dog IgG (Bethyl Laboratories
Inc., Montgomery, TX, USA) was used. The specificity
of this reagent for IgG is verified by the manufacturer
and has been documented in previous studies.27,31 Po¬
tential cross-reactivity of the reagent with canine IgE
is not relevant in colorimetric immunoblots because
the method is not sensitive enough to detect the low
concentrations of IgE present, even if specific anti-IgE
reagents are used.31
To assess IgG subclass responses to separated anti¬
gens from D. farinae, a panel of four mouse monoclonal
antibodies (mAbs) specific for the subclasses of canine
IgG were used. The preparation and characterisation
of these mAbs has been described.32"35 mAb B6 has re¬
stricted specificity for canine IgGl and IgG3, but reacts
specifically with IgGl in serological and immunohis-
tochemical assays. mAb E5 is specific for canine IgG2
and antibody A3G4 is specific for canine IgG3. mAb
A5 has restricted specificity for canine IgG2 and IgG4
but reacts specifically with IgG4 in serological and im-
munohistochemical assays. The specific activity of the
subclass-restricted mAbs B6 and A5 is probably due to
conformational differences between the target IgG sub¬
classes in solid-phase assays versus other serological and
immunohistochemical techniques.33,35 mAbsA5, E5 and
B6 were used as 45% ammonium sulphate precipitates
of tissue culture supernatants, and A3G4 was used as
a tissue culture supernatant. The applicability of these
mAbs in Western blotting was confirmed by probing a




nae proteins were cut longitudinally into 4-mm wide
strips to allow probing by individual dog sera. Strips
were placed in individual lanes of an eight-channel
incubation tray (Biorad), blocked with 5% skimmed
milk in Tris-buffered saline (TBS, pH 7.5) containing
20 mM Tris-HCl and 0.5 M NaCl (Sigma-Aldrich) for
1 hour at room temperature, and washed with 0.1%
Tween 20 (Fisher Scientific)/TBS (TTBS) three times
for 5 minutes. All sera and primary and secondary rea¬
gents were diluted with dilution buffer (1% skimmed
milk/TTBS) to a final volume of 1 ml and to concen¬
trations that had been determined in previous stud¬
ies to yield strong bands against a clear background27
(C. Hou, M.J. Day, T.J. Nuttall, RB. Hill, unpublished
data).
For total IgG immunoblots, duplicate strips were
probed with individual dog sera at 1/100 for 1 hour,
followed by a 1-hour incubation with the horseradish
peroxidase-conjugated goat anti-dog IgG at 1/1000.
After further washing with washing buffer, the strips
were developed for 1 minute with 3,3' -diaminobenzi-
dine (DAB) peroxidase substrate (Vector Laboratories
Inc., Burlingame,CA, USA), prepared according to the
manufacturer's recommendations. The strips were air-
dried overnight prior to analysis.
For detection of IgG subclass responses, duplicate
strips were probed for 1 hour with dog sera diluted to
1/20, followed by a 1-hour incubation with one of the
four IgG subclass-specific mAbs diluted to 1/500.After
washing, a horseradish peroxidase-conjugated bo¬
vine anti-mouse IgG (Bethyl Laboratories) diluted to
1/1000 was added for another hour followed by thor¬
ough washing. The surface of each strip containing the
detected proteins was then covered for 1 minute with
a chemiluminescent luminal solution (ECL, Amer-
sham-Pharmacia Biotech, Little Chalfont, UK), used
for its higher sensitivity. The excess liquid was then
drained off prior to immediate image acquisition as
described below.
Digital image acquisition and semi¬
quantitative analysis
Strips probed with the polyclonal anti-canine IgG and
developed with the colorimetric substrate DAB, along
with the molecularweight standards, were aligned and
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digitally scanned using a flatbed scanner (Epson Per¬
fection 1650, Hemel Hempstead, UK) set at 16-bit grey
scale. For IgG subclass-specific blots, developed with
the chemiluminescent substrate ECL, the strips were
wrapped in cling film and placed protein side down
on a Kodak Digital Science™ Image Station 440CF
(Kodak, Rochester, NY, USA) along with the Coomas-
sie blue-stained molecular weight standards. In this
system, the images are acquired with a charge coupled
device (CCD) camera. Three exposures, each lasting
5 minutes, were used to eliminate the possibility of
image saturation.
The scanned and acquired images were then im¬
ported into image analysis software (Kodak Digital
Science™ ID Image Analysis Software, Kodak, USA)
to detect the bands on the blots. This software can de¬
termine, without operator bias, the molecular weight
of bands by analysing their positions relative to the
molecular weight standards as well as the signal mag¬
nitude of individual bands.We have shown in previous
studies that this system can be used for semi-quantita¬
tive analysis of antibody concentrations because a lin¬
ear standard curve is obtained when band intensity is
plotted against log serum dilutions27 (C. Hou, M.J. Day,
T.J. Nuttall, P.B. Hill, unpublished data). Furthermore,
the coefficients of variation obtained from repeated
assay of samples are approximately 10-20%, and the
conditions used do not lead to saturation effects27 (C.
Hou,M.J. Day,T.J. Nuttall, P.B.Hill, unpublished data).
The sum of the band intensities on each strip there¬
fore provides an indication of the antibody response
to D. farinae as a whole, whereas the intensity of each
band provides an indication of the antibody response
to individual antigens. For each dog, the final band
intensity was derived from an average of each set of
duplicate strips.
Statistical analysis
Numerical data derived from the image analysis soft¬
ware were exported to Graphpad Prism, Version 3.0
for Windows (Graphpad software, San Diego, USA).
As antibody concentrations in dogs are not normally
distributed,36 the Kruskal-Wallis non-parametric
ANOVA was used to compare antibody responses at
multiple time points. If significant differences were de¬
tected by Kruskal-Wallis,comparisons between two in¬
dividual time pointswere made by the Mann-Whitney
test. The following comparisons were made: data from
four time points (days 0,90,180 and 270) when all the
dogs were combined as a single group; data from cor¬
responding time points when dogs were divided into
two groups based on those that showed no response
to ASIT versus dogs that showed some response (com¬
plete or partial); data from corresponding time points
when dogs were divided into three groups comprising
those that showed a complete, partial or no response
to ASIT; data from the four time points within each
response group; and data from eight time points when
dogs were divided into two groups based on those that
received the standard ASIT protocol versus those that
received the low-dose ASIT protocol. A p value of <
0.05 was considered to be significant.
Results
All the dogs had detectable levels ofD./annae-specific
total IgG, IgGl and IgG4 prior to the start of, and dur¬
ing, ASIT (Figure 1.9.1). There was no detectable re¬
sponse by IgG2 and IgG3 antibodies, despite attempts
to increase the sensitivity of the assay by increasing
reagent concentrations and incubation times (data
not shown). Both total IgG, and the subclasses IgGl
and IgG4, recognised multiple proteins from D. farinae
with the most visually obvious bands having molecu¬
lar weights of approximately 98 kDa and 44 kDa, both
ofwhich have been identified as major allergens26 (Fig.
1.9.1). The 66-kDa protein was often detected in sam¬
ples and it has also been classified as a minor allergen
for dogs.26
Visual analysis of the strips from individual dogs
showed that the strength of the bands varied during
ASIT. However, there was no clearly obvious trend for
the band intensity to increase or decrease with time.
Over the course of 9 months of ASIT, individual dogs
could show an obvious increase in band strength (Fig.
1.9. la), a decrease (Fig. 1.9.1b), remain relatively static
(Fig. 1.9.1c), or fluctuate. For each dog, the changes
seen with total D. farinae-specific IgG were approxi¬
matelymirrored by similar changes in IgGl and IgG4.
No consistent induction or disappearance of specific
bands at anymolecular weight was observed.
This visual impression was confirmed by the nu¬
merical data from the image analysis software which
showed that, during ASIT, there was no consistent
increase in the total antibody response (the sum
of all the band intensities on each strip) for IgG,
IgGl or IgG4 (Fig. 1.9.2a). There was also no con-
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(a)
Fig. 1.9.1 Examples of immunoblots showing total IgG-, IgG 1 - and lgG4-
binding profiles to Dermatophagoides farinae extract in dogs undergoing
allergen-specific immunotherapy. Serum samples were collected before and
after immunotherapy for 90, 180 and 270 days. The IgG responses to D.
fer/haeallergens varied widely between dogs and could increase (a), decrease
(b), remain the same (c) or fluctuate. Changes in total D. farinae-specific
IgG were usually paralleled by equivalent changes in lgG1 and lgG4. MW,
molecular weight in kilodaltons (kDa).
sistent change in the response to the 98-kDa band
(Fig. 1.9.2b) or the 44-kDa band (Fig. 1.9.2c) for any
of the antibodies.
When all the dogs were considered as a single group,
there was no significant difference in the total antibody
response to D. farinae (sum of the band intensities on
each strip) or the response to the 98-kDa and 44-kDa
proteins at any of the four time points during ASIT
for IgG, IgG 1 or IgG4 (p > 0.05 for all nine analyses).
However, when dogs that showed no response to ASIT
were compared to dogs that showed a response (partial
and complete response groups combined), there was a
significant difference among the time points for total
IgG. This difference was attributable to a significantly
greater total IgG response to D. farinae, and the 98-
kDa and 44-kDa proteins, in the group that was non-
responsive to ASIT at day 0, compared to the response
group at day 0. In the case of the 44-kDa band, there
was also a significantly greater total IgG response in
the non-responsive group at day 90 compared to the
response group at day 90.
21.5—
(c)
When the dogs were divided into three response
groups and compared separately, there was a significant
difference among time points for total IgG responses to
D. farinae. This was due to a significantly higher IgG
response in the non-responsive group at day 0, com¬
pared to the partial (p = 0.019) and the complete (p
= 0.011) response groups. The total IgG responses to
the 98-kDa and 44-kDa proteins were also significantly
higher at day 0 in the non-responsive group compared
with the complete response groups (p = 0.023 and p =
0.042, respectively).
In addition, there was also significant variation
among the time points in the standard- and low-dose
ASIT protocols for IgGl against total D. farinae anti¬
gens. This was attributable to significantly lower IgGl
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(a)
Fig. 1.9.2 Dermatophagoides farinae-specific total IgG, IgGI and lgG4 antibody responses during 9 months of allergen-specific immunotherapy, (a) The
total antibody response to D. farinae antigens (calculated as the sum of all band intensities on each immunoblot strip). The dogs are divided into three
groups categorized by dinical outcome. Dogs that received the standard-dose immunotherapy protocol are plotted in black. Dogs that received the low-dose
immunotherapy protocol are plotted in red.
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(b)
Fig. 1.9.2 Dermatophagoides fer/nae-specific total IgG, IgG 1 and lgG4 antibody responses during 9 months of allergen-specific immunotherapy, (b) Anti¬
body responses to the 98-kDa band. Dogs that received the standard-dose immunotherapy protocol are plotted in black. Dogs that received the low-dose
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(c)
Fig. 1.9.2 Dermatophagoides farinae-specific total IgG, IgGl and lgG4 antibody responses during 9 months of allergen-specific immunotherapy, (c)
Antibody responses to the 44-kDa band. The dogs are divided into three groups categorized by clinical outcome. Dogs that received the standard-dose
immunotherapy protocol are plotted in black. Dogs that received the low-dose immunotherapy protocol are plotted in red.
lgC4 >.
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levels to D. farinae at day 0 in the dogs receiving the
low-dose protocol compared with those receiving the
standard dose (p = 0.01). There were no other signifi¬
cant differences for D. farinae or the 98-kDa or 44-
kDa proteins at any time point for any other antibody
between the standard-dose and low-dose protocol
groups.
Discussion
In this study, we documented allergen-specific total
IgG, IgGl and IgG4 responses to various antigens of the
house dust mite D. farinae in dogs with AD. No IgG2
or IgG3 antibodies were detected with specificity for D.
farinae. These findings were in accordance with previ¬
ous studies recently conducted in our laboratory27 (C.
Hou, M.J. Day, T.J. Nuttall, P.B. Hill, unpublished data).
During ASIT, there was no consistent augmentation of
the total quantity ofD. /annoe-specific IgG or IgG sub¬
class antibodies to antigens from the mite. Levels of the
antibodies could increase or fall but there was no signifi¬
cant increase by day 270 compared to day 0. This was the
case for the total response to all the D. farinae proteins
(measured by summing all the band intensities on each
strip) as well as the response to the 98-kDa and 44-kDa
proteins. These latter proteins were chosen for specific
analysis because they were the strongest and most visu¬
ally obvious bands on the strips. The 98-kDa band is
likely to be the high molecular weight chitinase recently
designated Der f 15, a major D. farinae allergen for dogs
with AD.23,24,26 The identity of the 44-kDa protein is cur¬
rently unknown, but it may be a fragment of a larger
antigen because it only appeared on blots performed
with reducing buffers and not on blots performed with
non-reducing buffers in an earlier study.26
Although not exactly parallel, the changes in IgG I
and IgG4 tended to mirror the changes seen with total
IgG. The lack of significant increases in levels of aller¬
gen-specific IgG, IgGl and IgG4 is surprising. Previ¬
ous studies have demonstrated that increases in aller¬
gen-specific IgGl and IgG4 are seen following ASIT
in man.19,20,37 In atopic dogs, concentrations of pollen-
specific IgG were shown to increase following at least 6
months ofASIT using aqueous allergens.21 An increase
in total (non-allergen-specific) IgGl was also observed
in most dogs that were given ASIT using alum-precipi-
tated vaccines.22 The reason for the difference in the
findings between our study and previous studies is not
clear, but there are a number of possible explanations.
First, although administration of adjuvanted proteins
should lead to a marked IgG response, some studies
in humans have shown poor clinical efficacy to alum-
precipitated vaccines as well as a lack of alteration in
immune responses.38,39 It is possible that the vaccines
used in this study did not contain sufficient protein to
induce an allergen-specific IgG response, even though
they were shown to elicit an increase in total IgGl in
most of the dogs in a prior study.22 The allergen manu¬
facturer used in this study does not provide the specific
protein content of allergens within vaccines, so it is
not possible to know the precise amount ofD. farinae
that is present. Further, the quantity of D. farinae in
each vaccine is likely to be different depending on the
number of other allergens included. It is also possible
that the amount of D. farinae antigens may vary from
batch to batch, leading to further variation in specific
immune responses. Evidence for the above possibility
is provided by the lack of significant differences in IgG,
IgG 1 and IgG4 levels in dogs receiving either the stand¬
ard ASIT protocol or the low-dose protocol, which in¬
volved administering 1/10 of the recommended dose.
It would have been expected that dogs receiving the
higher doses would have mounted a greater antibody
response, as long as sufficient protein was present ini¬
tially. To resolve some of these issues, further studies
are required to compare the total and allergen-specific
IgG responses in dogs receiving different aqueous al¬
lergen and alum-precipitated ASIT protocols. It is also
important that allergen manufacturers work towards
standardisation of allergens so that the precise protein
concentrations can be included in vaccines, allowing
direct comparison.
A second possibility for the discrepancy may relate
to the different methods employed in the various stud¬
ies. In this study we used a validated semi-quantita¬
tive blot analysis system in which the net intensity of
bands shows a linear relationship to log antibody con¬
centrations27 (C. Hou, M.J. Day, T.J. Nuttall, P.B. Hill,
unpublished data). This system allows awhole range of
separated proteins from D. farinae to be studied simul¬
taneously. This is a major advantage compared with
ELISA assays, which can only measure a single protein
at a time. However, ELISA assays can provide a more
accurate measurement of a protein's concentration in
mg/ml and they tend to have lower coefficients of vari¬
ation, indicating superior repeatability. Hence, in fu¬
ture studies, we intend to directly compare the results
obtained by blot analysis to ELISA.
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Thirdly, the increase in total IgG 1 documented in the
earlier study26 was quantified using a radial-immuno-
diffusion technique. This method measured the total
quantity of IgG 1 present and did not relate to specific
allergens. Hence, the increase seen in that study could
have been due to other allergens or non-specific IgG ac¬
tivation and not directly related to D. farinae proteins.
Finally, it is possible that production of D. farinae-
specific IgG antibodies is not induced in dogs with AD
undergoing ASIT. This has not previously been stud¬
ied and it is not known whether the formulation of the
allergens, or the expression of the epitopes of major
allergens in ASIT, are appropriate or sufficient to stim¬
ulate this arm of the immune system. If not, clinical
efficacymaybe related to some other mechanism such
as down-regulation of cellular function or changes in
cytokine profiles.
An interesting finding arising from this study was
that dogs showing no response to ASIT had signifi¬
cantly higher D. farinae-specific total IgG levels on day
0 compared with dogs showing a partial or complete
response. This was the case both for total D. farinae
antigens, and the 98-kDa and 44-kDa proteins. This
suggested that if a dog with AD had a pre-existing high
level of IgG antibodies to D. farinae prior to the onset
ofASIT, it was less likely to respond. This is a potential¬
ly exciting finding, as it may suggest a means by which
dogs could be screened prior to initiation of ASIT.
Dogs with a low level of IgG antibodies could be given
a better prognosis than those with high levels. Alterna¬
tively, this might allow alterations in dosage schedule
to be predicted in advance. This finding clearly needs
to be substantiated using additional methods and in
a larger group of dogs to ensure that it is a repeatable
phenomenon. If so, the discriminatory power of the
measurement would have to be carefully determined.
A statistical quirk that arose in this study was the
finding that dogs receiving the standard-dose ASIT
protocol had significantly higher levels of IgG 1 to total
D. farinae proteins at day 0 compared with those re¬
ceiving the low-dose protocol. This can only have aris¬
en by chance, as the dogs were assigned to their rela¬
tive groups using block randomisation. This chance
occurrence did not seem to have any bearing on the
subsequent efficacy of the ASIT because there were no
significant differences in response rates between the
two groups.28
In summary, this study did not demonstrate the pro¬
duction of D. farinae-specific IgG blocking antibodies
in atopic dogs undergoing ASIT based on alum-pre¬
cipitated vaccines. However, a high pre-existing level
of total IgG to D. farinae antigens, including the 98-
kDa and 44-kDa proteins, suggested that dogs were less
likely to respond to ASIT.
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